

09/22/00
JC916 U.S. PTO

9-25-00 A

Docket Number S-130-4080C

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL034399825US
Express Mail Label Number

September 22, 2000
Date of Deposit

JC916 U.S. PTO
09/22/00
09/668650

Address to: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b)(1) is a **divisional** of prior Application No. 09/001,982, filed December 31, 1997.

Applicant (or identifier): BOSCH ET AL.

Title: GENES ENCODING HYBRID *BACILLUS THURINGIENSIS* TOXINS

Enclosed are:

1. Specification (Including Claims and Abstract) - 92 pages
 2. Drawings - 7 sheets (*formal*)
Declaration and Power of Attorney
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (signed or with indication that original was signed)
 - i. Deletion of Inventors
Signed statement attached deleting inventor(s) named in the prior application
 4. Incorporation By Reference
The entire disclosure of the prior application, from which a copy of the Declaration and Power of Attorney is supplied under Box 3b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
 5. Microfiche Computer Program (appendix)
 6. Nucleotide and/or Amino Acid Sequence Submission
 - Computer Readable Copy
 - Paper Copy
 - Statement Verifying Identity of Above Copies
 7. Preliminary Amendment
 8. Assignment Papers (Cover Sheet & Document(s))
 9. English Translation of
 10. Information Disclosure Statement
 11. Certified Copy of Priority Document(s)
 12. Return Receipt Postcard
 13. Other: Bibliographic Data Sheet
- The right to elect an invention or species that is different from that elected in parent Application No. 09/001,982 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent application is hereby reserved.

Filing fee calculation:

- Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
 Before calculating the filing fee, please cancel claims

Basic Filing Fee							\$ 690
Multiple Dependent Claim Fee (\$ 260)							\$
Foreign Language Surcharge (\$ 130)							\$
	For	Number Filed		Number Extra		Rate	
Extra Claims	Total Claims	29	-20	9	x \$ 18 =	\$ 162	
	Independent Claims	1	-3	0	x \$ 78 =	\$	
TOTAL FILING FEE							\$ 852

- Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$852. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 022847, which is currently:

Larry W. Stults
 Novartis Agribusiness Biotechnology Research Inc.
 Patent Department
 P.O. Box 12257
 Research Triangle Park, NC 27709-2257

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (919) 541-8689.

Respectfully submitted,



J. Timothy Meigs
 Attorney for Applicants
 Reg. No. 38,241
 Tel. No. (919) 541-8587

Date: September 22, 2000

INVENTOR INFORMATION

Inventor One Given Name:: Hendrick J
Family Name:: Bosch
Postal Address Line One:: Oortlaan 20
City:: Utrecht
Country:: NL
Postal or Zip Code:: 3572 ZM
Citizenship Country:: Netherlands
Inventor Two Given Name:: Willem J
Family Name:: Stiekema
Postal Address Line One:: Leonard Roggeveenstraat 21
City:: Wageningen
Country:: NL
Postal or Zip Code:: 6708 SL
Citizenship Country:: Netherlands

CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 022847

APPLICATION INFORMATION

Title Line One:: Genes Encoding Hybrid Bacillus thuringie
Title Line Two:: nsis Toxins
Total Drawing Sheets:: 7
Formal Drawings?:: Yes
Application Type:: Utility
Docket Number:: S-130-4080C
Secrecy Order in Parent Appl.?:: No

CONTINUITY INFORMATION

This application is a:: DIVISION OF
> Application One:: 09/001,982
Filing Date:: 12-31-1997

Which is a:: CONTINUATION IN PART OF
>> Application Two:: 08/602,737
Filing Date:: 02-21-1996
Patent Number:: 5736131

Which is a:: 371 OF
>>> Application Three:: EP94/02909
Filing Date:: 09-01-1994

PRIOR FOREIGN APPLICATIONS

Foreign Application One:: 9318207.9
Filing Date:: 09-02-1993
Country:: Great Britain
Priority Claimed:: Yes

Source:: PrintEFS Version 1.0.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BOSCH ET AL.

APPLICATION NO: TBA

FILED: SEPTEMBER 22, 2000

FOR: GENES ENCODING HYBRID *BACILLUS THURINGIENSIS* TOXINS
(AS AMENDED)

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Applicants respectfully request that the above-captioned application be amended as follows in advance of examination:

IN THE SPECIFICATION

Please change the title to -- Genes Encoding Hybrid *Bacillus thuringiensis* Toxins --.

Please replace the continuing data beneath the title with the following: -- This application is a division of application no. 09/001,982, filed December 31, 1997, which is a continuation-in-part of application no. 08/602,737, filed February 21, 1996, now U.S. Patent No. 5,736,131, which is a § 371 of international application no. PCT/EP94/02909, filed September 1, 1994. The aforementioned applications are incorporated herein by reference. --.

IN THE CLAIMS

Please cancel claims 1-16, 18-20, 29-31, 35-40 without prejudice or disclaimer.

Please amend claims 17 and 21 as follows:

17. (Amended) An isolated DNA molecule encoding [a protein that comprises the amino acid sequence of the hybrid toxin fragment of claim 1.] a polypeptide comprising an insecticidal *Bacillus thuringiensis* hybrid toxin fragment, comprising:

- a) at a C-terminus of said fragment, domain III of a first Cry protein; and
- b) at an N-terminus of said fragment, domains I and II of a second Cry protein different from the first Cry protein.

21. (Amended) An isolated [*Bacillus thuringiensis* hybrid toxin fragment] DNA molecule according to claim [1] 17, wherein said hybrid toxin fragment binds to a binding site in an insect gut that is different than the site bound by said first Cry protein.

Please add new claims 41-57 as follows:

41. An isolated DNA molecule according to claim 17, wherein said first Cry protein is CryIC.
42. An isolated DNA molecule according to claim 17, wherein said second Cry protein is selected from the group consisting of CryIA, CryIE, and CryIG.
43. An isolated DNA molecule according to claim 42, wherein said second Cry protein is CryIA.
44. An isolated DNA molecule according to claim 42, wherein said second Cry protein is CryIE.
45. An isolated DNA molecule according to claim 42, wherein said second Cry protein is CryIG.
46. An isolated DNA molecule according to claim 17, wherein said first Cry protein is CryIC, and wherein said second Cry protein is CryIA, CryIE, or CryIG.
47. An isolated DNA molecule according to claim 17, wherein said C-terminus comprises the sequence from amino acid position 454 to position 602 of SEQ ID NO:2.
48. An isolated DNA molecule according to claim 17, wherein said C-terminus comprises the sequence from amino acid position 478 to position 602 of SEQ ID NO:2.
49. An isolated DNA molecule according to claim 17, wherein said insecticidal *Bacillus thuringiensis* hybrid toxin fragment comprises an amino acid sequence at least 90% similar to amino acids 1-620 of SEQ ID NO:6.
50. An isolated DNA molecule according to claim 17, wherein said insecticidal *Bacillus thuringiensis* hybrid toxin fragment comprises an amino acid sequence at least 90% similar to amino acids 1-627 of SEQ ID NO:8.

51. An isolated DNA molecule according to claim 17, wherein said insecticidal *Bacillus thuringiensis* hybrid toxin fragment comprises an amino acid sequence at least 90% similar to amino acids 1-602 of SEQ ID NO:12.
52. An isolated DNA molecule according to claim 17, comprising a nucleotide sequence that hybridizes to nucleotides 1-1860 of SEQ ID NO:5 under the following set of conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C.
53. An isolated DNA molecule according to claim 17, comprising a nucleotide sequence that hybridizes to nucleotides 1-1881 of SEQ ID NO:7 under the following set of conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C.
54. An isolated DNA molecule according to claim 17, comprising a nucleotide sequence that hybridizes to nucleotides 1-1806 of SEQ ID NO:11 under the following set of conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C.
55. An isolated DNA molecule according to claim 17, comprising a nucleotide sequence that is at least 90% identical to nucleotides 1-1860 of SEQ ID NO:5.
56. An isolated DNA molecule according to claim 17, comprising a nucleotide sequence that is at least 90% identical to nucleotides 1-1881 of SEQ ID NO:7.
57. An isolated DNA molecule according to claim 17, comprising a nucleotide sequence that is at least 90% identical to nucleotides 1-1806 of SEQ ID NO:11.

REMARKS

The title has been changed to more accurately reflect what is being claimed. The continuing data has also been updated. Claims 1-16, 18-20, 29-31, 35-40 have been canceled; claims 17 and 21 have been amended; and new claims 41-57 have been added. Thus, the pending claims are 17, 21-28, 32-34, and 41-57.

Applicants note that claim 17 (now the sole independent claim) has been amended to recite the encoded hybrid *Bt* toxin using language identical to that in allowed claim 1 of parent application no. 09/001,982. Thus, it is believed that claim 17 of the instant application is allowable as amended. The

remaining claims in the instant application all depend either directly or indirectly from amended claim 17. Hence, it is believed that they too are in condition for allowance.

Applicants respectfully request that the instant amendment be entered and receive favorable consideration. The Examiner is invited to telephone the undersigned attorney if any questions or concerns arise during examination of the pending claims.

Respectfully submitted,



J. Timothy Meigs
Attorney for Applicant
Reg. No. 38,241

Novartis Agribusiness Biotechnology Research Inc.
Patent Department
P.O. Box 12257
Research Triangle Park, NC 27709-2257
(919) 541-8587

Date: September 22, 2000

HYBRID TOXIN

This application is a continuation-in-part of application serial no. 08/602,737, filed February 21, 1996, which is a 371 of international application no. PCT/EP94/02909, filed September 1, 5 1994. Both of the aforementioned applications are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to hybrid toxin fragments, and toxins comprising them, derived from *Bacillus thuringiensis* insecticidal crystal proteins.

BACKGROUND OF THE INVENTION

10 *Bacillus thuringiensis* (hereinafter B.t.) is capable of producing proteins that accumulate intra-cellularly as crystals. These crystal proteins are toxic to a number of insect larvae. Based on sequence homology and insecticidal specificity, crystal proteins have been categorized into different classes. Best studied are the CryI class of proteins, which are produced as 140 kDa protoxins and are active towards lepidopterans.

15 To some extent, the mode of action of crystal proteins has been elucidated. After oral uptake, the crystals dissolve in the alkaline environment of the larval midgut. The solubilized proteins are subsequently processed by midgut proteinases to a proteinase-resistant toxic fragment of about 65kDa, which binds to receptors on epithelial cells of the insect midgut and penetrates the cell membrane. This eventually leads to bursting of the cells and death of the larvae.

20 The activity spectrum of a particular crystal protein is to a large extent determined by the occurrence of receptors on the midgut epithelial cells of susceptible insects. The activity spectrum is co-determined by the efficiency of solubilization of the crystal protein and its proteolytic activation *in vivo*.

25 The importance of the binding of the crystal protein to midgut epithelial receptors is further demonstrated where insects have developed resistance to one of the crystal proteins, such that the binding of crystal proteins to midgut epithelial cells in resistant insects is significantly reduced.

Toxic fragments of crystal proteins are thought to be composed of three distinct structural domains. Domain I, the most N-terminal domain, consists of 7 α -helices. Domain II comprises 3 β -sheets. Domain III, the most C-terminal domain, folds into a β -sandwich. If projected on CryI sequences, domain I runs from about amino acid residues 28 to 260, domain II from about 260 to 5 460, and domain III from about 460 to 600.

DESCRIPTION OF THE INVENTION

The present invention concerns hybrid crystal proteins particularly, though not exclusively, involving CryIC together with CryIE, CryIA, or CryIG. The nucleotide sequence of the CryIC gene from B.t. sub. sp. *entomocidus* 60.5 is given in SEQ ID NO:1, and the corresponding amino acid sequence of the protein encoded by said nucleotide sequence is given in SEQ ID NO:2. The nucleotide sequence of the CryIE gene from B.t. sub. sp. *kenyae* 4FI is given in SEQ ID NO:3, and the corresponding amino acid sequence of the protein encoded by said nucleotide sequence is given in SEQ ID NO:4. The nucleotide sequence of a B.t. CryIG gene is given in SEQ ID NO:9, and the corresponding amino acid sequence of the protein encoded by said nucleotide sequence is given in SEQ ID NO:10. These proteins are toxic to lepidopterans, but within this order of insects, each protein has different specificity. CryIC, for example, is particularly active against *S. exigua* and *M. brassicae*.

According to the present invention, there is provided an isolated B.t. hybrid toxin fragment comprising at its C-terminus domain III of a first Cry protein, or a part of said domain or a protein substantially similar to said domain; and comprising at its N-terminus the N-terminal region of a second Cry protein, or a part of said region or a protein substantially similar to said region. For example, a preferred B.t. hybrid toxin fragment according to the present invention comprises at its C-terminus domain III of a first Cry protein and comprises at its N-terminus domains I and II of a second Cry protein. A preferred fragment is one that does not bind to the CryIC binding site in an insect gut when it comprises at its C-terminus domain III of CryIC, or a part of said domain or a protein substantially similar to said domain; or one that does not bind to a CryIA binding site when it comprises at its C-terminus domain III of CryIA, or a part of said domain or a protein substantially similar to said domain.

In the context of the present invention, "substantially similar" means a pure protein having an amino acid sequence that is at least 75% similar to the sequence of a protein according to the invention. It is preferred that the degree of similarity is at least 85%, more preferred that the degree of similarity is at least 90%, and still more preferred that the degree of similarity is at least 95%. In 5 the context of the present invention, two amino acid sequences with at least 75%, 85%, 90%, or 95% similarity to each other have at least 75%, 85%, 90%, or 95% identical or conservatively replaced amino acid residues in a like position when aligned optimally allowing for up to 6 gaps, with the proviso that, with respect to the gaps, a total not more than 15 amino acid residues are affected. For the purpose of the present invention, conservative replacements may be made 10 between amino acids within the following groups:

- (i) Serine and Threonine;
- (ii) Glutamic acid and Aspartic acid;
- (iii) Arginine and Lysine;
- (iv) Asparagine and Glutamine;
- (v) Isoleucine, Leucine, Valine, and Methionine;
- (vi) Phenylalanine, Tyrosine, and Tryptophan; and
- (vii) Alanine and Glycine,

with the proviso that in SEQ ID NO:6, Ser and Tyr are conservative replacements at position 620, and Ala and Glu are conservative replacements at position 618; and that in SEQ ID NO:8, Ser and 15 Tyr are conservative replacements at position 627, and Ala and Glu are conservative replacements at position 625.

In the context of the present invention, "part" of a protein means a peptide comprised by said protein and having at least 80% of the consecutive sequence thereof.

In the context of the present invention, "binding site" means a site on a molecule wherein 25 the binding between site and toxin is reversible such that the *K_a* between site and toxin is in the order of at least $10^4 \text{dm}^3 \text{mole}^{-1}$.

The toxin fragment may comprise at its N-terminus the N-terminal region of any insecticidal protein from B.t. being commonly known as "Cry" or "Cyt", including: CryIA(a),

CryIA(b) CryIA(c), CryIB, CryIC, CryID, CryIE, CryIF, CryIG, CryIH, CryIIA, CryIIB, CryIIC, CryIII A, CryIII B, CryIII B(b), CryIVA, CryIVB, CryIVC, CryIVD, CYTA, CryX1(III C), CryX2(III D), CryX3, CryV, and CryX4, or a part of said region or a protein substantially similar to said region. The toxin fragment may comprise at its C-terminus domain III of CryIC, or a part of 5 said domain or a protein substantially similar to said domain.

Thus, the fragment may comprise domain II of CryIE, CryIB, CryID, CryIA, or CryIG, or a part of said domain II or a protein substantially similar to said domain II, and domain III of CryIC or a part of said domain III or a protein substantially similar to said domain III. It is particularly preferred that the fragment comprises domains I and II of CryIE, CryIB, CryID, CryIA, or CryIG, or 10 a part thereof or a protein substantially similar to said domains I and II, and domain III of CryIC or a part thereof or a protein substantially similar to said domain III.

It is most preferred that the toxin fragment comprises a region at its C-terminus comprising the sequence from amino acid position 454 to position 602 of CryIC, or a sequence substantially similar to said sequence. The fragment may comprise a region at its C-terminus comprising the sequence from amino acid position 478 to 602 of Cry IC, or a sequence substantially similar to said sequence, with the proviso that if the sequence comprising amino acids 478 to 602 of CryIC is fused directly to the C-terminus of domain II of CryIA, CryIB, CryID, CryIE, or CryIG, then the folding of the fusion product is satisfactory to yield an insecticidal component of the fragment. The routineer in the art will recognize that it may be necessary to add a peptide region to the C- 20 terminus of domain II that spaces the C-terminal region of CryIC apart, thus enabling it to fold in such a way as to exhibit insecticidal activity.

It is most particularly preferred that the toxin fragment according to the invention comprises one of the following:

- i) an amino acid sequence from about amino acid 1 to about amino acid 620 in SEQ ID NO:6, 25 or an amino acid sequence from about amino acid 1 to about amino acid 620 in SEQ ID NO:6, wherein with respect to said sequence, at least one of the following alterations is present:

Ile at position 609 is replaced with Leu,

Ala at position 618 is replaced with Glu,

Ser at position 620 is replaced with Tyr;

- ii) an amino acid sequence from about amino acid 1 to about amino acid 627 in SEQ ID NO:8, or an amino acid sequence from about amino acid 1 to about amino acid 627 in SEQ ID NO:8, wherein with respect to said sequence, at least one of the following alterations is present:

5 Ile at position 616 is replaced with Leu,

Ala at position 625 is replaced with Glu,

Ser at position 627 is replaced with Tyr; and

- iii) an amino acid sequence from about amino acid 1 to about amino acid 602 in SEQ ID NO:12.

10 Whatever amino acid alterations are permitted, however, one or more of the following residues indicated sequence-wise with respect to the CryIC sequence is invariable: Phe (501), Val (478), Trp (479), and Thr (486).

15 The invention also includes a hybrid toxin comprising the above disclosed fragment or a toxin at least 85% similar to such a hybrid toxin, which has substantially similar insecticidal activity or receptor binding properties.

The invention still further includes pure proteins that are at least 90% similar to the toxin fragments or hybrid toxins according to the invention.

20 The invention still further includes recombinant DNA comprising a sequence encoding a protein comprising an amino acid sequence of one of the above-disclosed toxins or fragments thereof. The invention still further includes recombinant DNA comprising the sequence from about nucleotide 1 to about nucleotide 1860 given in SEQ ID NO:5, or DNA similar thereto encoding a substantially similar protein; or recombinant DNA comprising the sequence from about nucleotide 1 to about nucleotide 1881 in SEQ ID NO:7, or DNA similar thereto encoding a substantially similar protein; or recombinant DNA comprising the sequence from about nucleotide 1 to about nucleotide 1806 in SEQ ID NO:11, or DNA similar thereto encoding a substantially similar protein.

25 In the context of the present invention, “similar DNA” means a test sequence that is capable of hybridizing to the inventive recombinant sequence. When the test and inventive sequences are

double stranded, the nucleic acid constituting the test sequence preferably has a TM within 20°C of that of the inventive sequence. In the case that the test and inventive sequences are mixed together and denatured simultaneously, the TM values of the sequences are preferably within 10°C of each other. More preferably, the hybridization is performed under stringent conditions, with either the
5 test or inventive DNA preferably being supported. Thus, either a denatured test or inventive sequence is preferably first bound to a support and hybridization is effected for a specified period of time at a temperature of between 50 and 70°C in double strength citrate buffered saline containing 0.1% SDS, followed by rinsing of the support at the same temperature but with a buffer having a reduced SC concentration. Depending upon the degree of stringency required, and thus the degree
10 of similarity of the sequences, such reduced concentration buffers are typically single strength SC containing 0.1% SDS, half strength SC containing 0.1% SDS and one tenth strength SC containing 0.1% SDS. Sequences having the greatest degree of similarity are those the hybridization of which is least affected by washing in buffers of reduced concentration. It is most preferred that the test and inventive sequences are so similar that the hybridization between them is substantially unaffected by washing or incubation in one tenth strength sodium citrate buffer containing 0.1% SDS. Typical stringent conditions are as follows: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C.

20 The recombinant DNA may further encode a protein having herbicide resistance, plant growth-promoting, anti-fungal, anti bacterial, anti-viral, and/or anti-nematode properties. In the case that the DNA is to be introduced into a heterologous organism, it may be modified to remove known mRNA instability motifs (such as AT rich regions) and polyadenylation signals, and/or codons that are preferred by the organism into which the recombinant DNA is to be inserted may be used so that expression of the thus modified DNA in the organism yields substantially similar protein to that obtained by expression of the unmodified recombinant DNA in the organism in
25 which the protein components of the hybrid toxin or toxin fragments are endogenous.

The invention still further includes a DNA sequence complementary to one that hybridizes under stringent conditions with the recombinant DNA according to the invention.

Also included in the present invention are the following: a vector containing such a recombinant (or complementary thereto) DNA sequence; a plant or microorganism that includes and enables expression of such DNA; plants transformed with such DNA; the progeny of such plants that contain the DNA stably incorporated and heritable in a Mendelian manner; and/or the 5 seeds of such plants and such progeny.

The invention still further includes protein derived from expression of the recombinant DNA of the invention, and insecticidal protein produced by expression of the recombinant DNA within plants transformed therewith.

The invention still further includes the following: an insecticidal composition containing 10 one or more of the toxin fragments or toxins comprising them according to the invention; a process for combating insects that comprises exposing them to such fragments or toxins or compositions; and an extraction process for obtaining insecticidal proteins from organic material containing them, comprising submitting the material to maceration and solvent extraction.

DESCRIPTION OF THE FIGURES

Figure 1 shows the generation of hybrid crystal protein genes via *in vivo* recombination. Tandem plasmids (pBD560 and pBD 650) carrying two truncated crystal protein genes in direct repeat orientation are constructed. The 5' located gene (open bar) lacks the protoxin encoding region (solid bar) and of the 3' located gene (dashed bar) part of the domain I encoding region is deleted. *In vivo* recombination between homologous regions (domain II and III) occurs in *recA* + strain JM101. Selection against non-recombinants by digestion with *NotI* and *BamHI* and subsequent transformation results in sets of plasmids encoding hybrid crystal proteins.

Figure 2 shows the alignment of amino acid residues 420 to 630 of CryIE and CryIC. The border between domain II and III is indicated. Only amino acid residues of CryIC that differ from CryIE are depicted; identical residues are indicated by dots. The crossover positions (G27, H13, 25 H7, H8, H17, and H21) in the CryIE/CryIC hybrid toxin fragments according to the invention are indicated on the Figure.

Figure 3 shows the alignment of amino acid residues 420 to 630 of CryIE and CryIC. The border between domain II and III is indicated. Only amino acid residues of CryIC that differ from CryIE are depicted; identical residues are indicated by dots. The crossover positions (F59, F71, F26, and E7) in the CryIC/CryIE hybrid toxin fragments are indicated on the Figure.

5 Figure 4 shows the results of heterologous competition experiments. Biotinylated CryIC (panel A) and G27 (panel B) are incubated with *S. exigua* BBMV vesicles in the absence (lanes a) or presence of an excess of unlabelled protein as indicated. After the incubation, the vesicles are washed, loaded on a SDS-polyacrylamide gel and blotted to a nitrocellulose membrane. Biotinylated crystal proteins, re-isolated with the vesicles, are visualized using streptavidin-peroxidase conjugate and are indicated on the Figure with an arrow head.

10 Figure 5 shows the plasmid map of pSB456, which encodes the G27 hybrid toxin fragment and is used to transform the crystal toxin minus strain B.t. 51.

15 Figure 6A shows the alignment of the *cry1G* and *cry1C* genes with the crossover points of the *cry1G/cry1C* hybrids. The position relative to the first nucleotide of the start codon of *cry1G* is shown.

Figure 6B shows the alignment of the encoded Cry1G and Cry1C proteins with the crossover points of the Cry1G/Cry1C hybrids. The approximate position of the domain II-III border is indicated by #. The position relative to the initiation codon of Cry1G is also indicated.

20 Figure 7 shows the results of assays measuring the toxicity of Cry1G/Cry1C hybrid toxins towards *Spodoptera exigua*.

DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 shows the nucleotide sequence of the CryIC gene from B.t. sub. sp. *entomocidus* 60.5.

25 SEQ ID NO:2 shows the amino acid sequence of the protein encoded by the CryIC gene shown in SEQ ID NO:1.

SEQ ID NO:3 shows the nucleotide sequence of the CryIE gene from B.t. sub. sp. *kenyae* 4FL.

SEQ ID NO:4 shows the amino acid sequence of the protein encoded by the CryIE gene shown in SEQ ID NO:3.

5 SEQ ID NO:5 shows the nucleotide sequence encoding a preferred CryIE/CryIC B.t. hybrid toxin fragment according to the invention.

SEQ ID NO:6 shows the amino acid sequence of the protein encoded by the nucleotide sequence shown in SEQ ID NO:5.

10 SEQ ID NO:7 shows the nucleotide sequence of a CryIA/CryIC hybrid toxin fragment according to the invention.

SEQ ID NO:8 shows the amino acid sequence of the protein encoded by the nucleotide sequence depicted in SEQ ID NO:7.

SEQ ID NO:9 shows the nucleotide sequence of a B.t. CryIG gene.

15 SEQ ID NO:10 shows the amino acid sequence of the protein encoded by the CryIG gene shown in SEQ ID NO:9.

SEQ ID NO:11 shows the nucleotide sequence encoding a preferred CryIG/CryIC B.t. hybrid toxin fragment (hybrid HK28-24) according to the invention.

SEQ ID NO:12 shows the amino acid sequence of the protein encoded by the nucleotide sequence shown in SEQ ID NO:12.

20 SEQ ID NOs:13-15 are oligonucleotides.

The invention will be further apparent from the following non-limiting Examples, which describe the production of B.t. hybrid toxin fragments according to the invention, taken in conjunction with the associated Figures and Sequence Listing.

EXAMPLES

Production Of Plasmids Encoding Hybrid Toxin Fragments

In the production of plasmids carrying the CryIC or CryIE genes, *Escherichia coli* XLI-blue (Stratagene Inc.) is used as plasmid host except in cases where JM101 is used as *recA+* background.

- 5 A vector for the expression of crystal proteins in *E. coli* is derived from pKK233-2 (Pharmacia LKB Biotechnology). The size of pKK233-2 is reduced by deleting an *EcoRI-PvuII* fragment carrying the gene encoding tetracycline resistance. Subsequently a 6 bp *XhoI* linker is ligated into the *HindIII* site resulting in pBD10. Plasmid BK+ is created by insertion of a *BglII* linker in the *SacI* site of Bluescript SK+ (Stratagene Inc.). The polylinker of BK+ from *BglII* to *XhoI* is
 10 introduced between the *NcoI-XhoI* site in pBD10. The resulting expression vector pBD11 contains the highly expressed *trc* promoter, the *lacZ* ribosome binding site and ATG initiation codon. The initiation codon overlaps with a *NcoI* site and is followed by the polylinker to facilitate insertions into the vector. Transcription is terminated by the *rrnB* transcription terminator.

- 15 The cloning of the *cryIC* and *cryIE* genes from *B.t. sub. sp. entomocidus* 60.5 and *kenya* 4F1 respectively is as described previously (Honée *et al.*, 1990 (Appl. Environ. Microbiol. 56, pp. 823-825); Visser *et al.*, 1990 (J. Bacteriol. 172, pp. 6783-6788)). For cloning purposes, an *NcoI* site overlapping with the start codon of *cryIC* is created by *in vitro* mutagenesis. A *BglII* site is created directly downstream of the translation termination codon of *cryIC* by site directed mutagenesis, resulting in the sequence ATAAGATCTGTT (SEQ ID NO:13 - stop-codon
 20 underlined). The *NcoI-BglII* fragment containing the *cryIC* coding region is ligated into pBD11, resulting in CryIC expression plasmid pBD150. pBD155 is a derivative of pBD150, in which the polylinker sequences 3' of *cryIC* are deleted.

- A *DraI* fragment from pEM14 (Visser *et al.*, 1990) containing the complete *cryIE* gene is cloned in the *EcoRV* site of SK+, resulting in plasmid pEM15. Subsequently, an *NcoI* site is
 25 introduced by site directed mutagenesis at the start codon of the gene, and *cryIE* is transferred as an *NcoI-XhoI* fragment to pBD11, resulting in CryIE expression plasmid pBD160.

Plasmids carrying only toxic fragment-encoding regions of the *cryI* genes are constructed. *Bgl*II linkers are ligated to *Xmn*I sites present at bp position 1835 of *cryIC*, and to the *Hgi*A I site at position 1839 of *cryIE*. Subsequently, *Nco*I-*Bgl*II fragments containing the *cryIC* (1835 bp) and *cryIE* (1839 bp) toxic fragment-encoding regions are ligated into pBD11, resulting in pBD151 and 5 pBD161 respectively as described below.

Tandem plasmids used for the generation of *cryIC-cryIE* hybrid genes are constructed as follows: *Bam*HI linkers are ligated to pBD160 digested with *Hpa*I. This DNA is incubated with *Bam*HI and *Xho*I and the truncated *cryIE* gene running from bp 704 is ligated into pBD151 resulting in pBD560. To construct a tandem plasmid for the generation of *cryIE-cryIC* hybrids, 10 pBD155 is digested with *Nsi*I and *Xho*I. The fragment carrying the truncated *cryIC* gene, running from bp 266, is ligated into *Pst*I-*Xho*I digested pBD161, resulting in plasmid pBD650. Due to polylinker sequences, unique *Not*I and *Bam*H1 restriction sites are present between the truncated *cryI* genes present in the tandem plasmids pBD560 and pBD650.

DNA Manipulations And Construction Of Hybrid Toxins

All recombinant DNA techniques are as described by Sambrook *et al.* 1989 (in "Molecular Cloning, A Laboratory Manual: Cold Spring Harbour Press, Cold Spring Harbour). DNA sequencing is performed by the dideoxytriphosphate method with fluorescent dyes attached to the dideoxynucleotides. Analysis is automated by using an Applied Biosystems 370A nucleotide sequence analyzer.

The homology present between *cryI* genes permits intramolecular recombination *in vivo*. Two tandem plasmids are created, each carrying two truncated crystal protein genes overlapping only in domains II and III. Therefore, recombination occurs only in regions encoding domains II and III. In-frame recombinations, which can be selected for by restriction enzyme digestion, generate plasmids that express full size 140 kDa hybrid protoxins. To generate *in vivo* 25 recombinants, a tandem plasmid (either pBD560 or pBD650; Figure 2) is transferred to JM101. 5 mg of DNA is isolated from independently generated recombinants and is digested with *Not*I and *Bam*HI cutting between the two truncated *cryI* genes to select against non-recombinants, and the

DNA is transformed to *E. coli* XL1-blue. 5 single colonies are grown and protein patterns and plasmid content are analyzed.

CryIC/CryIE and CryIE/CryIC hybrid toxins are generated using the tandem plasmids pBD560 and pBD650 respectively, which are allowed to recombine in a *recA+* background. DNA 5 is isolated, digested, and transferred to *recA-* strain as described above.

100 colonies of 20 independent experiments are analyzed on SDS-PAGE. 85% of these clones produce a 140 kDa protein indicating in frame recombinations between *cryIC* and *cryIE*, and *cryIE* and *cryIC*, respectively. In *E. coli*, CryI proteins are produced as crystals that can be solubilized *in vitro* at high pH. Approximately 15% of hybrid toxins produced as above are 10 solubilized at high pH. The recombinants producing soluble hybrid toxins are first classified using restriction enzymes. Subsequently, for each class, the crossover point of selected hybrids is determined by DNA sequence analysis. All crossovers resulting in soluble hybrid toxins occur in or very close to domain III.

Protein Purification And Analysis

15 Crystal proteins are isolated essentially as described by Convents *et al.* (*J. Biol. Chem.* 265, pp. 1369-1375; *Eur. J. Biochem.*, 195, pp. 631-635). Briefly, recombinant *E. coli* are grown at 30°C in 250 ml TB medium to an OD₆₆₀ of 10-15. Crystals isolated from the *E. coli* lysate are solubilized during incubation for 2 hours in 20mM Na₂CO₃, 10 mM dithiothreitol, 100 mM NaCl, pH10, at 37°C. The pH of the solution is lowered to 8 with Tris-HCl and incubated with trypsin. 20 The toxin solution is dialysed against 20 mM Tris-HCl, 100 mM, NaCl pH9. Subsequently, the toxic fragment is purified on a Mono Q 5/5 column connected to a fast-protein liquid chromatography (FPLC) system (Pharmacia LKB Biotechnology). Proteins are separated by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoreses.

Biochemical Analysis And Isolation Of 65 kDa Toxic Fragments

25 Isolated crystals of purified CryIC, CryIE, and the hybrid proteins are solubilized at high pH and incubated with trypsin. Like CryIC and CryIE, all soluble hybrid toxins with crossovers in domain III are converted to stable 65 kDa fragments. The 65 kDa fragments can be purified using

anion exchange chromatography under similar conditions as the parental proteins. Hybrids F59 and F71, which have crossovers in domain II, are completely degraded by trypsin. Apparently, although these hybrids do not precipitate as insoluble aggregates, trypsin cleavage sites buried in the parental proteins may become exposed to trypsin. Because of this phenomenon, no 65 kDa fragments are 5 isolated from F59 and F71.

Table 1 shows the constitution of 5 CryIE/CryIC hybrid toxins: (G27, H8, H17, H13, H7, and H21) and 4 CryIC/CryIE hybrid toxins (F59, F71, F26, and E7) with reference to the CryIC and CryIE proteins from which they are derived. The amino acid sequences of the CryIE/CryIC toxins comprising the toxic fragments of the present invention run to amino acid 1189 of the CryIC parent 10 protein. The amino acid sequences of the CryIC/CryIE hybrid toxins run to amino acid 1171 of the CryIE parent protein. Table 1 also shows the relative insecticidal effectiveness of these various hybrid toxins with respect to the CryIC and CryIE proteins.

TABLE 1

Toxin	aa IE	aa IC	<i>M. sexta</i>	<i>S. exigua</i>	<i>M. brassicae</i>
IC	0	28-627	++	++	++
IE	29-612	0	++	-	-
G27	1-474	478-627	++	++(+)	+(+)
H8	1-497	501-627	++	-	-
H17	1-529	533-627	++	-	-
H7	1-577	588-627	-	-	-
H21	1-605	621-627			
F59	421-612	1-423	-	-	-
F71	428-612	1-430	-	-	-
F26	455-612 (1171)	1-458	++	-	-
E7	588-612 (1171)	1-602	++	++	++

Table 1. Constitution and toxicity of hybrid toxins with respect to the parent proteins. Most bioassays were performed with purified toxin fragments. In case of CryIC these run from about aa 28 to about aa 627, and in case of CryIE till 612. The length of complete protoxins is indicated between brackets.

5

Insect Toxicity Assays And Insecticidal Activity of *cryIC/cryIE* Hybrid Gene Products

Bacterial cultures are concentrated to OD₆₆₀ 6.0, and 100 ml are spotted on 2 cm² of artificial diet in a 24-well tissue culture plate. Alternatively, diluted samples of purified toxins are applied to the diet. Second instar larvae of either *S. exigua*, *M. brassicae*, or *M. sexta* are fed on this diet (16 per sample dilution) for 5 days, after which the larval weight is scored. The relative growth (EC50, the concentration giving 50% growth reduction) is determined by calculating the ratio between the mean weight of larvae grown on diet supplemented with toxin and the mean weight of control larvae grown on a diet without toxin. *M. sexta* egg layers are supplied by Carolina Biological Supply Company, North Carolina, USA.

The toxic fragments encoded by the hybrid gene products are tested for activity towards three different insect species as described above. *M. sexta* is susceptible to both CryIC and CryIE. As may be anticipated from their sensitivity to trypsin, hybrids F59 and F71 are not active against this insect (Table 1). Although H7 is converted by trypsin to stable 65 kDa proteins, it is not toxic to *M. sexta*. All of the other hybrids given in Table 1 are toxic and are apparently in the native, biologically active conformation.

The 65 kDa fragment of CryIC is highly toxic towards *S. exigua* and *M. brassicae*, whereas CryIE is not. G27 (Table 1; Figure 2), a CryIE-CryIC hybrid with a crossover at the junction of domain II and III is active towards both insects. This demonstrates that domain III of CryIC confers full activity towards *S. exigua* and *M. brassicae*. Hybrid H8, which differs in only three amino acid residues (see Figure 3) from G27, although active against *M. sexta*, is not active against *S. exigua* and *M. brassicae*.

F26 (Table 1; Figure 3), the reciprocal hybrid of G27, in which domain III of CryIC has been exchanged by domain III of CryIE, is not active against *S. exigua* or *M. brassicae*. Apparently, although the protein is toxic to *M. sexta*, the CryIC sequences running from amino acid

28-462 are not sufficient to kill *S. exigua* and *M. brassicae*. Only when CryIC sequences up to amino acid residue 602 are present in the hybrid (E7) is insecticidal activity against these insects restored.

The present disclosure indicates that amino acid residues from 478-602 of CryIC can confer
5 high insecticidal activity to CryIE against *S. exigua* and *M. brassicae*.

Biotinylation Of Crystal Proteins And Binding Assays

Biotinylation is performed using biotin-N-hydroxysuccinimide ester essentially as described by the manufacturer (Amersham). 1 mg of crystal protein is incubated with 40 ml biotinylation reagent in 50 mM NaHCO₃, 150 mM NaCl, pH8, for one hour at 20°C. The solution is loaded on a Sephadex 25 column equilibrated with the same buffer containing 0.1% BSA to remove unbound biotin, and samples of the fractions are spotted on a nitrocellulose membrane. Fractions containing biotinylated crystal proteins are visualized using streptavidine-peroxidase conjugate (Amersham) which catalyzes the oxidation of luminol, resulting in chemiluminescence (ECL, Amersham), and pooled.

Brush border membrane vesicles are isolated as described by Wolfersberger *et al.* (1987) (Comp. Biochem. Physiol. 86a, pp. 301-308) except that the vesicles are washed once more with isolation buffer containing 0.1% Tween 20. Binding of biotinylated crystal proteins to brush border membrane vesicles (100 mg/ml) is performed in 100 ml of PBS containing 1% BSA, 0.1% Tween-20 (pH 7.6). Vesicles (20 µg vesicle protein) are incubated with 10 ng biotinylated crystal proteins in the presence or absence of 1000-fold excess of unlabelled crystal proteins for 1 hour at 20°C. Subsequently, the vesicles are re-isolated by centrifugation for 10 minutes at 14,000 g in an Eppendorf centrifuge, washed twice with binding buffer, re-suspended in sample buffer, denatured by heating, and loaded on 7.5% polyacrylamide gels. After electrophoresis, proteins are blotted to nitrocellulose membranes and biotinylated crystal proteins that are re-isolated with the vesicles are visualized by incubation of the nitrocellulose with streptavidin-peroxidase conjugate (Amersham), which catalyzes the oxidation of luminol, resulting in chemiluminescence (ECL, Amersham).

Because binding to epithelial gut cells is a key step in the mode of action of crystal proteins, the binding of crystal proteins to *S. exigua* brush border membrane vesicles is investigated in heterologous competition experiments. Competition experiments demonstrate that the binding of labeled CryIC (Figure 4A, lane a) and labeled F26 (not shown) can be outcompeted by an excess of 5 both unlabelled CryIC (lane b) or F26 (lane e) but not with an excess of G27 (lane c) or CryIE (lane d). Furthermore, binding of labeled G27 (Figure 4B, lane a) and labeled CryIE (not shown) can be outcompeted by an excess of G27 (lane b) or CryIE (lane d), but not with an excess of CryIC (lane a) or F26 (lane e). From these results, it is concluded that G27 and CryIE recognize the same 10 binding sites on *S. exigua* midgut membranes and that these sites differ from those that are recognized by CryIC and F26. The toxicity and binding assays combined demonstrate that G27 is as toxic as CryIC but that it binds a receptor different therefrom. As insects can develop resistance against a crystal protein by changing receptor binding characteristics, G27 may be used in resistance management programs as an alternative to CryIC.

Expression of *cryIE/cryIC* Hybrid Toxin Genes In Heterologous Systems

The G27 *cryIE/cryIC* hybrid toxin gene is expressed in *E.coli*, and the gene product exhibits at least the same insecticidal activity (at least against *Spodoptera*) as CryIC. Moreover, the product exhibits an increase in such activity when expressed in a *Bacillus thuringiensis* strain (see below). The gene encoding the G27 hybrid toxin is introduced into a suitable shuttle vector system, which is then introduced into an appropriate B.t. host. Such transformed cells are then cultured, and the resulting toxin from both whole cultures and purified crystals is assayed for insecticidal activity.

Construction Of A G27-Containing Shuttle Vector, Transformation Of Bt51, And Purification Of Toxin Protein Therefrom

The gene encoding hybrid G27 (3.4 kb) is cleaved from a pKK233 *E. coli* expression plasmid using *NcoI* and *Xhol*. The *Xhol* site is filled in using the Klenow fragment of *E. coli* DNA 25 Polymerase I. The resulting fragment is ligated to *NcoI/SmaI*-digested pSB635 (pBluescriptKS+, *P_{cryIC}*, and the CryIA(c) transcription terminator). The resulting plasmid, pSB453, is digested with *Apal* and *NotI*, yielding a 4.2 kbp fragment carrying the promoter, the hybrid G27 ORF, and the terminator. This fragment is ligated to *Apal/NotI*-digested pSB634 (shuttle vector containing

pBC16.1 and pBluescriptKS+), yielding pSB456 (see Figure 5). Plasmid DNA isolated from *E. coli* DH10B is used to transform the crystal toxin minus B.t. strain, Bt51. Positive isolates are tetracycline resistant, show the presence of pSB456, and contain large inclusions corresponding to a 135 kDa protein (as determined by SDS-PAGE). G27 hybrid toxin samples are prepared from 5 cultures of transformed Bt51 grown through sporulation at 30°C in CYS-Tc¹⁰ media. Insecticidal bioassays (Table 2) are performed on both full whole cultures and on washed crystal protein preparations. Controls include Bt51 (pSB440) containing the CryIC toxin and Bt51 (pSB636) containing CryIE. Toxin concentrations are estimated by SDS-PAGE.

TABLE 2

Toxin	LC ₅₀			
	Whole Culture (ppt)		Washed Crystal Protein (ppm)	
CryIC	56(2)	36(2)	40(4)	7.8(2)
CryIE	79(1)	78(1)	33(4)	11.1(6)
G27	29(2)	21(2)	25(4)	4.7(4)
Ratio (IC/G27)	1.93	1.71	1.60	1.66
				1.35

Table 2. Bioassay of the hybrid toxin G27 in comparison to CryIC and CryIE. The number of samples is given in parentheses. The hybrid toxin G27 is about 50% more effective than either CryIE or CryIC with respect to toxicity to *Spodoptera* sp.

Production And Selection Of Cry1G/Cry1C Hybrid Toxins

To obtain Cry1G/Cry1C hybrid toxins by *in vivo* recombination, expression vector pHK26 was constructed with a C-terminal truncated *cry1G* (a.k.a. Cry9A) gene (see, SEQ ID NO:9) and a N-terminal truncated *cry1C* gene (see, SEQ ID NO:1) cloned in tandem. The plasmid pHK26 contains the *trc* promoter followed by bases 1-1650 of *cry1G*, part of the pBluescript SK+ polylinker, and bases 266-3570 of *cry1C*. pHK26 is a derivative of pRM7 in which the *cry1A(b)* coding sequences from *NcoI* to *BglII* have been replaced by part of the *cry1G* gene. The 1650 bp *NcoI-BglII* *cry1G* fragment was isolated by PCR amplification from plasmid pSB1501 using the primers dGCTAGCCATGGATCAAAATAACACCGAATTATTG (SEQ ID NO:14) and dCTGGTCAGATCTTGAAGTAGAGCTCC (SEQ ID NO:15). After allowing

intramolecular recombination of pHK26 in *E. coli* strain JM101, plasmid DNA was isolated and digested with *Bam*HI and *Pin*AI to linearize non-recombinant plasmids. Both *Bam*HI as well as *Pin*AI have unique recognition sites in pHK26, in the polylinker and at position 1074 of *cryIC*, respectively. The overlap between the two truncated *cry* genes in pHK26 that allows
5 recombination extends approximately 1400 base pairs, yet primary interest was in recombinations in or close to domain III. Therefore, *Pin*AI was chosen rather than a second enzyme with a recognition site in the polylinker. This strategy allowed linearization of recombinants with crossovers in front of the *Pin*AI site, thereby effectively selecting for recombinants with crossovers in or near the domain III-encoding sequences.

10 Digested plasmids were transferred to *E. coli* XL1 cells by transformation, and plasmids from transformants were subsequently analyzed by restriction enzyme digestion and DNA electrophoresis. Over 80% of the transformants contained a plasmid with an insert size corresponding to a single, intact *cry* gene, indicating that selection for homologous recombination events had been efficient. Thirty separate colonies were grown in TB medium and assayed for production of alkaline-soluble protoxins that could be converted to stable 65 kD toxic fragments upon trypsin incubation. This screening method yielded 6 colonies producing a stable 65 kD toxic fragment of the expected size. The location of the crossovers in the hybrid genes was first determined by restriction analysis and finally by nucleotide sequencing. Only three different crossover sites occurred in the 6 hybrid genes thus tested. The hybrid genes were
15 designated HK28-12, HK28-1, and HK28-24. The location of the three different crossover sites is shown in Figures 6A and 6B. The three crossovers are located close to the border between domains II and III, with the three hybrid toxins, designated HK28-12, HK28-1, and HK28-24, differing only one amino acid from each other. Both the solubility of the hybrid protoxins as
20 well as the occurrence of trypsin-resistant products of the expected size suggested that these hybrids proteins were properly folded and might have biological activity. This was subsequently tested against larvae of *Spodoptera exigua*.

Toxicity of CryIG/CryIC Hybrid Toxins Towards *Spodoptera exigua*

The *cryIC*, *cryIG*, and newly isolated *cryIG/cryIC* hybrid genes were introduced in *E. coli* strain XL1-blue and grown for 48 hours at 28°C in TB medium with ampicillin. Cells were disrupted by sonification, and protoxin-containing crystals were isolated by centrifugation. After 5 washing the crystals, the protoxins were solubilized at high pH and the concentration of the 140 kD protoxins in the supernatant was estimated by SDS-PAGE. These samples were assayed for their toxicity to *S. exigua* larvae. Results are shown in Figure 7.

CryIG protoxin is much less toxic to *S. exigua* than CryIC. The hybrids containing domain III of CryIC are significantly more toxic than Cry1G. These results show that, as was demonstrated earlier for CryIE and Cry1A(b), Cry1G can be made considerably more toxic to *S. exigua* by substituting its domain III with that of CryIC. For example, hybrid HK28-24 (SEQ ID NO:12) is much more toxic to *S. exigua* than Cry1G (SEQ ID NO:10). Hybrid HK28-24 is also much more toxic to *S. frugiperda* than Cry1G (data not shown).

Although the present invention has been particularly described with reference to the production of Cry1E/Cry1C and Cry1G/Cry1C hybrid toxins, the routineer in the art will appreciate that many other hybrid toxins having improved insecticidal characteristics may be produced according to the present disclosure. SEQ ID NOS:7 and 8, for example, depict the nucleotide and amino acid sequences, respectively, of a CryIA/CryIC hybrid toxin fragment according to the invention that has improved insecticidal activity. Hybrid toxins may be produced comprising domain III of CryIC and the N-terminal region, including domains I and II, of any other Cry protein. In terms of bioassays, the hybrid toxin-carrying transformants may be grown in SOP media to expedite the assay procedures and reduce the volumes of material required. Moreover, the genes encoding the Cry1E/Cry1C, Cry1G/Cry1C, Cry1A/Cry1C, and/or other hybrid toxins according to the invention may be transferred into toxin-encoding strains of B.t. and/or integrated 20 into the chromosome of selected strains of B.t. or introduced into plant genomes to provide for insecticidal activity *in situ* within the plant *per se*. In this regard, it is particularly preferred that the recombinant DNA encoding the toxins is modified so that codons that are preferred by the plant 25 into which the recombinant DNA is to be inserted are used, whereby expression of the thus

modified DNA in the plant yields substantially similar protein to that obtained by expression of the unmodified recombinant DNA in the organism in which the protein components of the hybrid toxin or toxin fragments are endogenous.

**Isolation of Additional B.t. Toxin Genes Based on Sequence Similarity to Known B.t. Toxin
5 Genes**

A library is plated at a density of approximately 8,000 pfu per 10 cm Petri dish, and filter lifts of the plaques are made after 7 hours growth at 37°C. The plaque lifts are probed with the cDNA set forth in SEQ ID NO:1, 3, or 9 labeled with 32P-dCTP by the random priming method by means of a PrimeTime kit (International Biotechnologies, Inc., New Haven, CT). Exemplary hybridization conditions are 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C. After hybridization overnight, the filters are washed with 2X SSC, 1% SDS at 50°C. Positively hybridizing plaques are detected by autoradiography. After purification to single plaques, cDNA inserts are isolated, and their sequences determined by the chain termination method using dideoxy terminators labeled with fluorescent dyes (Applied Biosystems, Inc., Foster City, CA). This experimental protocol can be used by one of ordinary skill in the art to obtain B.t. toxin genes substantially similar to those set forth in the Sequence Listing.

What Is Claimed Is:

1. An isolated *Bacillus thuringiensis* hybrid toxin fragment, comprising:
 - a) at a C-terminus of said fragment, domain III of a first Cry protein; and
 - b) at an N-terminus of said fragment, an N-terminal region of a second Cry protein.
2. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said first Cry protein is CryIC.
3. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said second Cry protein is selected from the group consisting of CryIA, CryIE, and CryIG.
4. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 3, wherein said second Cry protein is CryIA.
5. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 3, wherein said second Cry protein is CryIE.
6. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 3, wherein said second Cry protein is CryIG.
7. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said first Cry protein is CryIC, and wherein said second Cry protein is CryIA, CryIE, or CryIG.
8. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said N-terminal region of said second Cry protein comprises domain II of said second Cry protein.
9. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said N-terminal region of said second Cry protein comprises domains I and II of said second Cry protein.
10. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said C-terminus comprises the sequence from amino acid position 454 to position 602 of Cry IC, or a

sequence substantially similar to said sequence from amino acid position 454 to position 602 of Cry IC.

11. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 10, wherein said C-terminus comprises the sequence from amino acid position 454 to position 602 of SEQ ID NO:2, or a sequence substantially similar to said sequence from amino acid position 454 to position 602 of SEQ ID NO:2.

12. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said C-terminus comprises the sequence from amino acid position 478 to 602 of Cry IC, or a sequence substantially similar to said sequence from amino acid position 478 to 602 of Cry IC.

13. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 12, wherein said C-terminus comprises the sequence from amino acid position 478 to position 602 of SEQ ID NO:2, or a sequence substantially similar to said sequence from amino acid position 478 to position 602 of SEQ ID NO:2.

14. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, comprising a sequence selected from the group consisting of:

- a) amino acids 1-620 of SEQ ID NO:6;
- b) amino acids 1-620 of SEQ ID NO:6, wherein at least one of the following substitutions is present:

Ile at position 609 is replaced with Leu,

Ala at position 618 is replaced with Glu,

Ser at position 620 is replaced with Tyr; and

- c) a sequence substantially similar to amino acids 1-620 of SEQ ID NO:6.

15. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, comprising a sequence selected from the group consisting of:

- a) amino acids 1-627 of SEQ ID NO:8;
- b) amino acids 1-627 of SEQ ID NO:8, wherein at least one of the following substitutions is present:

Ile at position 617 is replaced with Leu,
Ala at position 625 is replaced with Glu,
Ser at position 627 is replaced with Tyr; and

- c) a sequence substantially similar to amino acids 1-627 of SEQ ID NO:8.

16. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, comprising a sequence selected from the group consisting of:

- a) amino acids 1-602 of SEQ ID NO:12; and
b) a sequence substantially similar to amino acids 1-602 of SEQ ID NO:12.

17. An isolated DNA molecule encoding a protein that comprises the amino acid sequence of the hybrid toxin fragment of claim 1.

18. An isolated DNA molecule encoding a protein that comprises the amino acid sequence of the hybrid toxin fragment of claim 14.

19. An isolated DNA molecule encoding a protein that comprises the amino acid sequence of the hybrid toxin fragment of claim 15.

20. An isolated DNA molecule encoding a protein that comprises the amino acid sequence of the hybrid toxin fragment of claim 16.

21. An isolated *Bacillus thuringiensis* hybrid toxin fragment according to claim 1, wherein said hybrid toxin fragment binds to a binding site in an insect gut that is different than the site bound by said first Cry protein.

22. An isolated DNA molecule according to claim 17, which further encodes a protein having at least one of the following properties: herbicide resistance, plant growth-promoting, anti-fungal, anti-bacterial, anti-viral, and anti-nematode properties.

23. An isolated DNA molecule according to claim 17, which is modified to optimize expression in a heterologous host, said modifications selected from the group consisting of codon optimization for the intended host and removal of known mRNA instability motifs or polyadenylation signals.

24. An isolated DNA molecule that is complementary to the DNA molecule of claim 17.
25. A recombinant vector comprising the DNA molecule of claim 17.
26. An isolated cell transformed with the DNA molecule of claim 17.
27. A plant transformed with the DNA molecule of claim 17, wherein the progeny of such plant contains the DNA molecule stably incorporated and heritable in a Mendelian manner.
28. Seeds of the plant of claim 27.
29. Protein derived from expression of the DNA molecule of claim 17.
30. An insecticidal composition comprising the hybrid toxin fragment of claim 1.
31. A process for controlling insects, comprising exposing them to the insecticidal composition of claim 30.
32. A method of producing a protein, comprising expressing the DNA molecule of claim 17.
33. An insecticidal composition comprising the isolated cell of claim 26.
34. A process for controlling insects, comprising exposing them to the insecticidal composition of claim 33.
35. An isolated *Bacillus thuringiensis* hybrid toxin fragment, comprising amino acids 1-602 of SEQ ID NO:12.
36. An isolated *Bacillus thuringiensis* hybrid toxin fragment that has at least 95% sequence identity with, and has substantially the same insecticidal specificity and substantially the same insecticidal activity as the hybrid toxin fragment of claim 35.
37. An isolated DNA molecule encoding a protein that comprises the sequence of the hybrid toxin fragment of claim 35.

38. An isolated DNA molecule encoding a protein that comprises the sequence of the hybrid toxin fragment of claim 36.

39. An isolated DNA molecule that comprises the sequence of nucleotides 1-1806 of SEQ ID NO:11.

40. An isolated DNA molecule that hybridizes to the DNA molecule of claim 39 under the following set of conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C.

ABSTRACT

The present invention provides, *inter alia*, a B.t. hybrid toxin fragment comprising at its C-terminus domain III of a first Cry protein, or a part of said domain or a protein substantially similar to said domain; and comprising at its N-terminus the N-terminal region of a second Cry protein, or 5 a part of said region or a protein substantially similar to said region.

FIG. 1




FIG. 2

CryIE-CryIC HYBRIDS




FIG. 3

CryIC-CryIE HYBRIDS




FIG. 4




FIG. 5





FIG. 6A

	1520	1530	1540	1550	1560	1570
CRYIGTOX	*	*	*	*	*	*
CRYICTOX	AAAAGTCGGCTCGTAACAATACCATTAAATCCAGATAGAATTACACAGATACCATTGACG ::: :::: :: ::::: :: ::::: ::::: :: ::::: :: :					
Hybrid HK28-	CGTAGTGCAACTCTTACAAATACAATTGATCCAGAGAGAATTAAATCAAATACCTTAGTG -12 -1 -24					

FIG. 6B

	490	500	510	520	530
CRYIGTOX	*	*	# *	*	*
CRYICTOX	GGLRQVASNRSSLVMYGWTHKSLARNNTINPDRITQIPLTKVDTRGTGV : TG-----VVFSWTHRSATLTNTIDPERINQIPLVKGFRVWGGT				
Hybrid HK28-	 -12 -1 -24				

FIG. 7



DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe I am an original, first and joint inventor of the subject matter which is claimed
and for which a patent is sought on the invention entitled

Hybrid Toxin

the specification of which was filed on December 31, 1997 as U.S. Application No. 09/001,982.

I hereby state that I have reviewed and understand the contents of the above identified
specification, including the claims.

I acknowledge my duty to disclose all information which is known by me to be material to
the patentability of this application as defined in 37 C.F.R. §1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign
application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any
PCT international application(s) designating at least one country other than the United States
listed below and have also listed below any foreign application(s) for patent or inventor's
certificate or any PCT international application(s) designating at least one country other than
the United States for the same subject matter and having a filing date before that of the
application the priority of which is claimed for that subject matter:

<u>Country, Region or PCT</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Priority Claimed</u>
Great Britain	9318207.9	September 2, 1993	Yes

I hereby claim the benefit under 35 USC §119(e) of any United States provisional
application(s) listed below:

None

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose all information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>United States Application No.</u>	<u>United States Filing or §371 Date</u>	<u>Status or U.S. Patent No.</u>	<u>International Application No.</u>	<u>International Filing Date</u>
08/602,737	February 21, 1996	Pending	PCT/EP94/02909	September 1, 1994

I hereby appoint the attorneys and agents associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please address all communications to J. Timothy Meigs, Novartis Corporation, Patent and Trademark Dept., P.O. Box 12257, Research Triangle Park, NC 27709-2257.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FIRST JOINT INVENTOR:

Full name : **Hendrik Jan Bosch**

Signature : 

Date : 04/09/98 (MM/DD/YY)

Citizenship : Netherlands

Residence : Oortlaan 20
NL-3572 ZM Utrecht
The Netherlands

SECOND JOINT INVENTOR:

Full name : **Willem Johannes Stiekema**

Signature : _____

Date : _____ (MM/DD/YY)

Citizenship : Netherlands

Residence : Leonard Roggeveenstraat 21
NL-6708 SL Wageningen
The Netherlands

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe I am an original, first and joint inventor of the subject matter which is claimed
and for which a patent is sought on the invention entitled

Hybrid Toxin

the specification of which was filed on December 31, 1997 as U.S. Application No. 09/001,982.

I hereby state that I have reviewed and understand the contents of the above identified
specification, including the claims.

I acknowledge my duty to disclose all information which is known by me to be material to
the patentability of this application as defined in 37 C.F.R. §1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign
application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any
PCT international application(s) designating at least one country other than the United States
listed below and have also listed below any foreign application(s) for patent or inventor's
certificate or any PCT international application(s) designating at least one country other than
the United States for the same subject matter and having a filing date before that of the
application the priority of which is claimed for that subject matter:

<u>Country, Region or PCT</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Priority Claimed</u>
Great Britain	9318207.9	September 2, 1993	Yes

I hereby claim the benefit under 35 USC §119(e) of any United States provisional
application(s) listed below:

None

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose all information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>United States Application No.</u>	<u>United States Filing or §371 Date</u>	<u>Status or U.S. Patent No.</u>	<u>International Application No.</u>	<u>International Filing Date</u>
08/602,737	February 21, 1996	Pending	PCT/EP94/02909	September 1, 1994

I hereby appoint the attorneys and agents associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Please address all communications to J. Timothy Meigs, Novartis Corporation, Patent and Trademark Dept., P.O. Box 12257, Research Triangle Park, NC 27709-2257.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FIRST JOINT INVENTOR:

Full name : **Hendrik Jan Bosch**

Signature : _____

Date : _____
(MM/DD/YY)

Citizenship : Netherlands

Residence : Oortlaan 20
NL-3572 ZM Utrecht
The Netherlands

SECOND JOINT INVENTOR:

Full name : **Willem Johannes Stiekema**

Signature : W.J. Stiekema

Date : 04/08/98
(MM/DD/YY)

Citizenship : Netherlands

Residence : Leonard Roggeveenstraat 21
NL-6708 SL Wageningen
The Netherlands

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Bosch, Hendrick J.
Stiekema, Willem J.
- (ii) TITLE OF INVENTION: Hybrid Toxin
- (iii) NUMBER OF SEQUENCES: 15
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Novartis Corporation
 - (B) STREET: 3054 Cornwallis Road
 - (C) CITY: Research Triangle Park
 - (D) STATE: NC
 - (E) COUNTRY: USA
 - (F) ZIP: 27709
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/602,737
 - (B) FILING DATE: 21-FEB-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Meigs, J. Timothy
 - (B) REGISTRATION NUMBER: 38,241
 - (C) REFERENCE/DOCKET NUMBER: 130-4080/PCT/CIP
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 919-541-8587
 - (B) TELEFAX: 919-541-8689

(2) INFORMATION FOR SEQ ID NO: 1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3567 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Bacillus thuringiensis*

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..3567

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATG GAG GAA AAT AAT CAA AAT CAA TGC ATA CCT TAC AAT TGT TTA AGT Met Glu Glu Asn Asn Gln Asn Gln Cys Ile Pro Tyr Asn Cys Leu Ser	48
1 5 10 15	15
AAT CCT GAA GAA GTA CTT TTG GAT GGA GAA CGG ATA TCA ACT GGT AAT Asn Pro Glu Glu Val Leu Leu Asp Gly Glu Arg Ile Ser Thr Gly Asn	96
20 25 30	
TCA TCA ATT GAT ATT TCT CTG TCA CTT GTT CAG TTT CTG GTA TCT AAC Ser Ser Ile Asp Ile Ser Leu Ser Leu Val Gln Phe Leu Val Ser Asn	144
35 40 45	
TTT GTA CCA GGG GGA TTT TTA GTT GGA TTA ATA GAT TTT GTA TGG Phe Val Pro Gly Gly Phe Leu Val Gly Leu Ile Asp Phe Val Trp	192
50 55 60	
GGA ATA GTT GGC CCT TCT CAA TGG GAT GCA TTT CTA GTA CAA ATT GAA Gly Ile Val Gly Pro Ser Gln Trp Asp Ala Phe Leu Val Gln Ile Glu	240
65 70 75 80	
CAA TTA ATT AAT GAA AGA ATA GCT GAA TTT GCT AGG AAT GCT GCT ATT Gln Leu Ile Asn Glu Arg Ile Ala Glu Phe Ala Arg Asn Ala Ala Ile	288
85 90 95	
GCT AAT TTA GAA GGA TTA GGA AAC AAT TTC AAT ATA TAT GTG GAA GCA Ala Asn Leu Glu Gly Leu Gly Asn Asn Phe Asn Ile Tyr Val Glu Ala	336
100 105 110	
TTT AAA GAA TGG GAA GAA GAT CCT AAT AAT CCA GAA ACC ACC AGA Phe Lys Glu Trp Glu Glu Asp Pro Asn Asn Pro Glu Thr Arg Thr Arg	384
115 120 125	
GTA ATT GAT CGC TTT CGT ATA CTT GAT GGG CTA CTT GAA AGG GAC ATT Val Ile Asp Arg Phe Arg Ile Leu Asp Gly Leu Leu Glu Arg Asp Ile	432
130 135 140	
CCT TCG TTT CGA ATT TCT GGA TTT GAA GTA CCC CTT TTA TCC GTT TAT	480

Pro Ser Phe Arg Ile Ser Gly Phe Glu Val Pro Leu Leu Ser Val Tyr			
145	150	155	160
GCT CAA GCG GCC AAT CTG CAT CTA GCT ATA TTA AGA GAT TCT GTA ATT			528
Ala Gln Ala Ala Asn Leu His Leu Ala Ile Leu Arg Asp Ser Val Ile			
165	170	175	
TTT GGA GAA AGA TGG GGA TTG ACA ACG ATA AAT GTC AAT GAA AAC TAT			576
Phe Gly Glu Arg Trp Gly Leu Thr Thr Ile Asn Val Asn Glu Asn Tyr			
180	185	190	
AAT AGA CTA ATT AGG CAT ATT GAT GAA TAT GCT GAT CAC TGT GCA AAT			624
Asn Arg Leu Ile Arg His Ile Asp Glu Tyr Ala Asp His Cys Ala Asn			
195	200	205	
ACG TAT AAT CGG GGA TTA AAT AAT TTA CCG AAA TCT ACG TAT CAA GAT			672
Thr Tyr Asn Arg Gly Leu Asn Asn Leu Pro Lys Ser Thr Tyr Gln Asp			
210	215	220	
TGG ATA ACA TAT AAT CGA TTA CGG AGA GAC TTA ACA TTG ACT GTA TTA			720
Trp Ile Thr Tyr Asn Arg Leu Arg Arg Asp Leu Thr Leu Thr Val Leu			
225	230	235	240
GAT ATC GCC GCT TTC TTT CCA AAC TAT GAC AAT AGG AGA TAT CCA ATT			768
Asp Ile Ala Ala Phe Phe Pro Asn Tyr Asp Asn Arg Arg Tyr Pro Ile			
245	250	255	
CAG CCA GTT GGT CAA CTA ACA AGG GAA GTT TAT ACG GAC CCA TTA ATT			816
Gln Pro Val Gly Gln Leu Thr Arg Glu Val Tyr Thr Asp Pro Leu Ile			
260	265	270	
AAT TTT AAT CCA CAG TTA CAG TCT GTA GCT CAA TTA CCT ACT TTT AAC			864
Asn Phe Asn Pro Gln Leu Gln Ser Val Ala Gln Leu Pro Thr Phe Asn			
275	280	285	
GTT ATG GAG AGC AGC GCA ATT AGA AAT CCT CAT TTA TTT GAT ATA TTG			912
Val Met Glu Ser Ser Ala Ile Arg Asn Pro His Leu Phe Asp Ile Leu			
290	295	300	
AAT AAT CTT ACA ATC TTT ACG GAT TGG TTT AGT GTT GGA CGC AAT TTT			960
Asn Asn Leu Thr Ile Phe Thr Asp Trp Phe Ser Val Gly Arg Asn Phe			
305	310	315	320
TAT TGG GGA GGA CAT CGA GTA ATA TCT AGC CTT ATA GGA GGT GGT AAC			1008
Tyr Trp Gly Gly His Arg Val Ile Ser Ser Leu Ile Gly Gly Gly Asn			
325	330	335	
ATA ACA TCT ATA TAT GGA AGA GAG GCG AAC CAG GAG CCT CCA AGA			1056
Ile Thr Ser Pro Ile Tyr Gly Arg Glu Ala Asn Gln Glu Pro Pro Arg			
340	345	350	
TCC TTT ACT TTT AAT GGA CCG GTA TTT AGG ACT TTA TCA AAT CCT ACT			1104
Ser Phe Thr Phe Asn Gly Pro Val Phe Arg Thr Leu Ser Asn Pro Thr			

355	360	365	
TTA CGA TTA TTA CAG CAA CCT TGG CCA GCG CCA CCA TTT AAT TT ^A CGT Leu Arg Leu Leu Gln Gln Pro Trp Pro Ala Pro Pro Phe Asn Leu Arg			1152
370	375	380	
GGT GTT GAA GGA GTA GAA TTT TCT ACA CCT ACA AAT AGC TTT ACG TAT Gly Val Glu Gly Val Glu Phe Ser Thr Pro Thr Asn Ser Phe Thr Tyr			1200
385	390	395	400
CGA GGA AGA GGT ACG GTT GAT TCT TTA ACT GAA TTA CCG CCT GAG GAT Arg Gly Arg Gly Thr Val Asp Ser Leu Thr Glu Leu Pro Pro Glu Asp			1248
405	410	415	
AAT AGT GTG CCA CCT CGC GAA GGA TAT AGT CAT CGT TTA TGT CAT GCA Asn Ser Val Pro Pro Arg Glu Gly Tyr Ser His Arg Leu Cys His Ala			1296
420	425	430	
ACT TTT GTT CAA AGA TCT GGA ACA CCT TTT TTA ACA ACT GGT GTA GTA Thr Phe Val Gln Arg Ser Gly Thr Pro Phe Leu Thr Thr Gly Val Val			1344
435	440	445	
TTT TCT TGG ACG CAT CGT AGT GCA ACT CTT ACA AAT ACA ATT GAT CCA Phe Ser Trp Thr His Arg Ser Ala Thr Leu Thr Asn Thr Ile Asp Pro			1392
450	455	460	
GAG AGA ATT AAT CAA ATA CCT TTA GTG AAA GGA TTT AGA GTT TGG GGG Glu Arg Ile Asn Gln Ile Pro Leu Val Lys Gly Phe Arg Val Trp Gly			1440
465	470	475	480
GGC ACC TCT GTC ATT ACA GGA CCA GGA TTT ACA GGA GGG GAT ATC CTT Gly Thr Ser Val Ile Thr Gly Pro Phe Thr Gly Gly Asp Ile Leu			1488
485	490	495	
CGA AGA AAT ACC TTT GGT GAT TTT GTA TCT CTA CAA GTC AAT ATT AAT Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gln Val Asn Ile Asn			1536
500	505	510	
TCA CCA ATT ACC CAA AGA TAC CGT TTA AGA TTT CGT TAC GCT TCC AGT Ser Pro Ile Thr Gln Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser			1584
515	520	525	
AGG GAT GCA CGA GTT ATA GTA TTA ACA GGA GCG GCA TCC ACA GGA GTG Arg Asp Ala Arg Val Ile Val Leu Thr Gly Ala Ala Ser Thr Gly Val			1632
530	535	540	
GGA GGC CAA GTT AGT GTA AAT ATG CCT CTT CAG AAA ACT ATG GAA ATA Gly Gly Gln Val Ser Val Asn Met Pro Leu Gln Lys Thr Met Glu Ile			1680
545	550	555	560
GGG GAG AAC TTA ACA TCT AGA ACA TTT AGA TAT ACC GAT TTT AGT AAT Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn			1728
565	570	575	

CCT TTT TCA TTT AGA GCT AAT CCA GAT ATA ATT GGG ATA AGT GAA CAA Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile Ile Gly Ile Ser Glu Gln 580 585 590	1776
CCT CTA TTT GGT GCA GGT TCT ATT AGT AGC GGT GAA CTT TAT ATA GAT Pro Leu Phe Gly Ala Gly Ser Ile Ser Ser Gly Glu Leu Tyr Ile Asp 595 600 605	1824
AAA ATT GAA ATT ATT CTA GCA GAT GCA ACA TTT GAA GCA GAA TCT GAT Lys Ile Glu Ile Ile Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp 610 615 620	1872
TTA GAA AGA GCA CAA AAG GCG GTG AAT GCC CTG TTT ACT TCT TCC AAT Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn 625 630 635 640	1920
CAA ATC GGG TTA AAA ACC GAT GTG ACG GAT TAT CAT ATT GAT CAA GTA Gln Ile Gly Leu Lys Thr Asp Val Thr Asp Tyr His Ile Asp Gln Val 645 650 655	1968
TCC AAT TTA GTG GAT TGT TTA TCA GAT GAA TTT TGT CTG GAT GAA AAG Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys 660 665 670	2016
CGA GAA TTG TCC GAG AAA GTC AAA CAT GCG AAG CGA CTC AGT GAT GAG Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu 675 680 685	2064
CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG ATC AAT AGA CAA CCA Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly Ile Asn Arg Gln Pro 690 695 700	2112
GAC CGT GGC TGG AGA GGA AGT ACA GAT ATT ACC ATC CAA GGA GGA GAT Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr Ile Gln Gly Gly Asp 705 710 715 720	2160
GAC GTA TTC AAA GAG AAT TAC GTC ACA CTA CCG GGT ACC GTT GAT GAG Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu 725 730 735	2208
TGC TAT CCA ACG TAT TTA TAT CAG AAA ATA GAT GAG TCG AAA TTA AAA Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp Glu Ser Lys Leu Lys 740 745 750	2256
GCT TAT ACC CGT TAT GAA TTA AGA GGG TAT ATC GAA GAT AGT CAA GAC Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile Glu Asp Ser Gln Asp 755 760 765	2304
TTA GAA ATC TAT TTG ATC CGT TAC AAT GCA AAA CAC GAA ATA GTA AAT Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys His Glu Ile Val Asn 770 775 780	2352

GTC CCA GGC ACG GGT TCC TTA TGG CCG CTT TCA GCC CAA AGT CCA ATC Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gln Ser Pro Ile 785	790	795	800	2400
GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA CAC CTT GAA TGG AAT Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn 805	810	815		2448
CCT GAT CTA GAT TGT TCC TGC AGA GAC GGG GAA AAA TGT GCA CAT CAT Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His 820	825	830		2496
TCC CAT CAT TTC ACC TTG GAT ATT GAT GTT GGA TGT ACA GAC TTA AAT Ser His His Phe Thr Leu Asp Ile Asp Val Gly Cys Thr Asp Leu Asn 835	840	845		2544
GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT AAG ACG CAA GAT GGC Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile Lys Thr Gln Asp Gly 850	855	860		2592
CAT GCA AGA CTA GGG AAT CTA GAG TTT CTC GAA GAG AAA CCA TTA TTA His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu 865	870	875	880	2640
GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG AAG AAG TGG AGA GAC Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp 885	890	895		2688
AAA CGA GAG AAA CTG CAG TTG GAA ACA AAT ATT GTT TAT AAA GAG GCA Lys Arg Glu Lys Leu Gln Leu Glu Thr Asn Ile Val Tyr Lys Glu Ala 900	905	910		2736
AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT CAA TAT GAT AGA TTA Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gln Tyr Asp Arg Leu 915	920	925		2784
CAA GTG GAT ACG AAC ATC GCG ATG ATT CAT GCG GCA GAT AAA CGC GTT Gln Val Asp Thr Asn Ile Ala Met Ile His Ala Ala Asp Lys Arg Val 930	935	940		2832
CAT AGA ATC CGG GAA GCG TAT CTG CCA GAG TTG TCT GTG ATT CCA GGT His Arg Ile Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val Ile Pro Gly 945	950	955	960	2880
GTC AAT GCG GCC ATT TTC GAA GAA TTA GAG GGA CGT ATT TTT ACA GCG Val Asn Ala Ala Ile Phe Glu Leu Glu Gly Arg Ile Phe Thr Ala 965	970	975		2928
TAT TCC TTA TAT GAT GCG AGA AAT GTC ATT AAA AAT GGC GAT TTC AAT Tyr Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys Asn Gly Asp Phe Asn 980	985	990		2976
AAT GGC TTA TTA TGC TGG AAC GTG AAA GGT CAT GTA GAT GTA GAA GAG				3024

Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu 995 1000 1005 .	
CAA AAC AAC CAC CGT TCG GTC CTT GTT ATC CCA GAA TGG GAG GCA GAA Gln Asn Asn His Arg Ser Val Leu Val Ile Pro Glu Trp Glu Ala Glu 1010 1015 1020	3072
G TG TCA CAA GAG GTT CGT GTC TGT CCA GGT CGT GGC TAT ATC CTT CGT Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg Gly Tyr Ile Leu Arg 1025 1030 1035 1040	3120
GTC ACA GCA TAT AAA GAG GGA TAT GGA GAG GGC TGC GTA ACG ATC CAT Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr Ile His 1045 1050 1055	3168
GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC AGC AAC TGT GTA GAA Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu 1060 1065 1070	3216
GAG GAA GTA TAT CCA AAC ACA GCA ACG TGT AAT AAT TAT ACT GGG Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly 1075 1080 1085	3264
ACT CAA GAA GAA TAT GAG GGT ACG TAC ACT TCT CGT AAT CAA GGA TAT Thr Gln Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gln Gly Tyr 1090 1095 1100	3312
GAC GAA GCC TAT GGT AAT AAC CCT TCC GTA CCA GCT GAT TAC GCT TCA Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser 1105 1110 1115 1120	3360
GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA GAG AAT CCT TGT Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys 1125 1130 1135	3408
GAA TCT AAC AGA GGC TAT GGG GAT TAC ACA CCA CTA CCG GCT GGT TAT Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr 1140 1145 1150	3456
GTA ACA AAG GAT TTA GAG TAC TTC CCA GAG ACC GAT AAG GTA TGG ATT Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp Ile 1155 1160 1165	3504
GAG ATC GGA GAA ACA GAA GGA ACA TTC ATC GTG GAT AGC GTG GAA TTA Glu Ile Gly Glu Thr Glu Gly Thr Phe Ile Val Asp Ser Val Glu Leu 1170 1175 1180	3552
CTC CTT ATG GAG GAA Leu Leu Met Glu Glu 1185	3567

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1189 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met	Glu	Glu	Asn	Asn	Gln	Asn	Gln	Cys	Ile	Pro	Tyr	Asn	Cys	Leu	Ser
1															15
Asn Pro Glu Glu Val Leu Leu Asp Gly Glu Arg Ile Ser Thr Gly Asn															
									20	25	30				
Ser Ser Ile Asp Ile Ser Leu Ser Leu Val Gln Phe Leu Val Ser Asn															
									35	40	45				
Phe Val Pro Gly Gly Phe Leu Val Gly Leu Ile Asp Phe Val Trp															
									50	55	60				
Gly Ile Val Gly Pro Ser Gln Trp Asp Ala Phe Leu Val Gln Ile Glu															
									65	70	75	80			
Gln Leu Ile Asn Glu Arg Ile Ala Glu Phe Ala Arg Asn Ala Ala Ile															
									85	90	95				
Ala Asn Leu Glu Gly Leu Gly Asn Asn Phe Asn Ile Tyr Val Glu Ala															
									100	105	110				
Phe Lys Glu Trp Glu Glu Asp Pro Asn Asn Pro Glu Thr Arg Thr Arg															
									115	120	125				
Val Ile Asp Arg Phe Arg Ile Leu Asp Gly Leu Leu Glu Arg Asp Ile															
									130	135	140				
Pro Ser Phe Arg Ile Ser Gly Phe Glu Val Pro Leu Leu Ser Val Tyr															
									145	150	155	160			
Ala Gln Ala Ala Asn Leu His Leu Ala Ile Leu Arg Asp Ser Val Ile															
									165	170	175				
Phe Gly Glu Arg Trp Gly Leu Thr Thr Ile Asn Val Asn Glu Asn Tyr															
									180	185	190				
Asn Arg Leu Ile Arg His Ile Asp Glu Tyr Ala Asp His Cys Ala Asn															
									195	200	205				
Thr Tyr Asn Arg Gly Leu Asn Asn Leu Pro Lys Ser Thr Tyr Gln Asp															
									210	215	220				
Trp Ile Thr Tyr Asn Arg Leu Arg Arg Asp Leu Thr Leu Thr Val Leu															

225	230	235	240
Asp Ile Ala Ala Phe Phe Pro Asn Tyr Asp Asn Arg Arg Tyr Pro Ile			
245		250	255
Gln Pro Val Gly Gln Leu Thr Arg Glu Val Tyr Thr Asp Pro Leu Ile			
260	265		270
Asn Phe Asn Pro Gln Leu Gln Ser Val Ala Gln Leu Pro Thr Phe Asn			
275	280		285
Val Met Glu Ser Ser Ala Ile Arg Asn Pro His Leu Phe Asp Ile Leu			
290	295		300
Asn Asn Leu Thr Ile Phe Thr Asp Trp Phe Ser Val Gly Arg Asn Phe			
305	310	315	320
Tyr Trp Gly Gly His Arg Val Ile Ser Ser Leu Ile Gly Gly Gly Asn			
325		330	335
Ile Thr Ser Pro Ile Tyr Gly Arg Glu Ala Asn Gln Glu Pro Pro Arg			
340	345		350
Ser Phe Thr Phe Asn Gly Pro Val Phe Arg Thr Leu Ser Asn Pro Thr			
355	360		365
Leu Arg Leu Leu Gln Gln Pro Trp Pro Ala Pro Pro Phe Asn Leu Arg			
370	375		380
Gly Val Glu Gly Val Glu Phe Ser Thr Pro Thr Asn Ser Phe Thr Tyr			
385	390	395	400
Arg Gly Arg Gly Thr Val Asp Ser Leu Thr Glu Leu Pro Pro Glu Asp			
405		410	415
Asn Ser Val Pro Pro Arg Glu Gly Tyr Ser His Arg Leu Cys His Ala			
420	425		430
Thr Phe Val Gln Arg Ser Gly Thr Pro Phe Leu Thr Thr Gly Val Val			
435	440		445
Phe Ser Trp Thr His Arg Ser Ala Thr Leu Thr Asn Thr Ile Asp Pro			
450	455		460
Glu Arg Ile Asn Gln Ile Pro Leu Val Lys Gly Phe Arg Val Trp Gly			
465	470	475	480
Gly Thr Ser Val Ile Thr Gly Pro Gly Phe Thr Gly Gly Asp Ile Leu			
485	490		495
Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gln Val Asn Ile Asn			
500	505		510

Ser Pro Ile Thr Gln Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser
 515 520 525

Arg Asp Ala Arg Val Ile Val Leu Thr Gly Ala Ala Ser Thr Gly Val
 530 535 540

Gly Gly Gln Val Ser Val Asn Met Pro Leu Gln Lys Thr Met Glu Ile
 545 550 555 560

Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn
 565 570 575

Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile Ile Gly Ile Ser Glu Gln
 580 585 590

Pro Leu Phe Gly Ala Gly Ser Ile Ser Ser Gly Glu Leu Tyr Ile Asp
 595 600 605

Lys Ile Glu Ile Ile Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp
 610 615 620

Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn
 625 630 635 640

Gln Ile Gly Leu Lys Thr Asp Val Thr Asp Tyr His Ile Asp Gln Val
 645 650 655

Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys
 660 665 670

Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu
 675 680 685

Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly Ile Asn Arg Gln Pro
 690 695 700

Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr Ile Gln Gly Gly Asp
 705 710 715 720

Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu
 725 730 735

Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp Glu Ser Lys Leu Lys
 740 745 750

Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile Glu Asp Ser Gln Asp
 755 760 765

Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys His Glu Ile Val Asn
 770 775 780

Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gln Ser Pro Ile
 785 790 795 800

Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn
 805 810 815

Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His
 820 825 830

Ser His His Phe Thr Leu Asp Ile Asp Val Gly Cys Thr Asp Leu Asn
 835 840 845

Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile Lys Thr Gln Asp Gly
 850 855 860

His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu
 865 870 875 880

Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp
 885 890 895

Lys Arg Glu Lys Leu Gln Leu Glu Thr Asn Ile Val Tyr Lys Glu Ala
 900 905 910

Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gln Tyr Asp Arg Leu
 915 920 925

Gln Val Asp Thr Asn Ile Ala Met Ile His Ala Ala Asp Lys Arg Val
 930 935 940

His Arg Ile Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val Ile Pro Gly
 945 950 955 960

Val Asn Ala Ala Ile Phe Glu Glu Leu Gly Arg Ile Phe Thr Ala
 965 970 975

Tyr Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys Asn Gly Asp Phe Asn
 980 985 990

Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu
 995 1000 1005

Gln Asn Asn His Arg Ser Val Leu Val Ile Pro Glu Trp Glu Ala Glu
 1010 1015 1020

Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg Gly Tyr Ile Leu Arg
 1025 1030 1035 1040

Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr Ile His
 1045 1050 1055

Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu
 1060 1065 1070

Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly

1075	1080	1085
Thr Gln Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gln Gly Tyr		
1090	1095	1100
Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser		
1105	1110	1115
Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys		
1125	1130	1135
Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr		
1140	1145	1150
Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp Ile		
1155	1160	1165
Glu Ile Gly Glu Thr Glu Gly Thr Phe Ile Val Asp Ser Val Glu Leu		
1170	1175	1180
Leu Leu Met Glu Glu		
1185		

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3513 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Bacillus thuringiensis*
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..3513
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATG GAG ATA GTG AAT AAT CAG AAT CAA TGC GTG CCT TAT AAT TGT TTA	48		
Met Glu Ile Val Asn Asn Gln Asn Gln Cys Val Pro Tyr Asn Cys Leu			
1	5	10	15

AAT AAT CCT GAA AAT GAG ATA TTA GAT ATT GAA AGG TCA AAT AGT ACT	96
Asn Asn Pro Glu Asn Glu Ile Leu Asp Ile Glu Arg Ser Asn Ser Thr	

20

25

30

GTA GCA ACA AAC ATC GCC TTG GAG ATT AGT CGT CTG CTC GCT TCC GCA Val Ala Thr Asn Ile Ala Leu Glu Ile Ser Arg Leu Leu Ala Ser Ala	35	40	45	144
ACT CCA ATA GGG GGG ATT TTA TTA GGA TTG TTT GAT GCA ATA TGG GGG Thr Pro Ile Gly Gly Ile Leu Leu Gly Leu Phe Asp Ala Ile Trp Gly	50	55	60	192
TCT ATA GGC CCT TCA CAA TGG GAT TTA TTT TTA GAG CAA ATT GAG CTA Ser Ile Gly Pro Ser Gln Trp Asp Leu Phe Leu Glu Gln Ile Glu Leu	65	70	75	240
TTG ATT GAC CAA AAA ATA GAG GAA TTC GCT AGA AAC CAG GCA ATT TCT Leu Ile Asp Gln Lys Ile Glu Glu Phe Ala Arg Asn Gln Ala Ile Ser	85	90	95	288
AGA TTG GAA GGG ATA AGC AGT CTG TAC GGA ATT TAT ACA GAA GCT TTT Arg Leu Glu Gly Ile Ser Ser Leu Tyr Gly Ile Tyr Thr Glu Ala Phe	100	105	110	336
AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AAA GAA GAG ATG Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met	115	120	125	384
CGT ACT CAA TTT AAT GAC ATG AAC AGT ATT CTT GTA ACA GCT ATT CCT Arg Thr Gln Phe Asn Asp Met Asn Ser Ile Leu Val Thr Ala Ile Pro	130	135	140	432
CTT TTT TCA GTT CAA AAT TAT CAA GTC CCA TTT TTA TCA GTA TAT GTT Leu Phe Ser Val Gln Asn Tyr Gln Val Pro Phe Leu Ser Val Tyr Val	145	150	155	480
CAA GCT GCA AAT TTA CAT TTA TCG GTT TTG AGA GAT GTT TCA GTG TTT Gln Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe	165	170	175	528
GGG CAG GCT TGG GGA TTT GAT ATA GCA ACA ATA AAT AGT CGT TAT AAT Gly Gln Ala Trp Gly Phe Asp Ile Ala Thr Ile Asn Ser Arg Tyr Asn	180	185	190	576
GAT CTG ACT AGA CTT ATT CCT ATA TAT ACA GAT TAT GCT GTA CGC TGG Asp Leu Thr Arg Leu Ile Pro Ile Tyr Thr Asp Tyr Ala Val Arg Trp	195	200	205	624
TAC AAT ACG GGA TTA GAT CGC TTA CCA CGA ACT GGT GGG CTG CGA AAC Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn	210	215	220	672
TGG GCA AGA TTT AAT CAG TTT AGA AGA GAG TTA ACA ATA TCA GTA TTA Trp Ala Arg Phe Asn Gln Phe Arg Arg Glu Leu Thr Ile Ser Val Leu	225	230	235	720
			240	

GAT ATT ATT TCT TTT TTC AGA AAT TAC GAT TCT AGA TTA TAT CCA ATT Asp Ile Ile Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro Ile 245 250 255	768
CCA ACA AGC TCC CAA TTA ACG CGG GAA GTA TAT ACA GAT CCG GTA ATT Pro Thr Ser Ser Gln Leu Thr Arg Glu Val Tyr Thr Asp Pro Val Ile 260 265 270	816
AAT ATA ACT GAC TAT AGA GTT GGC CCC AGC TTC GAG AAT ATT GAG AAC Asn Ile Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn Ile Glu Asn 275 280 285	864
TCA GCC ATT AGA AGC CCC CAC CTT ATG GAC TTC TTA AAT AAT TTG ACC Ser Ala Ile Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr 290 295 300	912
ATT GAT ACG GAT TTG ATT AGA GGT GTT CAC TAT TGG GCA GGG CAT CGT Ile Asp Thr Asp Leu Ile Arg Gly Val His Tyr Trp Ala Gly His Arg 305 310 315 320	960
GTA ACT TCT CAT TTT ACA GGT AGT TCT CAA GTG ATA ACA ACC CCT CAA Val Thr Ser His Phe Thr Gly Ser Ser Gln Val Ile Thr Thr Pro Gln 325 330 335	1008
TAT GGG ATA ACC GCA AAT GCG GAA CCA AGA CGA ACT ATT GCT CCT AGT Tyr Gly Ile Thr Ala Asn Ala Glu Pro Arg Arg Thr Ile Ala Pro Ser 340 345 350	1056
ACT TTT CCA GGT CTT AAC CTA TTT TAT AGA ACA TTA TCA AAT CCT TTC Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe 355 360 365	1104
TTC CGA AGA TCA GAA AAT ATT ACT CCT ACC TTA GGG ATA AAT GTA GTA Phe Arg Arg Ser Glu Asn Ile Thr Pro Thr Leu Gly Ile Asn Val Val 370 375 380	1152
CAG GGA GTA GGG TTC ATT CAA CCA AAT AAT GCT GAA GTT CTA TAT AGA Gln Gly Val Gly Phe Ile Gln Pro Asn Asn Ala Glu Val Leu Tyr Arg 385 390 395 400	1200
AGT AGG GGG ACA GTA GAT TCT CTT AAT GAG TTA CCA ATT GAT GGT GAG Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro Ile Asp Gly Glu 405 410 415	1248
AAT TCA TTA GTT GGA TAT AGT CAT CGA TTA AGT CAT GTT ACA CTA ACC Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr 420 425 430	1296
AGG TCG TTA TAT AAT ACT AAT ATA ACT AGC CTG CCA ACA TTT GTT TGG Arg Ser Leu Tyr Asn Thr Asn Ile Thr Ser Leu Pro Thr Phe Val Trp 435 440 445	1344

ACA CAT CAC AGT GCT ACT AAT ACA AAT ACA ATT AAT CCA GAT ATT ATT Thr His His Ser Ala Thr Asn Thr Asn Thr Ile Asn Pro Asp Ile Ile 450 455 460	1392
ACA CAA ATA CCT TTA GTG AAA GGA TTT AGA CTT GGT GGT GGC ACC TCT Thr Gln Ile Pro Leu Val Lys Gly Phe Arg Leu Gly Gly Thr Ser 465 470 475 480	1440
GTC ATT AAA GGA CCA GGA TTT ACA GGA GGG GAT ATC CTT CGA AGA AAT Val Ile Lys Gly Pro Gly Phe Thr Gly Gly Asp Ile Leu Arg Arg Asn 485 490 495	1488
ACC ATT GGT GAG TTT GTG TCT TTA CAA GTC AAT ATT AAC TCA CCA ATT Thr Ile Gly Glu Phe Val Ser Leu Gln Val Asn Ile Asn Ser Pro Ile 500 505 510	1536
ACC CAA AGA TAC CGT TTA AGA TTT CGT TAT GCT TCC AGT AGG GAT GCA Thr Gln Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala 515 520 525	1584
CGA ATT ACT GTA GCG ATA GGA GGA CAA ATT AGA GTA GAT ATG ACC CTT Arg Ile Thr Val Ala Ile Gly Gly Gln Ile Arg Val Asp Met Thr Leu 530 535 540	1632
GAA AAA ACC ATG GAA ATT GGG GAG AGC TTA ACA TCT AGA ACA TTT AGC Glu Lys Thr Met Glu Ile Gly Glu Ser Leu Thr Ser Arg Thr Phe Ser 545 550 555 560	1680
TAT ACC AAT TTT AGT AAT CCT TTT TCA TTT AGG GCT AAT CCA GAT ATA Tyr Thr Asn Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile 565 570 575	1728
ATT AGA ATA GCT GAA GAA CTT CCT ATT CGT GGT GAG CTT TAT ATA Ile Arg Ile Ala Glu Glu Leu Pro Ile Arg Gly Gly Glu Leu Tyr Ile 580 585 590	1776
GAT AAA ATT GAA CTT ATT CTA GCA GAT GCA ACA TTT GAA GAA GAA TAT Asp Lys Ile Glu Leu Ile Leu Ala Asp Ala Thr Phe Glu Glu Glu Tyr 595 600 605	1824
GAT TTG GAA AGA GCA CAG AAG GCG GTG AAT GCC CTG TTT ACT TCT ACA Asp Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu Phe Thr Ser Thr 610 615 620	1872
AAT CAA CTA GGG CTA AAA ACA GAT GTG ACG GAT TAT CAT ATT GAT CAA Asn Gln Leu Gly Leu Lys Thr Asp Val Thr Asp Tyr His Ile Asp Gln 625 630 635 640	1920
GTT TCC AAT TTA GTT GAG TGT TTA TCG GAT GAA TTT TGT CTG GAT GAA Val Ser Asn Leu Val Glu Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu 645 650 655	1968
AAG AGA GAA TTA TCC GAG AAA GTC AAA CAT GCG AAG CGA CTC AGT GAT	2016

Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp			
660	665	670	
GAA CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG ATC AAT AGG CAA			2064
Glu Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly Ile Asn Arg Gln			
675	680	685	
CCA GAC CGT GGC TGG AGA GGA AGC ACG GAT ATT ACT ATC CAA GGT GGA			2112
Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr Ile Gln Gly Gly			
690	695	700	
GAT GAC GTA TTC AAA GAG AAT TAC GTC ACA TTA CCG GGT ACC TTT GAT			2160
Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Phe Asp			
705	710	715	720
GAG TGC TAT CCA ACG TAT TTA TAT CAA AAA ATA GAT GAG TCG AAG TTA			2208
Glu Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp Glu Ser Lys Leu			
725	730	735	
AAA GCT TAT ACC CGC TAT GAA TTA AGA GGG TAT ATC GAG GAT AGT CAA			2256
Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile Glu Asp Ser Gln			
740	745	750	
GAC TTA GAA ATC TAT TTA ATT CGC TAC AAT GCA AAA CAC GAG ACA GTA			2304
Asp Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys His Glu Thr Val			
755	760	765	
AAC GTG CCA GGT ACG GGT TCC TTA TGG CCG CTT TCA GCC CAA AGT CCA			2352
Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gln Ser Pro			
770	775	780	
ATC GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA CAC CTT GAA TGG			2400
Ile Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp			
785	790	795	800
AAT CCT AAT CTA GAT TGC TCC AGA GAC GGG GAA AAA TGT GCC CAT			2448
Asn Pro Asn Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His			
805	810	815	
CAT TCC CAT CAT TTC TCC TTG GAC ATT GAT GTT GGA TGT ACA GAC TTA			2496
His Ser His His Phe Ser Leu Asp Ile Asp Val Gly Cys Thr Asp Leu			
820	825	830	
AAT GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT AAG ACA CAA GAT			2544
Asn Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile Lys Thr Gln Asp			
835	840	845	
GGC TAT GCA AGA CTA GGA AAT CTA GAG TTT CTC GAA GAG AAC CCA CTA			2592
Gly Tyr Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Asn Pro Leu			
850	855	860	
TTA GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG AAA AAA TGG AGA			2640
Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg			

865	870	875	880	
GAC AAA TGC GAA AAA TTG GAA TGG GAA ACA AAT ATT GTT TAT AAA GAG Asp Lys Cys Glu Lys Leu Glu Trp Glu Thr Asn Ile Val Tyr Lys Glu 885 890 895				2688
GCA AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT CAA TAT GAT AGA Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gln Tyr Asp Arg 900 905 910				2736
TTA CAA GCG GAT ACG AAT ATC GCG ATG ATT CAT GCG GCA GAT AAA CGC Leu Gln Ala Asp Thr Asn Ile Ala Met Ile His Ala Ala Asp Lys Arg 915 920 925				2784
GTT CAT AGC ATT CGA GAA GCG TAT CTG CCA GAG CTG TCT GTG ATT CCG Val His Ser Ile Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val Ile Pro 930 935 940				2832
GGT GTC AAT GCG GCT ATT TTT GAA GAA TTA GAA GGG CGT ATT TTC ACT Gly Val Asn Ala Ala Ile Phe Glu Glu Leu Glu Gly Arg Ile Phe Thr 945 950 955 960				2880
GCA TTC TCC CTA TAT GAT GCG AGA AAT GTC ATT AAA AAT GGC GAT TTC Ala Phe Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys Asn Gly Asp Phe 965 970 975				2928
AAT AAT GGC TTA TCA TGC TGG AAC GTG AAA GGG CAT GTA GAT GTA GAA Asn Asn Gly Leu Ser Cys Trp Asn Val Lys Gly His Val Asp Val Glu 980 985 990				2976
GAA CAG AAC AAC CAT CGT TCG GTC CTT GTT CCA GAA TGG GAA GCA Glu Gln Asn Asn His. Arg Ser Val Leu Val Val Pro Glu Trp Glu Ala 995 1000 1005				3024
GAA GTG TCA CAA GAA GTT CGT GTT TGT CCG GGT CGT GGC TAT ATC CTT Glu Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg Gly Tyr Ile Leu 1010 1015 1020				3072
CGT GTT ACA GCG TAC AAA GAG GGA TAT GGA GAG GGC TGT GTA ACG ATT Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr Ile 1025 1030 1035 1040				3120
CAT GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC AGC AAC TGT GTA His Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val 1045 1050 1055				3168
GAA GAG GAA GTA TAT CCA AAC AAC ACG GTA ACG TGT AAT AAT TAT ACT Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr 1060 1065 1070				3216
GCG ACT CAA GAA GAA CAT GAG GGT ACG TAC ACT TCC CGT AAT CGA GGA Ala Thr Gln Glu Glu His Glu Gly Thr Tyr Thr Ser Arg Asn Arg Gly 1075 1080 1085				3264

TAT GAC GAA GCC TAT GAA AGC AAT TCT TCT GTA CAT GCG TCA GTC TAT Tyr Asp Glu Ala Tyr Glu Ser Asn Ser Ser Val His Ala Ser Val Tyr 1090 1095 1100	3312
GAA GAA AAA TCG TAT ACA GAT AGA CGA AGA GAG AAT CCT TGT GAA TCT Glu Glu Lys Ser Tyr Thr Asp Arg Arg Arg Glu Asn Pro Cys Glu Ser 1105 1110 1115 1120	3360
AAC AGA GGA TAT GGG GAT TAC ACA CCA CTA CCA GCT GGC TAT GTG ACA Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr 1125 1130 1135	3408
AAA GAA TTA GAG TAC TTC CCA GAA ACC GAT AAG GTA TGG ATT GAG ATC Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val^Trp Ile Glu Ile 1140 1145 1150	3456
GGA GAA ACG GAA GGA ACA TTC ATC GTG GAC AGC GTG GAA TTA CTT CTT Gly Glu Thr Glu Gly Thr Phe Ile Val Asp Ser Val Glu Leu Leu Leu 1155 1160 1165	3504 *
ATG GAG GAA Met Glu Glu 1170	3513

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1171 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Glu Ile Val Asn Asn Gln Asn Gln Cys Val Pro Tyr Asn Cys Leu 1 5 10 15
Asn Asn Pro Glu Asn Glu Ile Leu Asp Ile Glu Arg Ser Asn Ser Thr 20 25 30
Val Ala Thr Asn Ile Ala Leu Glu Ile Ser Arg Leu Leu Ala Ser Ala 35 40 45
Thr Pro Ile Gly Gly Ile Leu Leu Gly Leu Phe Asp Ala Ile Trp Gly 50 55 60
Ser Ile Gly Pro Ser Gln Trp Asp Leu Phe Leu Glu Gln Ile Glu Leu 65 70 75 80
Leu Ile Asp Gln Lys Ile Glu Glu Phe Ala Arg Asn Gln Ala Ile Ser

85	90	95
Arg Leu Glu Gly Ile Ser Ser Leu Tyr Gly Ile Tyr Thr Glu Ala Phe 100	105	110
Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met 115	120	125
Arg Thr Gln Phe Asn Asp Met Asn Ser Ile Leu Val Thr Ala Ile Pro 130	135	140
Leu Phe Ser Val Gln Asn Tyr Gln Val Pro Phe Leu Ser Val Tyr Val 145	150	155
Gln Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe 165	170	175
Gly Gln Ala Trp Gly Phe Asp Ile Ala Thr Ile Asn Ser Arg Tyr Asn 180	185	190
Asp Leu Thr Arg Leu Ile Pro Ile Tyr Thr Asp Tyr Ala Val Arg Trp 195	200	205
Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn 210	215	220
Trp Ala Arg Phe Asn Gln Phe Arg Arg Glu Leu Thr Ile Ser Val Leu 225	230	235
Asp Ile Ile Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro Ile 245	250	255
Pro Thr Ser Ser Gln Leu Thr Arg Glu Val Tyr Thr Asp Pro Val Ile 260	265	270
Asn Ile Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn Ile Glu Asn 275	280	285
Ser Ala Ile Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr 290	295	300
Ile Asp Thr Asp Leu Ile Arg Gly Val His Tyr Trp Ala Gly His Arg 305	310	315
Val Thr Ser His Phe Thr Gly Ser Ser Gln Val Ile Thr Thr Pro Gln 325	330	335
Tyr Gly Ile Thr Ala Asn Ala Glu Pro Arg Arg Thr Ile Ala Pro Ser 340	345	350
Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe 355	360	365

Phe Arg Arg Ser Glu Asn Ile Thr Pro Thr Leu Gly Ile Asn Val Val
 370 375 380

 Gln Gly Val Gly Phe Ile Gln Pro Asn Asn Ala Glu Val Leu Tyr Arg
 385 390 395 400

 Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro Ile Asp Gly Glu
 405 410 415

 Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr
 420 425 430

 Arg Ser Leu Tyr Asn Thr Asn Ile Thr Ser Leu Pro Thr Phe Val Trp
 435 440 445

 Thr His His Ser Ala Thr Asn Thr Asn Thr Ile Asn Pro Asp Ile Ile
 450 455 460

 Thr Gln Ile Pro Leu Val Lys Gly Phe Arg Leu Gly Gly Thr Ser
 465 470 475 480

 Val Ile Lys Gly Pro Gly Phe Thr Gly Gly Asp Ile Leu Arg Arg Asn
 485 490 495

 Thr Ile Gly Glu Phe Val Ser Leu Gln Val Asn Ile Asn Ser Pro Ile
 500 505 510

 Thr Gln Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala
 515 520 525

 Arg Ile Thr Val Ala Ile Gly Gly Gln Ile Arg Val Asp Met Thr Leu
 530 535 540

 Glu Lys Thr Met Glu Ile Gly Glu Ser Leu Thr Ser Arg Thr Phe Ser
 545 550 555 560

 Tyr Thr Asn Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile
 565 570 575

 Ile Arg Ile Ala Glu Glu Leu Pro Ile Arg Gly Gly Glu Leu Tyr Ile
 580 585 590

 Asp Lys Ile Glu Leu Ile Leu Ala Asp Ala Thr Phe Glu Glu Glu Tyr
 595 600 605

 Asp Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu Phe Thr Ser Thr
 610 615 620

 Asn Gln Leu Gly Leu Lys Thr Asp Val Thr Asp Tyr His Ile Asp Gln
 625 630 635 640

 Val Ser Asn Leu Val Glu Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu
 645 650 655

Lys Arg Glu Leu Ser Glu Val Lys His Ala Lys Arg Leu Ser Asp
 660 665 670

 Glu Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly Ile Asn Arg Gln
 675 680 685

 Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr Ile Gln Gly Gly
 690 695 700

 Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Phe Asp
 705 710 715 720

 Glu Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp Glu Ser Lys Leu
 725 730 735

 Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile Glu Asp Ser Gln
 740 745 750

 Asp Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys His Glu Thr Val
 755 760 765

 Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala Gln Ser Pro
 770 775 780

 Ile Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp
 785 790 795 800

 Asn Pro Asn Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His
 805 810 815

 His Ser His His Phe Ser Leu Asp Ile Asp Val Gly Cys Thr Asp Leu
 820 825 830

 Asn Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile Lys Thr Gln Asp
 835 840 845

 Gly Tyr Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu Asn Pro Leu
 850 855 860

 Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg
 865 870 875 880

 Asp Lys Cys Glu Lys Leu Glu Trp Glu Thr Asn Ile Val Tyr Lys Glu
 885 890 895

 Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gln Tyr Asp Arg
 900 905 910

 Leu Gln Ala Asp Thr Asn Ile Ala Met Ile His Ala Ala Asp Lys Arg
 915 920 925

 Val His Ser Ile Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val Ile Pro

930

935

940

Gly Val Asn Ala Ala Ile Phe Glu Glu Leu Glu Gly Arg Ile Phe Thr
 945 950 955 960

Ala Phe Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys Asn Gly Asp Phe
 965 970 975

Asn Asn Gly Leu Ser Cys Trp Asn Val Lys Gly His Val Asp Val Glu
 980 985 990

Glu Gln Asn Asn His Arg Ser Val Leu Val Val Pro Glu Trp Glu Ala
 995 1000 1005

Glu Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg~Gly Tyr Ile Leu
 1010 1015 1020

Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr Ile
 1025 1030 1035 1040

His Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val
 1045 1050 1055

Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr
 1060 1065 1070

Ala Thr Gln Glu Glu His Glu Gly Thr Tyr Thr Ser Arg Asn Arg Gly
 1075 1080 1085

Tyr Asp Glu Ala Tyr Glu Ser Asn Ser Ser Val His Ala Ser Val Tyr
 1090 1095 1100

Glu Glu Lys Ser Tyr Thr Asp Arg Arg Glu Asn Pro Cys Glu Ser
 1105 1110 1115 1120

Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr
 1125 1130 1135

Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp Ile Glu Ile
 1140 1145 1150

Gly Glu Thr Glu Gly Thr Phe Ile Val Asp Ser Val Glu Leu Leu Leu
 1155 1160 1165

Met Glu Glu
 1170

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3558 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Hybrid sequence

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..3558

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATG GAG ATA GTG AAT AAT CAG AAT CAA TGC GTG CCT TAT AAT TGT TTA Met Glu Ile Val Asn Asn Gln Asn Gln Cys Val Pro Tyr Asn Cys Leu	48
1 5 10 15	
AAT AAT CCT GAA AAT GAG ATA TTA GAT ATT GAA AGG TCA AAT AGT ACT Asn Asn Pro Glu Asn Glu Ile Leu Asp Ile Glu Arg Ser Asn Ser Thr	96
20 25 30	
GTA GCA ACA AAC ATC GCC TTG GAG ATT AGT CGT CTG CTC GCT TCC GCA Val Ala Thr Asn Ile Ala Leu Glu Ile Ser Arg Leu Leu Ala Ser Ala	144
35 40 45	
ACT CCA ATA GGG GGG ATT TTA TTA GGA TTG TTT GAT GCA ATA TGG GGG Thr Pro Ile Gly Gly Ile Leu Leu Gly Leu Phe Asp Ala Ile Trp Gly	192
50 55 60	
TCT ATA GGC CCT TCA CAA TGG GAT TTA TTT TTA GAG CAA ATT GAG CTA Ser Ile Gly Pro Ser Gln Trp Asp Leu Phe Leu Glu Gln Ile Glu Leu	240
65 70 75 80	
TTG ATT GAC CAA AAA ATA GAG GAA TTC GCT AGA AAC CAG GCA ATT TCT Leu Ile Asp Gln Lys Ile Glu Glu Phe Ala Arg Asn Gln Ala Ile Ser	288
85 90 95	
AGA TTG GAA GGG ATA AGC AGT CTG TAC GGA ATT TAT ACA GAA GCT TTT Arg Leu Glu Gly Ile Ser Ser Leu Tyr Gly Ile Tyr Thr Glu Ala Phe	336
100 105 110	
AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AAA GAA GAG ATG Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met	384
115 120 125	
CGT ACT CAA TTT AAT GAC ATG AAC AGT ATT CTT GTA ACA GCT ATT CCT Arg Thr Gln Phe Asn Asp Met Asn Ser Ile Leu Val Thr Ala Ile Pro	432
130 135 140	

CTT TTT TCA GTT CAA AAT TAT CAA GTC CCA TTT TTA TCA GTA TAT GTT Leu Phe Ser Val Gln Asn Tyr Gln Val Pro Phe Leu Ser Val Tyr Val 145 150 155 160	480
CAA GCT GCA AAT TTA CAT TTA TCG GTT TTG AGA GAT GTT TCA GTG TTT Gln Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe 165 170 175	528
GGG CAG GCT TGG GGA TTT GAT ATA GCA ACA ATA AAT AGT CGT TAT AAT Gly Gln Ala Trp Gly Phe Asp Ile Ala Thr Ile Asn Ser Arg Tyr Asn 180 185 190	576
GAT CTG ACT AGA CTT ATT CCT ATA TAT ACA GAT TAT GCT GTA CGC TGG Asp Leu Thr Arg Leu Ile Pro Ile Tyr Thr Asp Tyr Ala Val Arg Trp 195 200 205	624
TAC AAT ACG GGA TTA GAT CGC TTA CCA CGA ACT GGT GGG CTG CGA AAC Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn 210 215 220	672
TGG GCA AGA TTT AAT CAG TTT AGA AGA GAG TTA ACA ATA TCA GTA TTA Trp Ala Arg Phe Asn Gln Phe Arg Arg Glu Leu Thr Ile Ser Val Leu 225 230 235 240	720
GAT ATT ATT TCT TTT TTC AGA AAT TAC GAT TCT AGA TTA TAT CCA ATT Asp Ile Ile Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro Ile 245 250 255	768
CCA ACA AGC TCC CAA TTA ACG CGG GAA GTA TAT ACA GAT CCG GTA ATT Pro Thr Ser Ser Gln Leu Thr Arg Glu Val Tyr Thr Asp Pro Val Ile 260 265 270	816
AAT ATA ACT GAC TAT AGA GTT GGC CCC AGC TTC GAG AAT ATT GAG AAC Asn Ile Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn Ile Glu Asn 275 280 285	864
TCA GCC ATT AGA AGC CCC CAC CTT ATG GAC TTC TTA AAT AAT TTG ACC Ser Ala Ile Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr 290 295 300	912
ATT GAT ACG GAT TTG ATT AGA GGT GTT CAC TAT TGG GCA GGG CAT CGT Ile Asp Thr Asp Leu Ile Arg Gly Val His Tyr Trp Ala Gly His Arg 305 310 315 320	960
GTA ACT TCT CAT TTT ACA GGT AGT TCT CAA GTG ATA ACA ACC CCT CAA Val Thr Ser His Phe Thr Gly Ser Ser Gln Val Ile Thr Thr Pro Gln 325 330 335	1008
TAT GGG ATA ACC GCA AAT GCG GAA CCA AGA CGA ACT ATT GCT CCT AGT Tyr Gly Ile Thr Ala Asn Ala Glu Pro Arg Arg Thr Ile Ala Pro Ser 340 345 350	1056

ACT TTT CCA GGT CTT AAC CTA TTT TAT AGA ACA TTA TCA AAT CCT TTC Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe 355 360 365	1104
TTC CGA AGA TCA GAA AAT ATT ACT CCT ACC TTA GGG ATA AAT GTA GTA Phe Arg Arg Ser Glu Asn Ile Thr Pro Thr Leu Gly Ile Asn Val Val 370 375 380	1152
CAG GGA GTA GGG TTC ATT CAA CCA AAT AAT GCT GAA GTT CTA TAT AGA Gln Gly Val Gly Phe Ile Gln Pro Asn Asn Ala Glu Val Leu Tyr Arg 385 390 395 400	1200
AGT AGG GGG ACA GTA GAT TCT CTT AAT GAG TTA CCA ATT GAT GGT GAG Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro Ile Asp Gly Glu 405 410 415	1248
AAT TCA TTA GTT GGA TAT AGT CAT CGA TTA AGT CAT GTT ACA CTA ACC Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr 420 425 430	1296
AGG TCG TTA TAT AAT ACT AAT ATA ACT AGC CTG CCA ACA TTT GTT TGG Arg Ser Leu Tyr Asn Thr Asn Ile Thr Ser Leu Pro Thr Phe Val Trp 435 440 445	1344
ACA CAT CAC AGT GCT ACT AAT ACA AAT ACA ATT AAT CCA GAT ATT ATT Thr His His Ser Ala Thr Asn Thr Asn Thr Ile Asn Pro Asp Ile Ile 450 455 460	1392
ACA CAA ATA CCT TTA GTG AAA GGA TTT AGA GTT TGG GGG GGC ACC TCT Thr Gln Ile Pro Leu Val Lys Gly Phe Arg Val Trp Gly Gly Thr Ser 465 470 475 480	1440
GTC ATT ACA GGA CCA GGA TTT ACA GGA GGG GAT ATC CTT CGA AGA AAT Val Ile Thr Gly Pro Gly Phe Thr Gly Gly Asp Ile Leu Arg Arg Asn 485 490 495	1488
ACC TTT GGT GAT TTT GTA TCT CTA CAA GTC AAT ATT AAT TCA CCA ATT Thr Phe Gly Asp Phe Val Ser Leu Gln Val Asn Ile Asn Ser Pro Ile 500 505 510	1536
ACC CAA AGA TAC CGT TTA AGA TTT CGT TAC GCT TCC AGT AGG GAT GCA Thr Gln Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala 515 520 525	1584
CGA GTT ATA GTA TTA ACA GGA GCG GCA TCC ACA GGA GTG GGA GGC CAA Arg Val Ile Val Leu Thr Gly Ala Ala Ser Thr Gly Val Gly Gly Gln 530 535 540	1632
GTT AGT GTA AAT ATG CCT CTT CAG AAA ACT ATG GAA ATA GGG GAG AAC Val Ser Val Asn Met Pro Leu Gln Lys Thr Met Glu Ile Gly Glu Asn 545 550 555 560	1680
TTA ACA TCT AGA ACA TTT AGA TAT ACC GAT TTT AGT AAT CCT TTT TCA	1728

Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn Pro Phe Ser			
565	570	575	
TTT AGA GCT AAT CCA GAT ATA ATT GGG ATA AGT GAA CAA CCT CTA TTT			1776
Phe Arg Ala Asn Pro Asp Ile Ile Gly Ile Ser Glu Gln Pro Leu Phe			
580	585	590	
GGT GCA GGT TCT ATT AGT AGC GGT GAA CTT TAT ATA GAT AAA ATT GAA			1824
Gly Ala Gly Ser Ile Ser Ser Gly Glu Leu Tyr Ile Asp Lys Ile Glu			
595	600	605	
ATT ATT CTA GCA GAT GCA ACA TTT GAA GCA GAA TCT GAT TTA GAA AGA			1872
Ile Ile Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp Leu Glu Arg			
610	615	620	
GCA CAA AAG GCG GTG AAT GCC CTG TTT ACT TCT TCC AAT CAA ATC GGG			1920
Ala Gln Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn Gln Ile Gly			
625	630	635	640
TTA AAA ACC GAT GTG ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA			1968
Leu Lys Thr Asp Val Thr Asp Tyr His Ile Asp Gln Val Ser Asn Leu			
645	650	655	
GTG GAT TGT TTA TCA GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG			2016
Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu			
660	665	670	
TCC GAG AAA GTC AAA CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA			2064
Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu			
675	680	685	
CTT CAA GAT CCA AAC TTC AGA GGG ATC AAT AGA CAA CCA GAC CGT GGC			2112
Leu Gln Asp Pro Asn Phe Arg Gly Ile Asn Arg Gln Pro Asp Arg Gly			
690	695	700	
TGG AGA GGA AGT ACA GAT ATT ACC ATC CAA GGA GGA GAT GAC GTA TTC			2160
Trp Arg Gly Ser Thr Asp Ile Thr Ile Gln Gly Asp Asp Val Phe			
705	710	715	720
AAA GAG AAT TAC GTC ACA CTA CCG GGT ACC GTT GAT GAG TGC TAT CCA			2208
Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu Cys Tyr Pro			
725	730	735	
ACG TAT TTA TAT CAG AAA ATA GAT GAG TCG AAA TTA AAA GCT TAT ACC			2256
Thr Tyr Leu Tyr Gln Lys Ile Asp Glu Ser Lys Leu Lys Ala Tyr Thr			
740	745	750	
CGT TAT GAA TTA AGA GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC			2304
Arg Tyr Glu Leu Arg Gly Tyr Ile Glu Asp Ser Gln Asp Leu Glu Ile			
755	760	765	
TAT TTG ATC CGT TAC AAT GCA AAA CAC GAA ATA GTA AAT GTG CCA GGC			2352
Tyr Leu Ile Arg Tyr Asn Ala Lys His Glu Ile Val Asn Val Pro Gly			

770

775

780

2400

ACG GGT TCC TTA TGG CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT
 Thr Gly Ser Leu Trp Pro Leu Ser Ala Gln Ser Pro Ile Gly Lys Cys
 785 790 795 800

GGA GAA CCG AAT CGA TGC GCG CCA CAC CTT GAA TGG AAT CCT GAT CTA
 Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu
 805 810 815

GAT TGT TCC TGC AGA GAC GGG GAA AAA TGT GCA CAT CAT TCC CAT CAT
 Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His Ser His His
 820 825 830

TTC ACC TTG GAT ATT GAT GTT GGA TGT ACA GAC TTA~AAT GAG GAC TTA
 Phe Thr Leu Asp Ile Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu
 835 840 845

GGT GTA TGG GTG ATA TTC AAG ATT AAG ACG CAA GAT GGC CAT GCA AGA
 Gly Val Trp Val Ile Phe Lys Ile Lys Thr Gln Asp Gly His Ala Arg
 850 855 860

CTA GGG AAT CTA GAG TTT CTC GAA GAG AAA CCA TTA TTA GGG GAA GCA
 Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu Gly Glu Ala
 865 870 875 880

CTA GCT CGT GTG AAA AGA GCG GAG AAG TGG AGA GAC AAA CGA GAG
 Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu
 885 890 895

AAA CTG CAG TTG GAA ACA AAT ATT GTT TAT AAA GAG GCA AAA GAA TCT
 Lys Leu Gln Leu Glu Thr Asn Ile Val Tyr Lys Glu Ala Lys Glu Ser
 900 905 910

GTA GAT GCT TTA TTT GTA AAC TCT CAA TAT GAT AGA TTA CAA GTG GAT
 Val Asp Ala Leu Phe Val Asn Ser Gln Tyr Asp Arg Leu Gln Val Asp
 915 920 925

ACG AAC ATC GCG ATG ATT CAT GCG GCA GAT AAA CGC GTT CAT AGA ATC
 Thr Asn Ile Ala Met Ile His Ala Ala Asp Lys Arg Val His Arg Ile
 930 935 940

CGG GAA GCG TAT CTG CCA GAG TTG TCT GTG ATT CCA GGT GTC AAT GCG
 Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val Ile Pro Gly Val Asn Ala
 945 950 955 960

GCC ATT TTC GAA GAA TTA GAG GGA CGT ATT TTT ACA GCG TAT TCC TTA
 Ala Ile Phe Glu Glu Leu Glu Gly Arg Ile Phe Thr Ala Tyr Ser Leu
 965 970 975

TAT GAT GCG AGA AAT GTC ATT AAA AAT GGC GAT TTC AAT AAT GGC TTA
 Tyr Asp Ala Arg Asn Val Ile Lys Asn Gly Asp Phe Asn Asn Gly Leu
 980 985 990

TTA TGC TGG AAC GTG AAA GGT CAT GTA GAT GTA GAA GAG CAA AAC AAC Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu Gln Asn Asn 995 1000 1005	3024
CAC CGT TCG GTC CTT GTT ATC CCA GAA TGG GAG GCA GAA GTG TCA CAA His Arg Ser Val Leu Val Ile Pro Glu Trp Ala Glu Val Ser Gln 1010 1015 1020	3072
GAG GTT CGT GTC TGT CCA GGT CGT GGC TAT ATC CTT CGT GTC ACA GCA Glu Val Arg Val Cys Pro Gly Arg Gly Tyr Ile Leu Arg Val Thr Ala 1025 1030 1035 1040	3120
TAT AAA GAG GGA TAT GGA GAG GGC TGC GTA ACG ATC CAT GAG ATC GAA Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr Ile His Glu Ile Glu 1045 1050 1055	3168
GAC AAT ACA GAC GAA CTG AAA TTC AGC AAC TGT GTA GAA GAG GAA GTA Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu Glu Val 1060 1065 1070	3216
TAT CCA AAC AAC ACA GTA ACG TGT AAT AAT TAT ACT GGG ACT CAA GAA Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly Thr Gln Glu 1075 1080 1085	3264
GAA TAT GAG GGT ACG TAC ACT TCT CGT AAT CAA GGA TAT GAC GAA GCC Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gln Gly Tyr Asp Glu Ala 1090 1095 1100	3312
TAT GGT AAT AAC CCT TCC GTA CCA GCT GAT TAC GCT TCA GTC TAT GAA Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser Val Tyr Glu 1105 1110 1115 1120	3360
GAA AAA TCG TAT ACA GAT GGA CGA AGA GAG AAT CCT TGT GAA TCT AAC Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys Glu Ser Asn 1125 1130 1135	3408
AGA GGC TAT GGG GAT TAC ACA CCA CTA CCG GCT GGT TAT GTA ACA AAG Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr Lys 1140 1145 1150	3456
GAT TTA GAG TAC TTC CCA GAG ACC GAT AAG GTA TGG ATT GAG ATC GGA Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp Ile Glu Ile Gly 1155 1160 1165	3504
GAA ACA GAA GGA ACA TTC ATC GTG GAT AGC GTG GAA TTA CTC CTT ATG Glu Thr Glu Gly Thr Phe Ile Val Asp Ser Val Glu Leu Leu Met 1170 1175 1180	3552
GAG GAA Glu Glu 1185	3558

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1186 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met	Glu	Ile	Val	Asn	Asn	Gln	Asn	Gln	Cys	Val	Pro	Tyr	Asn	Cys	Leu
1			5						10					15	
Asn Asn Pro Glu Asn Glu Ile Leu Asp Ile Glu Arg Ser Asn Ser Thr															
			20				25						30		
Val Ala Thr Asn Ile Ala Leu Glu Ile Ser Arg Leu Leu Ala Ser Ala															
			35				40						45		
Thr Pro Ile Gly Gly Ile Leu Leu Gly Leu Phe Asp Ala Ile Trp Gly															
			50				55						60		
Ser Ile Gly Pro Ser Gln Trp Asp Leu Phe Leu Glu Gln Ile Glu Leu															
			65				70						75		80
Leu Ile Asp Gln Lys Ile Glu Glu Phe Ala Arg Asn Gln Ala Ile Ser															
			85				90						95		
Arg Leu Glu Gly Ile Ser Ser Leu Tyr Gly Ile Tyr Thr Glu Ala Phe															
			100				105						110		
Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Lys Glu Glu Met															
			115				120						125		
Arg Thr Gln Phe Asn Asp Met Asn Ser Ile Leu Val Thr Ala Ile Pro															
			130				135						140		
Leu Phe Ser Val Gln Asn Tyr Gln Val Pro Phe Leu Ser Val Tyr Val															
			145				150						155		160
Gln Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser Val Phe															
			165				170						175		
Gly Gln Ala Trp Gly Phe Asp Ile Ala Thr Ile Asn Ser Arg Tyr Asn															
			180				185						190		
Asp Leu Thr Arg Leu Ile Pro Ile Tyr Thr Asp Tyr Ala Val Arg Trp															
			195				200						205		
Tyr Asn Thr Gly Leu Asp Arg Leu Pro Arg Thr Gly Gly Leu Arg Asn															
			210				215						220		

Trp Ala Arg Phe Asn Gln Phe Arg Arg Glu Leu Thr Ile Ser Val Leu
 225 230 235 240

Asp Ile Ile Ser Phe Phe Arg Asn Tyr Asp Ser Arg Leu Tyr Pro Ile
 245 250 255

Pro Thr Ser Ser Gln Leu Thr Arg Glu Val Tyr Thr Asp Pro Val Ile
 260 265 270

Asn Ile Thr Asp Tyr Arg Val Gly Pro Ser Phe Glu Asn Ile Glu Asn
 275 280 285

Ser Ala Ile Arg Ser Pro His Leu Met Asp Phe Leu Asn Asn Leu Thr
 290 295 300

Ile Asp Thr Asp Leu Ile Arg Gly Val His Tyr Trp Ala Gly His Arg
 305 310 315 320

Val Thr Ser His Phe Thr Gly Ser Ser Gln Val Ile Thr Thr Pro Gln
 325 330 335

Tyr Gly Ile Thr Ala Asn Ala Glu Pro Arg Arg Thr Ile Ala Pro Ser
 340 345 350

Thr Phe Pro Gly Leu Asn Leu Phe Tyr Arg Thr Leu Ser Asn Pro Phe
 355 360 365

Phe Arg Arg Ser Glu Asn Ile Thr Pro Thr Leu Gly Ile Asn Val Val
 370 375 380

Gln Gly Val Gly Phe Ile Gln Pro Asn Asn Ala Glu Val Leu Tyr Arg
 385 390 395 400

Ser Arg Gly Thr Val Asp Ser Leu Asn Glu Leu Pro Ile Asp Gly Glu
 405 410 415

Asn Ser Leu Val Gly Tyr Ser His Arg Leu Ser His Val Thr Leu Thr
 420 425 430

Arg Ser Leu Tyr Asn Thr Asn Ile Thr Ser Leu Pro Thr Phe Val Trp
 435 440 445

Thr His His Ser Ala Thr Asn Thr Asn Thr Ile Asn Pro Asp Ile Ile
 450 455 460

Thr Gln Ile Pro Leu Val Lys Gly Phe Arg Val Trp Gly Gly Thr Ser
 465 470 475 480

Val Ile Thr Gly Pro Gly Phe Thr Gly Gly Asp Ile Leu Arg Arg Asn
 485 490 495

Thr Phe Gly Asp Phe Val Ser Leu Gln Val Asn Ile Asn Ser Pro Ile

500	505	510
Thr Gln Arg Tyr Arg Leu Arg Phe Arg Tyr Ala Ser Ser Arg Asp Ala		
515	520	525
Arg Val Ile Val Leu Thr Gly Ala Ala Ser Thr Gly Val Gly Gly Gln		
530	535	540
Val Ser Val Asn Met Pro Leu Gln Lys Thr Met Glu Ile Gly Glu Asn		
545	550	555
Leu Thr Ser Arg Thr Phe Arg Tyr Thr Asp Phe Ser Asn Pro Phe Ser		
565	570	575
Phe Arg Ala Asn Pro Asp Ile Ile Gly Ile Ser Glu Gln Pro Leu Phe		
580	585	590
Gly Ala Gly Ser Ile Ser Ser Gly Glu Leu Tyr Ile Asp Lys Ile Glu		
595	600	605
Ile Ile Leu Ala Asp Ala Thr Phe Glu Ala Glu Ser Asp Leu Glu Arg		
610	615	620
Ala Gln Lys Ala Val Asn Ala Leu Phe Thr Ser Ser Asn Gln Ile Gly		
625	630	635
Leu Lys Thr Asp Val Thr Asp Tyr His Ile Asp Gln Val Ser Asn Leu		
645	650	655
Val Asp Cys Leu Ser Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu		
660	665	670
Ser Glu Lys Val Lys His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu		
675	680	685
Leu Gln Asp Pro Asn Phe Arg Gly Ile Asn Arg Gln Pro Asp Arg Gly		
690	695	700
Trp Arg Gly Ser Thr Asp Ile Thr Ile Gln Gly Gly Asp Asp Val Phe		
705	710	715
Lys Glu Asn Tyr Val Thr Leu Pro Gly Thr Val Asp Glu Cys Tyr Pro		
725	730	735
Thr Tyr Leu Tyr Gln Lys Ile Asp Glu Ser Lys Leu Lys Ala Tyr Thr		
740	745	750
Arg Tyr Glu Leu Arg Gly Tyr Ile Glu Asp Ser Gln Asp Leu Glu Ile		
755	760	765
Tyr Leu Ile Arg Tyr Asn Ala Lys His Glu Ile Val Asn Val Pro Gly		
770	775	780

Thr Gly Ser Leu Trp Pro Leu Ser Ala Gln Ser Pro Ile Gly Lys Cys
 785 790 795 800

 Gly Glu Pro Asn Arg Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu
 805 810 815

 Asp Cys Ser Cys Arg Asp Gly Glu Lys Cys Ala His His Ser His His
 820 825 830

 Phe Thr Leu Asp Ile Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu
 835 840 845

 Gly Val Trp Val Ile Phe Lys Ile Lys Thr Gln Asp Gly His Ala Arg
 850 855 860

 Leu Gly Asn Leu Glu Phe Leu Glu Glu Lys Pro Leu Leu Gly Glu Ala
 865 870 875 880

 Leu Ala Arg Val Lys Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu
 885 890 895

 Lys Leu Gln Leu Glu Thr Asn Ile Val Tyr Lys Glu Ala Lys Glu Ser
 900 905 910

 Val Asp Ala Leu Phe Val Asn Ser Gln Tyr Asp Arg Leu Gln Val Asp
 915 920 925

 Thr Asn Ile Ala Met Ile His Ala Ala Asp Lys Arg Val His Arg Ile
 930 935 940

 Arg Glu Ala Tyr Leu Pro Glu Leu Ser Val Ile Pro Gly Val Asn Ala
 945 950 955 960

 Ala Ile Phe Glu Glu Leu Glu Gly Arg Ile Phe Thr Ala Tyr Ser Leu
 965 970 975

 Tyr Asp Ala Arg Asn Val Ile Lys Asn Gly Asp Phe Asn Asn Gly Leu
 980 985 990

 Leu Cys Trp Asn Val Lys Gly His Val Asp Val Glu Glu Gln Asn Asn
 995 1000 1005

 His Arg Ser Val Leu Val Ile Pro Glu Trp Glu Ala Glu Val Ser Gln
 1010 1015 1020

 Glu Val Arg Val Cys Pro Gly Arg Gly Tyr Ile Leu Arg Val Thr Ala
 1025 1030 1035 1040

 Tyr Lys Glu Gly Tyr Gly Glu Gly Cys Val Thr Ile His Glu Ile Glu
 1045 1050 1055

 Asp Asn Thr Asp Glu Leu Lys Phe Ser Asn Cys Val Glu Glu Val
 1060 1065 1070

Tyr Pro Asn Asn Thr Val Thr Cys Asn Asn Tyr Thr Gly Thr Gln Glu
 1075 1080 1085

Glu Tyr Glu Gly Thr Tyr Thr Ser Arg Asn Gln Gly Tyr Asp Glu Ala
 1090 1095 1100

Tyr Gly Asn Asn Pro Ser Val Pro Ala Asp Tyr Ala Ser Val Tyr Glu
 1105 1110 1115 1120

Glu Lys Ser Tyr Thr Asp Gly Arg Arg Glu Asn Pro Cys Glu Ser Asn
 1125 1130 1135

Arg Gly Tyr Gly Asp Tyr Thr Pro Leu Pro Ala Gly Tyr Val Thr Lys
 1140 1145 1150

Asp Leu Glu Tyr Phe Pro Glu Thr Asp Lys Val Trp Ile Glu Ile Gly
 1155 1160 1165

Glu Thr Glu Gly Thr Phe Ile Val Asp Ser Val Glu Leu Leu Leu Met
 1170 1175 1180

Glu Glu
 1185

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3579 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Hybrid toxin

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 1..3579

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA
 Met Asp Asn Asn Pro Asn Ile Asn Glu Cys Ile Pro Tyr Asn Cys Leu
 1 5 10 15

48

AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg Ile Glu Thr Gly	20 25 30	96
TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT Tyr Thr Pro Ile Asp Ile Ser Leu Ser Leu Thr Gln Phe Leu Leu Ser	35 40 45	144
GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp Ile Ile	50 55 60	192
TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT Trp Gly Ile Phe Gly Pro Ser Gln Trp Asp Ala Phe Leu Val Gln Ile	65 70 75 80	240
GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC Glu Gln Leu Ile Asn Gln Arg Ile Glu Glu Phe Ala Arg Asn Gln Ala	85 90 95	288
ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA Ile Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gln Ile Tyr Ala Glu	100 105 110	336
TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu	115 120 125	384
GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT Glu Met Arg Ile Gln Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala	130 135 140	432
ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA Ile Pro Leu Phe Ala Val Gln Asn Tyr Gln Val Pro Leu Leu Ser Val	145 150 155 160	480
TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA Tyr Val Gln Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser	165 170 175	528
GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT Val Phe Gly Gln Arg Trp Gly Phe Asp Ala Ala Thr Ile Asn Ser Arg	180 185 190	576
TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT CAT GCT GTA Tyr Asn Asp Leu Thr Arg Leu Ile Gly Asn Tyr Thr Asp His Ala Val	195 200 205	624
CGC TGG TAC AAT ACG GGA TTA GAG CGT GTA TGG GGA CCG GAT TCT AGA Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg	210 215 220	672
GAT TGG ATA AGA TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA		720

Asp Trp Ile Arg Tyr Asn Gln Phe Arg Arg Glu Leu Thr Leu Thr Val			
225	230	235	240
TTA GAT ATC GTT TCT CTA TTT CCG AAC TAT GAT AGT AGA ACG TAT CCA			768
Leu Asp Ile Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro			
245	250	255	
ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA			816
Ile Arg Thr Val Ser Gln Leu Thr Arg Glu Ile Tyr Thr Asn Pro Val			
260	265	270	
TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA			864
Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gln Gly Ile Glu			
275	280	285	
GGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC			912
Gly Ser Ile Arg Ser Pro His Leu Met Asp Ile Leu Asn Ser Ile Thr			
290	295	300	
ATC TAT ACG GAT GCT CAT AGA GGA GAA TAT TAT TGG TCA GGG CAT CAA			960
Ile Tyr Thr Asp Ala His Arg Gly Glu Tyr Tyr Trp Ser Gly His Gln			
305	310	315	320
ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG			1008
Ile Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro			
325	330	335	
CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CGT ATT GTT GCT			1056
Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gln Gln Arg Ile Val Ala			
340	345	350	
CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA			1104
Gln Leu Gly Gln Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg			
355	360	365	
AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC			1152
Arg Pro Phe Asn Ile Gly Ile Asn Asn Gln Gln Leu Ser Val Leu Asp			
370	375	380	
GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA			1200
Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val			
385	390	395	400
TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG			1248
Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu Ile Pro Pro Gln			
405	410	415	
AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT			1296
Asn Asn Asn Val Pro Pro Arg Gln Gly Phe Ser His Arg Leu Ser His			
420	425	430	
GTG TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GCA AGT ATA ATA			1344
Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser Ile Ile			

435	440	445	
AGA GCT CCT ATG TTC TCT TGG ATA CAT CGT AGT GCA ACT CTT ACA AAT Arg Ala Pro Met Phe Ser Trp Ile His Arg Ser Ala Thr Leu Thr Asn			1392
450	455	460	
ACA ATT GAT CCA GAG AGA ATT AAT CAA ATA CCT TTA GTG AAA GGA TTT Thr Ile Asp Pro Glu Arg Ile Asn Gln Ile Pro Leu Val Lys Gly Phe			1440
465	470	475	480
AGA GTT TGG GGG GGC ACC TCT GTC ATT ACA GGA CCA GGA TTT ACA GGA Arg Val Trp Gly Gly Thr Ser Val Ile Thr Gly Pro Gly Phe Thr Gly			1488
485	490	495	
GGG GAT ATC CTT CGA AGA AAT ACC TTT GGT GAT TTT GTA TCT CTA CAA Gly Asp Ile Leu Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gln			1536
500	505	510	
GTC AAT ATT AAT TCA CCA ATT ACC CAA AGA TAC CGT TTA AGA TTT CGT Val Asn Ile Asn Ser Pro Ile Thr Gln Arg Tyr Arg Leu Arg Phe Arg			1584
515	520	525	
TAC GCT TCC AGT AGG GAT GCA CGA GTT ATA GTA TTA ACA GGA GCG GCA Tyr Ala Ser Ser Arg Asp Ala Arg Val Ile Val Leu Thr Gly Ala Ala			1632
530	535	540	
TCC ACA GGA GTG GGA GGC CAA GTT AGT GTA AAT ATG CCT CTT CAG AAA Ser Thr Gly Val Gly Gln Val Ser Val Asn Met Pro Leu Gln Lys			1680
545	550	555	560
ACT ATG GAA ATA GGG GAG AAC TTA ACA TCT AGA ACA TTT AGA TAT ACC Thr Met Glu Ile Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr			1728
565	570	575	
GAT TTT AGT AAT CCT TTT TCA TTT AGA GCT AAT CCA GAT ATA ATT GGG Asp Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile Ile Gly			1776
580	585	590	
ATA AGT GAA CAA CCT CTA TTT GGT GCA GGT TCT ATT AGT AGC GGT GAA Ile Ser Glu Gln Pro Leu Phe Gly Ala Gly Ser Ile Ser Ser Gly Glu			1824
595	600	605	
CTT TAT ATA GAT AAA ATT GAA ATT ATT CTA GCA GAT GCA ACA TTT GAA Leu Tyr Ile Asp Lys Ile Glu Ile Ile Leu Ala Asp Ala Thr Phe Glu			1872
610	615	620	
GCA GAA TCT GAT TTA GAA AGA GCA CAA AAG GCG GTG AAT GCC CTG TTT Ala Glu Ser Asp Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu Phe			1920
625	630	635	640
ACT TCT TCC AAT CAA ATC GGG TTA AAA ACC GAT GTG ACG GAT TAT CAT Thr Ser Ser Asn Gln Ile Gly Leu Lys Thr Asp Val Thr Asp Tyr His			1968
645	650	655	

ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA GAT GAA TTT TGT Ile Asp Gln Val Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys 660 665 670	2016
CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA CAT GCG AAG CGA Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg 675 680 685	2064
CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG ATC Leu Ser Asp Glu Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly Ile 690 695 700	2112
AAT AGA CAA CCA GAC CGT GGC TGG AGA GGA AGT ACA GAT ATT ACC ATC Asn Arg Gln Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr Ile 705 710 715 720	2160
CAA GGA GGA GAT GAC GTA TTC AAA GAG AAT TAC GTC ACA CTA CCG GGT Gln Gly Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly 725 730 735	2208
ACC GTT GAT GAG TGC TAT CCA ACG TAT TTA TAT CAG AAA ATA GAT GAG Thr Val Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp Glu 740 745 750	2256
TCG AAA TTA AAA GCT TAT ACC CGT TAT GAA TTA AGA GGG TAT ATC GAA Ser Lys Leu Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile Glu 755 760 765	2304
GAT AGT CAA GAC TTA GAA ATC TAT TTG ATC CGT TAC AAT GCA AAA CAC Asp Ser Gln Asp Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys His 770 775 780	2352
GAA ATA GTA AAT GTG CCA GGC ACG GGT TCC TTA TGG CCG CTT TCA GCC Glu Ile Val Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala 785 790 795 800	2400
CAA AGT CCA ATC GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA CAC Gln Ser Pro Ile Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His 805 810 815	2448
CTT GAA TGG AAT CCT GAT CTA GAT TGT TCC TGC AGA GAC GGG GAA AAA Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys 820 825 830	2496
TGT GCA CAT CAT TCC CAT CAT TTC ACC TTG GAT ATT GAT GTT GGA TGT Cys Ala His His Ser His His Phe Thr Leu Asp Ile Asp Val Gly Cys 835 840 845	2544
ACA GAC TTA AAT GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT AAG Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile Lys 850 855 860	2592

ACG CAA GAT GGC CAT GCA AGA CTA GGG AAT CTA GAG TTT CTC GAA GAG Thr Gln Asp Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu 865	870	875	880	2640
AAA CCA TTA TTA GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG AAG Lys Pro Leu Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys 885	890	895		2688
AAG TGG AGA GAC AAA CGA GAG AAA CTG CAG TTG GAA ACA AAT ATT GTT Lys Trp Arg Asp Lys Arg Glu Lys Leu Gln Leu Glu Thr Asn Ile Val 900	905	910		2736
TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT CAA Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gln 915	920	925		2784
TAT GAT AGA TTA CAA GTG GAT ACG AAC ATC GCG ATG ATT CAT GCG GCA Tyr Asp Arg Leu Gln Val Asp Thr Asn Ile Ala Met Ile His Ala Ala 930	935	940		2832
GAT AAA CGC GTT CAT AGA ATC CGG GAA GCG TAT CTG CCA GAG TTG TCT Asp Lys Arg Val His Arg Ile Arg Glu Ala Tyr Leu Pro Glu Leu Ser 945	950	955	960	2880
GTG ATT CCA GGT GTC AAT GCG GCC ATT TTC GAA GAA TTA GAG GGA CGT Val Ile Pro Gly Val Asn Ala Ala Ile Phe Glu Glu Leu Glu Gly Arg 965	970	975		2928
ATT TTT ACA GCG TAT TCC TTA TAT GAT GCG AGA AAT GTC ATT AAA AAT Ile Phe Thr Ala Tyr Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys Asn 980	985	990		2976
GGC GAT TTC AAT AAT GGC TTA TTA TGC TGG AAC GTG AAA GGT CAT GTA Gly Asp Phe Asn Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val 995	1000	1005		3024
GAT GTA GAA GAG CAA AAC AAC CAC CGT TCG GTC CTT GTT ATC CCA GAA Asp Val Glu Glu Gln Asn Asn His Arg Ser Val Leu Val Ile Pro Glu 1010	1015	1020		3072
TGG GAG GCA GAA GTG TCA CAA GAG GTT CGT GTC TGT CCA GGT CGT GGC Trp Glu Ala Glu Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg Gly 1025	1030	1035	1040	3120
TAT ATC CTT CGT GTC ACA GCA TAT AAA GAG GGA TAT GGA GAG GGC TGC Tyr Ile Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys 1045	1050	1055		3168
GTA ACG ATC CAT GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC AGC Val Thr Ile His Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser 1060	1065	1070		3216
AAC TGT GTA GAA GAG GAA GTA TAT CCA AAC AAC ACA GTA ACG TGT AAT				3264

Asn Cys Val Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn			
1075	1080	1085	
AAT TAT ACT GGG ACT CAA GAA GAA TAT GAG GGT ACG TAC ACT TCT CGT			3312
Asn Tyr Thr Gly Thr Gln Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg			
1090	1095	1100	
AAT CAA GGA TAT GAC GAA GCC TAT GGT AAT AAC CCT TCC GTA CCA GCT			3360
Asn Gln Gly Tyr Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala			
1105	1110	1115	1120
GAT TAC GCT TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA			3408
Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg			
1125	1130	1135	
GAG AAT CCT TGT GAA TCT AAC AGA GGC TAT GGG GAT TAC ACA CCA CTA			3456
Glu Asn Pro Cys Glu Ser Asn Arg Gly Tyr Asp Tyr Thr Pro Leu			
1140	1145	1150	
CCG GCT GGT TAT GTA ACA AAG GAT TTA GAG TAC TTC CCA GAG ACC GAT			3504
Pro Ala Gly Tyr Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp			
1155	1160	1165	
AAG GTA TGG ATT GAG ATC GGA GAA ACA GAA GGA ACA TTC ATC GTG GAT			3552
Lys Val Trp Ile Glu Ile Gly Glu Thr Glu Gly Thr Phe Ile Val Asp			
1170	1175	1180	
AGC GTG GAA TTA CTC CTT ATG GAG GAA			3579
Ser Val Glu Leu Leu Leu Met Glu Glu			
1185	1190		

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1193 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Asp Asn Asn Pro Asn Ile Asn Glu Cys Ile Pro Tyr Asn Cys Leu
1 5 10 15

Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg Ile Glu Thr Gly
 20 25 30

Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp Ile Ile

50	55	60
Trp Gly Ile Phe Gly Pro Ser Gln Trp Asp Ala Phe Leu Val Gln Ile		
65	70	75
Glu Gln Leu Ile Asn Gln Arg Ile Glu Glu Phe Ala Arg Asn Gln Ala		
85	90	95
Ile Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gln Ile Tyr Ala Glu		
100	105	110
Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu		
115	120	125
Glu Met Arg Ile Gln Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala		
130	135	140
Ile Pro Leu Phe Ala Val Gln Asn Tyr Gln Val Pro Leu Leu Ser Val		
145	150	155
Tyr Val Gln Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser		
165	170	175
Val Phe Gly Gln Arg Trp Gly Phe Asp Ala Ala Thr Ile Asn Ser Arg		
180	185	190
Tyr Asn Asp Leu Thr Arg Leu Ile Gly Asn Tyr Thr Asp His Ala Val		
195	200	205
Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg		
210	215	220
Asp Trp Ile Arg Tyr Asn Gln Phe Arg Arg Glu Leu Thr Leu Thr Val		
225	230	235
Leu Asp Ile Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro		
245	250	255
Ile Arg Thr Val Ser Gln Leu Thr Arg Glu Ile Tyr Thr Asn Pro Val		
260	265	270
Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gln Gly Ile Glu		
275	280	285
Gly Ser Ile Arg Ser Pro His Leu Met Asp Ile Leu Asn Ser Ile Thr		
290	295	300
Ile Tyr Thr Asp Ala His Arg Gly Glu Tyr Tyr Trp Ser Gly His Gln		
305	310	315
Ile Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro		
325	330	335

Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gln Gln Arg Ile Val Ala
 340 345 350

Gln Leu Gly Gln Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg
 355 360 365

Arg Pro Phe Asn Ile Gly Ile Asn Asn Gln Gln Leu Ser Val Leu Asp
 370 375 380 385

Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val
 385 390 395 400

Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu Ile Pro Pro Gln
 405 410 415

Asn Asn Asn Val Pro Pro Arg Gln Gly Phe Ser His Arg Leu Ser His
 420 425 430

Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser Ile Ile
 435 440 445

Arg Ala Pro Met Phe Ser Trp Ile His Arg Ser Ala Thr Leu Thr Asn
 450 455 460

Thr Ile Asp Pro Glu Arg Ile Asn Gln Ile Pro Leu Val Lys Gly Phe
 465 470 475 480

Arg Val Trp Gly Gly Thr Ser Val Ile Thr Gly Pro Gly Phe Thr Gly
 485 490 495

Gly Asp Ile Leu Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gln
 500 505 510

Val Asn Ile Asn Ser Pro Ile Thr Gln Arg Tyr Arg Leu Arg Phe Arg
 515 520 525

Tyr Ala Ser Ser Arg Asp Ala Arg Val Ile Val Leu Thr Gly Ala Ala
 530 535 540

Ser Thr Gly Val Gly Gly Gln Val Ser Val Asn Met Pro Leu Gln Lys
 545 550 555 560

Thr Met Glu Ile Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr
 565 570 575

Asp Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile Ile Gly
 580 585 590

Ile Ser Glu Gln Pro Leu Phe Gly Ala Gly Ser Ile Ser Ser Gly Glu
 595 600 605

Leu Tyr Ile Asp Lys Ile Glu Ile Ile Leu Ala Asp Ala Thr Phe Glu
 610 615 620

Ala Glu Ser Asp Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu Phe
 625 630 635 640

Thr Ser Ser Asn Gln Ile Gly Leu Lys Thr Asp Val Thr Asp Tyr His
 645 650 655

Ile Asp Gln Val Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys
 660 665 670

Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg
 675 680 685

Leu Ser Asp Glu Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly Ile
 690 695 700

Asn Arg Gln Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr Ile
 705 710 715 720

Gln Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly
 725 730 735

Thr Val Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp Glu
 740 745 750

Ser Lys Leu Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile Glu
 755 760 765

Asp Ser Gln Asp Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys His
 770 775 780

Glu Ile Val Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala
 785 790 795 800

Gln Ser Pro Ile Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His
 805 810 815

Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys
 820 825 830

Cys Ala His His Ser His His Phe Thr Leu Asp Ile Asp Val Gly Cys
 835 840 845

Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile Lys
 850 855 860

Thr Gln Asp Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu
 865 870 875 880

Lys Pro Leu Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys
 885 890 895

Lys Trp Arg Asp Lys Arg Glu Lys Leu Gln Leu Glu Thr Asn Ile Val

900	905	910
Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gln		
915	920	925
Tyr Asp Arg Leu Gln Val Asp Thr Asn Ile Ala Met Ile His Ala Ala		
930	935	940
Asp Lys Arg Val His Arg Ile Arg Glu Ala Tyr Leu Pro Glu Leu Ser		
945	950	955
Val Ile Pro Gly Val Asn Ala Ala Ile Phe Glu Glu Leu Glu Gly Arg		
965	970	975
Ile Phe Thr Ala Tyr Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys Asn		
980	985	990
Gly Asp Phe Asn Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val		
995	1000	1005
Asp Val Glu Glu Gln Asn Asn His Arg Ser Val Leu Val Ile Pro Glu		
1010	1015	1020
Trp Glu Ala Glu Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg Gly		
1025	1030	1035
Tyr Ile Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys		
1045	1050	1055
Val Thr Ile His Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser		
1060	1065	1070
Asn Cys Val Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn		
1075	1080	1085
Asn Tyr Thr Gly Thr Gln Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg		
1090	1095	1100
Asn Gln Gly Tyr Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala		
1105	1110	1115
Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg		
1125	1130	1135
Glu Asn Pro Cys Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu		
1140	1145	1150
Pro Ala Gly Tyr Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp		
1155	1160	1165
Lys Val Trp Ile Glu Ile Gly Glu Thr Glu Gly Thr Phe Ile Val Asp		
1170	1175	1180

Ser Val Glu Leu Leu Met Glu Glu
1185 1190

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3468 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Bacillus thuringiensis*

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..3468

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATG AAT CAA AAT AAA CAC GGA ATT ATT GGC GCT TCC AAT TGT GGT TGT	48
Met Asn Gln Asn Lys His Gly Ile Ile Gly Ala Ser Asn Cys Gly Cys	
1 5 10 15	
GCA TCT GAT GAT GTT GCG AAA TAT CCT TTA GCC AAC AAT CCA TAT TCA	96
Ala Ser Asp Asp Val Ala Lys Tyr Pro Leu Ala Asn Asn Pro Tyr Ser	
20 25 30	
TCT GCT TTA AAT TTA AAT TCT TGT CAA AAT AGT AGT ATT CTC AAC TGG	144
Ser Ala Leu Asn Leu Asn Ser Cys Gln Asn Ser Ser Ile Leu Asn Trp	
35 40 45	
ATT AAC ATA ATA GGC GAT GCA GCA AAA GAA GCA GTA TCT ATT GGG ACA	192
Ile Asn Ile Ile Gly Asp Ala Ala Lys Glu Ala Val Ser Ile Gly Thr	
50 55 60	
ACC ATA GTC TCT CTT ATC ACA GCA CCT TCT CTT ACT GGA TTA ATT TCA	240
Thr Ile Val Ser Leu Ile Thr Ala Pro Ser Leu Thr Gly Leu Ile Ser	
65 70 75 80	
ATA GTA TAT GAC CTT ATA GGT AAA GTA CTA GGA GGT AGT AGT GGA CAA	288
Ile Val Tyr Asp Leu Ile Gly Lys Val Leu Gly Gly Ser Ser Gly Gln	
85 90 95	
TCC ATA TCA GAT TTG TCT ATA TGT GAC TTA TTA TCT ATT ATT GAT TTA	336
Ser Ile Ser Asp Leu Ser Ile Cys Asp Leu Leu Ser Ile Ile Asp Leu	
100 105 110	
CGG GTA AGT CAG AGT GTT TTA AAT GAT GGG ATT GCA GAT TTT AAT GGT	384

Arg Val Ser Gln Ser Val Leu Asn Asp Gly Ile Ala Asp Phe Asn Gly			
115	120	125	
TCT GTA CTC TTA TAC AGG AAC TAT TTA GAG GCT CTG GAT AGC TGG AAT			432
Ser Val Leu Leu Tyr Arg Asn Tyr Leu Glu Ala Leu Asp Ser Trp Asn			
130	135	140	
AAG AAT CCT AAT TCT GCT TCT GCT GAA GAA CTC CGT ACT CGT TTT AGA			480
Lys Asn Pro Asn Ser Ala Ser Ala Glu Glu Leu Arg Thr Arg Phe Arg			
145	150	155	160
ATC GCC GAC TCA GAA TTT GAT AGA ATT TTA ACC CGA GGG TCT TTA ACG			528
Ile Ala Asp Ser Glu Phe Asp Arg Ile Leu Thr Arg Gly Ser Leu Thr			
165	170	175	
AAT GGT GGC TCG TTA GCT AGA CAA AAT GCC CAA ATA TTA TTA CCT			576
Asn Gly Gly Ser Leu Ala Arg Gln Asn Ala Gln Ile Leu Leu Leu Pro			
180	185	190	
TCT TTT GCG AGC GCT GCA TTT TTC CAT TTA CTA CTA AGG GAT GCT			624
Ser Phe Ala Ser Ala Ala Phe Phe His Leu Leu Leu Leu Arg Asp Ala			
195	200	205	
ACT AGA TAT GGC ACT AAT TGG GGG CTA TAC AAT GCT ACA CCT TTT ATA			672
Thr Arg Tyr Gly Thr Asn Trp Gly Leu Tyr Asn Ala Thr Pro Phe Ile			
210	215	220	
AAT TAT CAA TCA AAA CTA GTA GAG CTT ATT GAA CTA TAT ACT GAT TAT			720
Asn Tyr Gln Ser Lys Leu Val Glu Leu Ile Glu Leu Tyr Thr Asp Tyr			
225	230	235	240
TGC GTA CAT TGG TAT AAT CGA GGT TTC AAC GAA CTA AGA CAA CGA GGC			768
Cys Val His Trp Tyr Asn Arg Gly Phe Asn Glu Leu Arg Gln Arg Gly			
245	250	255	
ACT AGT GCT ACA GCT TGG TTA GAA TTT CAT AGA TAT CGT AGA GAG ATG			816
Thr Ser Ala Thr Ala Trp Leu Glu Phe His Arg Tyr Arg Arg Glu Met			
260	265	270	
ACA TTG ATG GTA TTA GAT ATA GTA GCA TCA TTT TCA AGT CTT GAT ATT			864
Thr Leu Met Val Leu Asp Ile Val Ala Ser Phe Ser Ser Leu Asp Ile			
275	280	285	
ACT AAT TAC CCA ATA GAA ACA GAT TTT CAG TTG AGT AGG GTC ATT TAT			912
Thr Asn Tyr Pro Ile Glu Thr Asp Phe Gln Leu Ser Arg Val Ile Tyr			
290	295	300	
ACA GAT CCA ATT GGT TTT GTA CAT CGT AGT AGT CTT AGG GGA GAA AGT			960
Thr Asp Pro Ile Gly Phe Val His Arg Ser Ser Leu Arg Gly Glu Ser			
305	310	315	320
TGG TTT AGC TTT GTT AAT AGA GCT AAT TTC TCA GAT TTA GAA AAT GCA			1008
Trp Phe Ser Phe Val Asn Arg Ala Asn Phe Ser Asp Leu Glu Asn Ala			

	325	330	335	
ATA CCT AAT CCT AGA CCG TCT TGG TTT TTA AAT AAT ATG ATT ATA TCT Ile Pro Asn Pro Arg Pro Ser Trp Phe Leu Asn Asn Met Ile Ile Ser	340	345	350	1056
ACT GGT TCA CTT ACA TTG CCG GTT AGC CCA AGT ACT GAT AGA GCG AGG Thr Gly Ser Leu Thr Leu Pro Val Ser Pro Thr Asp Arg Ala Arg	355	360	365	1104
GTA TGG TAT GGA AGT CGA GAT CGA ATT TCC CCT GCT AAT TCA CAA TTT Val Trp Tyr Gly Ser Arg Asp Arg Ile Ser Pro Ala Asn Ser Gln Phe	370	375	380	1152
ATT ACT GAA CTA ATC TCT GGA CAA CAT ACG ACT GCT ACA CAA ACT ATT Ile Thr Glu Leu Ile Ser Gly Gln His Thr Thr Ala Thr Gln Thr Ile	385	390	395	1200
TTA GGG CGA AAT ATA TTT AGA GTA GAT TCT CAA GCT TGT AAT TTA AAT Leu Gly Arg Asn Ile Phe Arg Val Asp Ser Gln Ala Cys Asn Leu Asn	405	410	415	1248
GAT ACC ACA TAT GGA GTG AAT AGG GCG GTA TTT TAT CAT GAT GCG AGT Asp Thr Thr Tyr Gly Val Asn Arg Ala Val Phe Tyr His Asp Ala Ser	420	425	430	1296
GAA GGT TCT CAA AGA TCC GTG TAC GAG GGG TAT ATT CGA ACA ACT GGG Glu Gly Ser Gln Arg Ser Val Tyr Glu Gly Tyr Ile Arg Thr Thr Gly	435	440	445	1344
ATA GAT AAC CCT AGA GTT CAA AAT ATT AAC ACT TAT TTA CCT GGA GAA Ile Asp Asn Pro Arg Val Gln Asn Ile Asn Thr Tyr Leu Pro Gly Glu	450	455	460	1392
AAT TCA GAT ATC CCA ACT CCA GAA GAC TAT ACT CAT ATA TTA AGC ACA Asn Ser Asp Ile Pro Thr Pro Glu Asp Tyr Thr His Ile Leu Ser Thr	465	470	475	1440
ACA ATA AAT TTA ACA GGA GGA CTT AGA CAA GTA GCA TCT AAT CGC CGT Thr Ile Asn Leu Thr Gly Leu Arg Gln Val Ala Ser Asn Arg Arg	485	490	495	1488
TCA TCT TTA GTA ATG TAT GGT TGG ACA CAT AAA AGT CTG GCT CGT AAC Ser Ser Leu Val Met Tyr Gly Trp Thr His Lys Ser Leu Ala Arg Asn	500	505	510	1536
AAT ACC ATT AAT CCA GAT AGA ATT ACA CAG ATA CCA TTG ACG AAG GTT Asn Thr Ile Asn Pro Asp Arg Ile Thr Gln Ile Pro Leu Thr Lys Val	515	520	525	1584
GAT ACC CGA GGC ACA GGT GTT TCT TAT GTG AAT GAT CCA GGA TTT ATA Asp Thr Arg Gly Thr Gly Val Ser Tyr Val Asn Asp Pro Gly Phe Ile	530	535	540	1632

GGA GGA GCT CTA CTT CAA AGG ACT GAC CAT GGT TCG CTT GGA GTA TTG Gly Gly Ala Leu Leu Gln Arg Thr Asp His Gly Ser Leu Gly Val Leu 545 550 555 560	1680
AGG GTC CAA TTT CCA CTT CAC TTA AGA CAA CAA TAT CGT ATT AGA GTC Arg Val Gln Phe Pro Leu His Leu Arg Gln Gln Tyr Arg Ile Arg Val 565 570 575	1728
CGT TAT GCT TCT ACA ACA AAT ATT CGA TTG AGT GTG AAT GGC AGT TTC Arg Tyr Ala Ser Thr Thr Asn Ile Arg Leu Ser Val Asn Gly Ser Phe 580 585 590	1776
GGT ACT ATT TCT CAA AAT CTC CCT AGT ACA ATG AGA TTA GGA GAG GAT Gly Thr Ile Ser Gln Asn Leu Pro Ser Thr Met Arg Leu Gly Glu Asp 595 600 605	1824
TTA AGA TAC GGA TCT TTT GCT ATA AGA GAG TTT AAT ACT TCT ATT AGA Leu Arg Tyr Gly Ser Phe Ala Ile Arg Glu Phe Asn Thr Ser Ile Arg 610 615 620	1872
CCC ACT GCA AGT CCG GAC CAA ATT CGA TTG ACA ATA GAA CCA TCT TTT Pro Thr Ala Ser Pro Asp Gln Ile Arg Leu Thr Ile Glu Pro Ser Phe 625 630 635 640	1920
ATT AGA CAA GAG GTC TAT GTA GAT AGA ATT GAG TTC ATT CCA GTT AAT Ile Arg Gln Glu Val Tyr Val Asp Arg Ile Glu Phe Ile Pro Val Asn 645 650 655	1968
CCG ACG CGA GAG GCG AAA GAG GAT CTA GAA GCA GCA AAA AAA GCG GTG Pro Thr Arg Glu Ala Lys Glu Asp Leu Glu Ala Ala Lys Lys Ala Val 660 665 670	2016
GCG AGC TTG TTT ACA CGC ACA AGG GAC GGA TTA CAA GTA AAT GTG AAA Ala Ser Leu Phe Thr Arg Thr Arg Asp Gly Leu Gln Val Asn Val Lys 675 680 685	2064
GAT TAT CAA GTC GAT CAA GCG GCA AAT TTA GTG TCA TGC TTA TCA GAT Asp Tyr Gln Val Asp Gln Ala Ala Asn Leu Val Ser Cys Leu Ser Asp 690 695 700	2112
GAA CAA TAT GGG TAT GAC AAA AAG ATG TTA TTG GAA GCG GTA CGT GCG Glu Gln Tyr Gly Tyr Asp Lys Lys Met Leu Leu Glu Ala Val Arg Ala 705 710 715 720	2160
GCA AAA CGA CTT AGC CGA GAA CGC AAC TTA CTT CAG GAT CCA GAT TTT Ala Lys Arg Leu Ser Arg Glu Arg Asn Leu Leu Gln Asp Pro Asp Phe 725 730 735	2208
AAT ACA ATC AAT AGT ACA GAA GAA AAT GGA TGG AAA GCA AGT AAC GGC Asn Thr Ile Asn Ser Thr Glu Glu Asn Gly Trp Lys Ala Ser Asn Gly 740 745 750	2256

GTT ACT ATT AGT GAG GGC GGG CCA TTC TAT AAA GGC CGT GCA ATT CAG Val Thr Ile Ser Glu Gly Gly Pro Phe Tyr Lys Gly Arg Ala Ile Gln 755 760 765	2304
CTA GCA AGT GCA CGA GAA AAT TAC CCA ACA TAC ATC TAT CAA AAA GTA Leu Ala Ser Ala Arg Glu Asn Tyr Pro Thr Tyr Ile Tyr Gln Lys Val 770 775 780	2352
GAT GCA TCG GAG TTA AAG CCG TAT ACA CGT TAT AGA CTG GAT GGG TTC Asp Ala Ser Glu Leu Lys Pro Tyr Thr Arg Tyr Arg Leu Asp Gly Phe 785 790 795 800	2400
GTG AAG AGT AGT CAA GAT TTA GAA ATT GAT CTC ATT CAC CAT CAT AAA Val Lys Ser Ser Gln Asp Leu Glu Ile Asp Leu Ile His His His Lys 805 810 815	2448
GTC CAT CTT GTG AAA AAT GTA CCA GAT AAT TTA GTA TCT GAT ACT TAC Val His Leu Val Lys Asn Val Pro Asp Asn Leu Val Ser Asp Thr Tyr 820 825 830	2496
CCA GAT GAT TCT TGT AGT GGA ATC AAT CGA TGT CAG GAA CAA CAG ATG Pro Asp Asp Ser Cys Ser Gly Ile Asn Arg Cys Gln Glu Gln Gln Met 835 840 845	2544
GTA AAT GCG CAA CTG GAA ACA GAG CAT CAT CCG ATG GAT TGC TGT Val Asn Ala Gln Leu Glu Thr Glu His His Pro Met Asp Cys Cys 850 855 860	2592
GAA GCA GCT CAA ACA CAT GAG TTT TCT TCC TAT ATT GAT ACA GGG GAT Glu Ala Ala Gln Thr His Glu Phe Ser Ser Tyr Ile Asp Thr Gly Asp 865 870 875 880	2640
TTA AAT TCG AGT GTA GAC CAG GGA ATC TGG GCG ATC TTT AAA GTT CGA Leu Asn Ser Ser Val Asp Gln Gly Ile Trp Ala Ile Phe Lys Val Arg 885 890 895	2688
ACA ACC GAT GGT TAT GCG ACG TTA GGA AAT CTT GAA TTG GTA GAG GTC Thr Thr Asp Gly Tyr Ala Thr Leu Gly Asn Leu Glu Leu Val Glu Val 900 905 910	2736
GGA CCG TTA TCG GGT GAA TCT TTA GAA CGT GAA CAA AGG GAT AAT ACA Gly Pro Leu Ser Gly Glu Ser Leu Glu Arg Glu Gln Arg Asp Asn Thr 915 920 925	2784
AAA TGG AGT GCA GAG CTA GGA AGA AAG CGT GCA GAA ACA GAT CGC GTG Lys Trp Ser Ala Glu Leu Gly Arg Lys Arg Ala Glu Thr Asp Arg Val 930 935 940	2832
TAT CAA GAT GCC AAA CAA TCC ATC AAT CAT TTA TTT GTG GAT TAT CAA Tyr Gln Asp Ala Lys Gln Ser Ile Asn His Leu Phe Val Asp Tyr Gln 945 950 955 960	2880
GAT CAA CAA TTA AAT CCA GAA ATA GGG ATG GCA GAT ATT ATG GAC GCT	2928

Asp Gln Gln Leu Asn Pro Glu Ile Gly Met Ala Asp Ile Met Asp Ala			
965	970	975	
CAA AAT CTT GTC GCA TCA ATT TCA GAT GTA TAT AGC GAT GCC GTA CTG			2976
Gln Asn Leu Val Ala Ser Ile Ser Asp Val Tyr Ser Asp Ala Val Leu			
980	985	990	
CAA ATC CCT GGA ATT AAC TAT GAG ATT TAC ACA GAG CTG TCC AAT CGC			3024
Gln Ile Pro Gly Ile Asn Tyr Glu Ile Tyr Thr Glu Leu Ser Asn Arg			
995	1000	1005	
TTA CAA CAA GCA TCG TAT CTG TAT ACG TCT CGA AAT GCG GTG CAA AAT			3072
Leu Gln Gln Ala Ser Tyr Leu Tyr Thr Ser Arg Asn Ala Val Gln Asn			
1010	1015	1020	
GGG GAC TTT AAC AAC GGG CTA GAT AGC TGG AAT GCA ACA GCG GGT GCA			3120
Gly Asp Phe Asn Asn Gly Leu Asp Ser Trp Asn Ala Thr Ala Gly Ala			
1025	1030	1035	1040
TCG GTA CAA CAG GAT GGC AAT ACG CAT TTC TTA GTT CTT TCT CAT TGG			3168
Ser Val Gln Gln Asp Gly Asn Thr His Phe Leu Val Leu Ser His Trp			
1045	1050	1055	
GAT GCA CAA GTT TCT CAA CAA TTT AGA GTG CAG CCG AAT TGT AAA TAT			3216
Asp Ala Gln Val Ser Gln Gln Phe Arg Val Gln Pro Asn Cys Lys Tyr			
1060	1065	1070	
GTA TTA CGT GTA ACA GCA GAG AAA GTA GGC GGC GGA GAC GGA TAC GTG			3264
Val Leu Arg Val Thr Ala Glu Lys Val Gly Gly Asp Gly Tyr Val			
1075	1080	1085	
ACT ATC CGG GAT GAT GCT CAT CAT ACA GAA ACG CTT ACA TTT AAT GCA			3312
Thr Ile Arg Asp Asp Ala His His Thr Glu Thr Leu Thr Phe Asn Ala			
1090	1095	1100	
TGT GAT TAT GAT ATA AAT GGC ACG TAC GTG ACT GAT AAT ACG TAT CTA			3360
Cys Asp Tyr Asp Ile Asn Gly Thr Tyr Val Thr Asp Asn Thr Tyr Leu			
1105	1110	1115	1120
ACA AAA GAA GTG GTA TTC CAT CCG GAG ACA CAA CAC ATG TGG GTA GAG			3408
Thr Lys Glu Val Val Phe His Pro Glu Thr Gln His Met Trp Val Glu			
1125	1130	1135	
GTA AAT GAA ACA GAA GGT GCA TTT CAT ATA GAT AGT ATT GAA TTC GTT			3456
Val Asn Glu Thr Glu Gly Ala Phe His Ile Asp Ser Ile Glu Phe Val			
1140	1145	1150	
GAA ACA GAA AAG			3468
Glu Thr Glu Lys			
1155			

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1156 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met	Asn	Gln	Asn	Lys	His	Gly	Ile	Ile	Gly	Ala	Ser	Asn	Cys	Gly	Cys	
1																
														15		
Ala	Ser	Asp	Asp	Val	Ala	Lys	Tyr	Pro	Leu	Ala	Asn	Asn	Pro	Tyr	Ser	
														30		
Ser	Ala	Leu	Asn	Leu	Asn	Ser	Cys	Gln	Asn	Ser	Ser	Ile	Leu	Asn	Trp	
														45		
Ile	Asn	Ile	Ile	Gly	Asp	Ala	Ala	Lys	Glu	Ala	Val	Ser	Ile	Gly	Thr	
														50		
														55		
														60		
Thr	Ile	Val	Ser	Leu	Ile	Thr	Ala	Pro	Ser	Leu	Thr	Gly	Leu	Ile	Ser	
														65		
														70		
														75		
														80		
Ile	Val	Tyr	Asp	Leu	Ile	Gly	Lys	Val	Leu	Gly	Gly	Ser	Ser	Gly	Gln	
														85		
														90		
														95		
Ser	Ile	Ser	Asp	Leu	Ser	Ile	Cys	Asp	Leu	Leu	Ser	Ile	Ile	Asp	Leu	
														100		
														105		
														110		
Arg	Val	Ser	Gln	Ser	Val	Leu	Asn	Asp	Gly	Ile	Ala	Asp	Phe	Asn	Gly	
														115		
														120		
														125		
Ser	Val	Leu	Leu	Tyr	Arg	Asn	Tyr	Leu	Glu	Ala	Leu	Asp	Ser	Trp	Asn	
														130		
														135		
														140		
Lys	Asn	Pro	Asn	Ser	Ala	Ser	Ala	Glu	Glu	Leu	Arg	Thr	Arg	Phe	Arg	
														145		
														150		
														155		
														160		
Ile	Ala	Asp	Ser	Glu	Phe	Asp	Arg	Ile	Leu	Thr	Arg	Gly	Ser	Leu	Thr	
														165		
														170		
														175		
Asn	Gly	Gly	Ser	Leu	Ala	Arg	Gln	Asn	Ala	Gln	Ile	Leu	Leu	Pro		
														180		
														185		
														190		
Ser	Phe	Ala	Ser	Ala	Ala	Phe	Phe	His	Leu	Leu	Leu	Arg	Asp	Ala		
														195		
														200		
														205		
Thr	Arg	Tyr	Gly	Thr	Asn	Trp	Gly	Leu	Tyr	Asn	Ala	Thr	Pro	Phe	Ile	
														210		
														215		
														220		
Asn	Tyr	Gln	Ser	Lys	Leu	Val	Glu	Leu	Ile	Glu	Leu	Tyr	Thr	Asp	Tyr	

225	230	235	240
Cys Val His Trp Tyr Asn Arg Gly Phe Asn Glu Leu Arg Gln Arg Gly			
245		250	255
Thr Ser Ala Thr Ala Trp Leu Glu Phe His Arg Tyr Arg Arg Glu Met			
260		265	270
Thr Leu Met Val Leu Asp Ile Val Ala Ser Phe Ser Ser Leu Asp Ile			
275		280	285
Thr Asn Tyr Pro Ile Glu Thr Asp Phe Gln Leu Ser Arg Val Ile Tyr			
290		295	300
Thr Asp Pro Ile Gly Phe Val His Arg Ser Ser Leu Arg Gly Glu Ser			
305		310	315
Trp Phe Ser Phe Val Asn Arg Ala Asn Phe Ser Asp Leu Glu Asn Ala			
325		330	335
Ile Pro Asn Pro Arg Pro Ser Trp Phe Leu Asn Asn Met Ile Ile Ser			
340		345	350
Thr Gly Ser Leu Thr Leu Pro Val Ser Pro Ser Thr Asp Arg Ala Arg			
355		360	365
Val Trp Tyr Gly Ser Arg Asp Arg Ile Ser Pro Ala Asn Ser Gln Phe			
370		375	380
Ile Thr Glu Leu Ile Ser Gly Gln His Thr Thr Ala Thr Gln Thr Ile			
385		390	395
Leu Gly Arg Asn Ile Phe Arg Val Asp Ser Gln Ala Cys Asn Leu Asn			
405		410	415
Asp Thr Thr Tyr Gly Val Asn Arg Ala Val Phe Tyr His Asp Ala Ser			
420		425	430
Glu Gly Ser Gln Arg Ser Val Tyr Glu Gly Tyr Ile Arg Thr Thr Gly			
435		440	445
Ile Asp Asn Pro Arg Val Gln Asn Ile Asn Thr Tyr Leu Pro Gly Glu			
450		455	460
Asn Ser Asp Ile Pro Thr Pro Glu Asp Tyr Thr His Ile Leu Ser Thr			
465		470	475
Thr Ile Asn Leu Thr Gly Gly Leu Arg Gln Val Ala Ser Asn Arg Arg			
485		490	495
Ser Ser Leu Val Met Tyr Gly Trp Thr His Lys Ser Leu Ala Arg Asn			
500		505	510

Asn Thr Ile Asn Pro Asp Arg Ile Thr Gln Ile Pro Leu Thr Lys Val
 515 520 525
 Asp Thr Arg Gly Thr Gly Val Ser Tyr Val Asn Asp Pro Gly Phe Ile
 530 535 540
 Gly Gly Ala Leu Leu Gln Arg Thr Asp His Gly Ser Leu Gly Val Leu
 545 550 555 560
 Arg Val Gln Phe Pro Leu His Leu Arg Gln Gln Tyr Arg Ile Arg Val
 565 570 575
 Arg Tyr Ala Ser Thr Thr Asn Ile Arg Leu Ser Val Asn Gly Ser Phe
 580 585 590
 Gly Thr Ile Ser Gln Asn Leu Pro Ser Thr Met Arg Leu Gly Glu Asp
 595 600 605
 Leu Arg Tyr Gly Ser Phe Ala Ile Arg Glu Phe Asn Thr Ser Ile Arg
 610 615 620
 Pro Thr Ala Ser Pro Asp Gln Ile Arg Leu Thr Ile Glu Pro Ser Phe
 625 630 635 640
 Ile Arg Gln Glu Val Tyr Val Asp Arg Ile Glu Phe Ile Pro Val Asn
 645 650 655
 Pro Thr Arg Glu Ala Lys Glu Asp Leu Glu Ala Ala Lys Lys Ala Val
 660 665 670
 Ala Ser Leu Phe Thr Arg Thr Arg Asp Gly Leu Gln Val Asn Val Lys
 675 680 685
 Asp Tyr Gln Val Asp Gln Ala Ala Asn Leu Val Ser Cys Leu Ser Asp
 690 695 700
 Glu Gln Tyr Gly Tyr Asp Lys Lys Met Leu Leu Glu Ala Val Arg Ala
 705 710 715 720
 Ala Lys Arg Leu Ser Arg Glu Arg Asn Leu Leu Gln Asp Pro Asp Phe
 725 730 735
 Asn Thr Ile Asn Ser Thr Glu Glu Asn Gly Trp Lys Ala Ser Asn Gly
 740 745 750
 Val Thr Ile Ser Glu Gly Gly Pro Phe Tyr Lys Gly Arg Ala Ile Gln
 755 760 765
 Leu Ala Ser Ala Arg Glu Asn Tyr Pro Thr Tyr Ile Tyr Gln Lys Val
 770 775 780
 Asp Ala Ser Glu Leu Lys Pro Tyr Thr Arg Tyr Arg Leu Asp Gly Phe
 785 790 795 800

Val Lys Ser Ser Gln Asp Leu Glu Ile Asp Leu Ile His His His Lys
 805 810 815

Val His Leu Val Lys Asn Val Pro Asp Asn Leu Val Ser Asp Thr Tyr
 820 825 830

Pro Asp Asp Ser Cys Ser Gly Ile Asn Arg Cys Gln Glu Gln Gln Met
 835 840 845

Val Asn Ala Gln Leu Glu Thr Glu His His His Pro Met Asp Cys Cys
 850 855 860

Glu Ala Ala Gln Thr His Glu Phe Ser Ser Tyr Ile Asp Thr Gly Asp
 865 870 875 880

Leu Asn Ser Ser Val Asp Gln Gly Ile Trp Ala Ile Phe Lys Val Arg
 885 890 895

Thr Thr Asp Gly Tyr Ala Thr Leu Gly Asn Leu Glu Leu Val Glu Val
 900 905 910

Gly Pro Leu Ser Gly Glu Ser Leu Glu Arg Glu Gln Arg Asp Asn Thr
 915 920 925

Lys Trp Ser Ala Glu Leu Gly Arg Lys Arg Ala Glu Thr Asp Arg Val
 930 935 940

Tyr Gln Asp Ala Lys Gln Ser Ile Asn His Leu Phe Val Asp Tyr Gln
 945 950 955 960

Asp Gln Gln Leu Asn Pro Glu Ile Gly Met Ala Asp Ile Met Asp Ala
 965 970 975

Gln Asn Leu Val Ala Ser Ile Ser Asp Val Tyr Ser Asp Ala Val Leu
 980 985 990

Gln Ile Pro Gly Ile Asn Tyr Glu Ile Tyr Thr Glu Leu Ser Asn Arg
 995 1000 1005

Leu Gln Gln Ala Ser Tyr Leu Tyr Thr Ser Arg Asn Ala Val Gln Asn
 1010 1015 1020

Gly Asp Phe Asn Asn Gly Leu Asp Ser Trp Asn Ala Thr Ala Gly Ala
 1025 1030 1035 1040

Ser Val Gln Gln Asp Gly Asn Thr His Phe Leu Val Leu Ser His Trp
 1045 1050 1055

Asp Ala Gln Val Ser Gln Gln Phe Arg Val Gln Pro Asn Cys Lys Tyr
 1060 1065 1070

Val Leu Arg Val Thr Ala Glu Lys Val Gly Gly Asp Gly Tyr Val

1075	1080	1085
Thr Ile Arg Asp Asp Ala His His Thr Glu Thr Leu Thr Phe Asn Ala		
1090	1095	1100
Cys Asp Tyr Asp Ile Asn Gly Thr Tyr Val Thr Asp Asn Thr Tyr Leu		
1105	1110	1115
1120		
Thr Lys Glu Val Val Phe His Pro Glu Thr Gln His Met Trp Val Glu		
1125	1130	1135
Val Asn Glu Thr Glu Gly Ala Phe His Ile Asp Ser Ile Glu Phe Val		
1140	1145	1150
Glu Thr Glu Lys		
1155		

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3726 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..3726

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATG AAT CAA AAT AAA CAC GGA ATT ATT GGC GCT TCC AAT TGT GGT TGT	48		
Met Asn Gln Asn Lys His Gly Ile Ile Gly Ala Ser Asn Cys Gly Cys			
1	5	10	15
GCA TCT GAT GAT GTT GCG AAA TAT CCT TTA GCC AAC AAT CCA TAT TCA	96		
Ala Ser Asp Asp Val Ala Lys Tyr Pro Leu Ala Asn Asn Pro Tyr Ser			
20	25	30	
TCT GCT TTA AAT TTA AAT TCT TGT CAA AAT AGT AGT ATT CTC AAC TGG	144		
Ser Ala Leu Asn Leu Asn Ser Cys Gln Asn Ser Ser Ile Leu Asn Trp			
35	40	45	
ATT AAC ATA ATA GGC GAT GCA GCA AAA GAA GCA GTA TCT ATT GGG ACA	192		
Ile Asn Ile Ile Gly Asp Ala Ala Lys Glu Ala Val Ser Ile Gly Thr			
50	55	60	
ACC ATA GTC TCT CTT ATC ACA GCA CCT TCT CTT ACT GGA TTA ATT TCA	240		

Thr Ile Val Ser Leu Ile Thr Ala Pro Ser Leu Thr Gly Leu Ile Ser			
65	70	75	80
ATA GTA TAT GAC CTT ATA GGT AAA GTA CTA GGA GGT AGT AGT GGA CAA			288
Ile Val Tyr Asp Leu Ile Gly Lys Val Leu Gly Gly Ser Ser Gly Gln			
85	90	95	
TCC ATA TCA GAT TTG TCT ATA TGT GAC TTA TTA TCT ATT ATT GAT TTA			336
Ser Ile Ser Asp Leu Ser Ile Cys Asp Leu Leu Ser Ile Ile Asp Leu			
100	105	110	
CGG GTA AGT CAG AGT GTT TTA AAT GAT GGG ATT GCA GAT TTT AAT GGT			384
Arg Val Ser Gln Ser Val Leu Asn Asp Gly Ile Ala Asp Phe Asn Gly			
115	120	125	
TCT GTA CTC TTA TAC AGG AAC TAT TTA GAG GCT CTG GAT AGC TGG AAT			432
Ser Val Leu Leu Tyr Arg Asn Tyr Leu Glu Ala Leu Asp Ser Trp Asn			
130	135	140	
AAG AAT CCT AAT TCT GCT TCT GCT GAA GAA CTC CGT ACT CGT TTT AGA			480
Lys Asn Pro Asn Ser Ala Ser Ala Glu Glu Leu Arg Thr Arg Phe Arg			
145	150	155	160
ATC GCC GAC TCA GAA TTT GAT AGA ATT TTA ACC CGA GGG TCT TTA ACG			528
Ile Ala Asp Ser Glu Phe Asp Arg Ile Leu Thr Arg Gly Ser Leu Thr			
165	170	175	
AAT GGT GGC TCG TTA GCT AGA CAA AAT GCC CAA ATA TTA TTA TTA CCT			576
Asn Gly Ser Leu Ala Arg Gln Asn Ala Gln Ile Leu Leu Leu Pro			
180	185	190	
TCT TTT GCG AGC GCT GCA TTT TTC CAT TTA CTA CTA AGG GAT GCT			624
Ser Phe Ala Ser Ala Ala Phe Phe His Leu Leu Leu Leu Arg Asp Ala			
195	200	205	
ACT AGA TAT GGC ACT AAT TGG GGG CTA TAC AAT GCT ACA CCT TTT ATA			672
Thr Arg Tyr Gly Thr Asn Trp Gly Leu Tyr Asn Ala Thr Pro Phe Ile			
210	215	220	
AAT TAT CAA TCA AAA CTA GTA GAG CTT ATT GAA CTA TAT ACT GAT TAT			720
Asn Tyr Gln Ser Lys Leu Val Glu Leu Ile Glu Leu Tyr Thr Asp Tyr			
225	230	235	240
TGC GTA CAT TGG TAT AAT CGA GGT TTC AAC GAA CTA AGA CAA CGA GGC			768
Cys Val His Trp Tyr Asn Arg Gly Phe Asn Glu Leu Arg Gln Arg Gly			
245	250	255	
ACT AGT GCT ACA GCT TGG TTA GAA TTT CAT AGA TAT CGT AGA GAG ATG			816
Thr Ser Ala Thr Ala Trp Leu Glu Phe His Arg Tyr Arg Arg Glu Met			
260	265	270	
ACA TTG ATG GTA TTA GAT ATA GTA GCA TCA TTT TCA AGT CTT GAT ATT			864
Thr Leu Met Val Leu Asp Ile Val Ala Ser Phe Ser Ser Leu Asp Ile			

275	280	285	
ACT AAT TAC CCA ATA GAA ACA GAT TTT CAG TTG AGT AGG GTC ATT TAT Thr Asn Tyr Pro Ile Glu Thr Asp Phe Gln Leu Ser Arg Val Ile Tyr 290	295	300	912
ACA GAT CCA ATT GGT TTT GTA CAT CGT AGT AGT CTT AGG GGA GAA AGT Thr Asp Pro Ile Gly Phe Val His Arg Ser Ser Leu Arg Gly Glu Ser 305	310	315	960
TGG TTT AGC TTT GTT AAT AGA GCT AAT TTC TCA GAT TTA GAA AAT GCA Trp Phe Ser Phe Val Asn Arg Ala Asn Phe Ser Asp Leu Glu Asn Ala 325	330	335	1008
ATA CCT AAT CCT AGA CCG TCT TGG TTT TTA AAT AAT ATG ATT ATA TCT Ile Pro Asn Pro Arg Pro Ser Trp Phe Leu Asn Asn Met Ile Ile Ser 340	345	350	1056
ACT GGT TCA CTT ACA TTG CCG GTT AGC CCA AGT ACT GAT AGA GCG AGG Thr Gly Ser Leu Thr Leu Pro Val Ser Pro Ser Thr Asp Arg Ala Arg 355	360	365	1104
GTA TGG TAT GGA AGT CGA GAT CGA ATT TCC CCT GCT AAT TCA CAA TTT Val Trp Tyr Gly Ser Arg Asp Arg Ile Ser Pro Ala Asn Ser Gln Phe 370	375	380	1152
ATT ACT GAA CTA ATC TCT GGA CAA CAT ACG ACT GCT ACA CAA ACT ATT Ile Thr Glu Leu Ile Ser Gly Gln His Thr Thr Ala Thr Gln Thr Ile 385	390	395	1200
TTA GGG CGA AAT ATA TTT AGA GTA GAT TCT CAA GCT TGT AAT TTA AAT Leu Gly Arg Asn Ile Phe Arg Val Asp Ser Gln Ala Cys Asn Leu Asn 405	410	415	1248
GAT ACC ACA TAT GGA GTG AAT AGG GCG GTA TTT TAT CAT GAT GCG AGT Asp Thr Thr Tyr Gly Val Asn Arg Ala Val Phe Tyr His Asp Ala Ser 420	425	430	1296
GAA GGT TCT CAA AGA TCC GTG TAC GAG GGG TAT ATT CGA ACA ACT GGG Glu Gly Ser Gln Arg Ser Val Tyr Glu Gly Tyr Ile Arg Thr Thr Gly 435	440	445	1344
ATA GAT AAC CCT AGA GTT CAA AAT ATT AAC ACT TAT TTA CCT GGA GAA Ile Asp Asn Pro Arg Val Gln Asn Ile Asn Thr Tyr Leu Pro Gly Glu 450	455	460	1392
AAT TCA GAT ATC CCA ACT CCA GAA GAC TAT ACT CAT ATA TTA AGC ACA Asn Ser Asp Ile Pro Thr Pro Glu Asp Tyr Thr His Ile Leu Ser Thr 465	470	475	1440
ACA ATA AAT TTA AGA GGA GGA CTT AGA CAA GTA GCA TCT AAT CGC CGT Thr Ile Asn Leu Thr Gly Gly Leu Arg Gln Val Ala Ser Asn Arg Arg 485	490	495	1488

TCA TCT TTA GTA ATG TAT GGT TGG ACA CAT AAA AGT CTG GCT CGT AAC Ser Ser Leu Val Met Tyr Gly Trp Thr His Lys Ser Leu Ala Arg Asn 500	505	510	1536
AAT ACC ATT AAT CCA GAT AGA ATT ACA CAG ATA CCT TTA GTG AAA GGA Asn Thr Ile Asn Pro Asp Arg Ile Thr Gln Ile Pro Leu Val Lys Gly 515	520	525	1584
TTT AGA GTT TGG GGG GGC ACC TCT GTC ATT ACA GGA CCA GGA TTT ACA Phe Arg Val Trp Gly Gly Thr Ser Val Ile Thr Gly Pro Gly Phe Thr 530	535	540	1632
GGA GGG GAT ATC CTT CGA AGA AAT ACC TTT GGT GAT TTT GTA TCT CTA Gly Gly Asp Ile Leu Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu 545	550	555	1680
CAA GTC AAT ATT AAT TCA CCA ATT ACC CAA AGA TAC CGT TTA AGA TTT Gln Val Asn Ile Asn Ser Pro Ile Thr Gln Arg Tyr Arg Leu Arg Phe 565	570	575	1728
CGT TAC GCT TCC AGT AGG GAT GCA CGA GTT ATA GTA TTA ACA GGA GCG Arg Tyr Ala Ser Ser Arg Asp Ala Arg Val Ile Val Leu Thr Gly Ala 580	585	590	1776
GCA TCC ACA GGA GTG GGA GGC CAA GTT AGT GTA AAT ATG CCT CTT CAG Ala Ser Thr Gly Val Gly Gly Gln Val Ser Val Asn Met Pro Leu Gln 595	600	605	1824
AAA ACT ATG GAA ATA GGG GAG AAC TTA ACA TCT AGA ACA TTT AGA TAT Lys Thr Met Glu Ile Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr 610	615	620	1872
ACC GAT TTT AGT AAT CCT TTT TCA TTT AGA GCT AAT CCA GAT ATA ATT Thr Asp Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile Ile 625	630	635	1920
GGG ATA AGT GAA CAA CCT CTA TTT GGT GCA GGT TCT ATT AGT AGC GGT Gly Ile Ser Glu Gln Pro Leu Phe Gly Ala Gly Ser Ile Ser Ser Gly 645	650	655	1968
GAA CTT TAT ATA GAT AAA ATT GAA ATT ATT CTA GCA GAT GCA ACA TTT Glu Leu Tyr Ile Asp Lys Ile Glu Ile Ile Leu Ala Asp Ala Thr Phe 660	665	670	2016
GAA GCA GAA TCT GAT TTA GAA AGA GCA CAA AAG GCG GTG AAT GCC CTG Glu Ala Glu Ser Asp Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu 675	680	685	2064
TTT ACT TCT TCC AAT CAA ATC GGG TTA AAA ACC GAT GTG ACG GAT TAT Phe Thr Ser Ser Asn Gln Ile Gly Leu Lys Thr Asp Val Thr Asp Tyr 690	695	700	2112

CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA GAT GAA TTT His Ile Asp Gln Val Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe 705 710 715 720	2160
TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA CAT GCG AAG Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys 725 730 735	2208
CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG Arg Leu Ser Asp Glu Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly 740 745 750	2256
ATC AAT AGA CAA CCA GAC CGT GGC TGG AGA GGA AGT ACA GAT ATT ACC Ile Asn Arg Gln Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr 755 760 765	2304
ATC CAA GGA GGA GAT GAC GTA TTC AAA GAG AAT TAC GTC ACA CTA CCG Ile Gln Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro 770 775 780	2352
GGT ACC GTT GAT GAG TGC TAT CCA ACG TAT TTA TAT CAG AAA ATA GAT Gly Thr Val Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp 785 790 795 800	2400
GAG TCG AAA TTA AAA GCT TAT ACC CGT TAT GAA TTA AGA GGG TAT ATC Glu Ser Lys Leu Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile 805 810 815	2448
GAA GAT AGT CAA GAC TTA GAA ATC TAT TTG ATC CGT TAC AAT GCA AAA Glu Asp Ser Gln Asp Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys 820 825 830	2496
CAC GAA ATA GTA AAT GTG CCA GGC ACG GGT TCC TTA TGG CCG CTT TCA His Glu Ile Val Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser 835 840 845	2544
GCC CAA AGT CCA ATC GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA Ala Gln Ser Pro Ile Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro 850 855 860	2592
CAC CTT GAA TGG AAT CCT GAT CTA GAT TGT TCC TGC AGA GAC GGG GAA His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu 865 870 875 880	2640
AAA TGT GCA CAT CAT TCC CAT CAT TTC ACC TTG GAT ATT GAT GTT GGA Lys Cys Ala His His Ser His His Phe Thr Leu Asp Ile Asp Val Gly 885 890 895	2688
TGT ACA GAC TTA AAT GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile 900 905 910	2736
AAG ACG CAA GAT GGC CAT GCA AGA CTA GGG AAT CTA GAG TTT CTC GAA	2784

Lys Thr Gln Asp Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu			
915	920	925	
GAG AAA CCA TTA TTA GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG			2832
Glu Lys Pro Leu Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu			
930	935	940	
AAG AAG TGG AGA GAC AAA CGA GAG AAA CTG CAG TTG GAA ACA AAT ATT			2880
Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Gln Leu Glu Thr Asn Ile			
945	950	955	960
GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT			2928
Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser			
965	970	975	
CAA TAT GAT AGA TTA CAA GTG GAT ACG AAC ATC GCG ATG ATT CAT GCG			2976
Gln Tyr Asp Arg Leu Gln Val Asp Thr Asn Ile Ala Met Ile His Ala			
980	985	990	
GCA GAT AAA CGC GTT CAT AGA ATC CGG GAA GCG TAT CTG CCA GAG TTG			3024
Ala Asp Lys Arg Val His Arg Ile Arg Glu Ala Tyr Leu Pro Glu Leu			
995	1000	1005	
TCT GTG ATT CCA GGT GTC AAT GCG GCC ATT TTC GAA GAA TTA GAG GGA			3072
Ser Val Ile Pro Gly Val Asn Ala Ala Ile Phe Glu Glu Leu Glu Gly			
1010	1015	1020	
CGT ATT TTT ACA GCG TAT TCC TTA TAT GAT GCG AGA AAT GTC ATT AAA			3120
Arg Ile Phe Thr Ala Tyr Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys			
1025	1030	1035	1040
AAT GGC GAT TTC AAT AAT GGC TTA TTA TGC TGG AAC GTG AAA GGT CAT			3168
Asn Gly Asp Phe Asn Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His			
1045	1050	1055	
GTA GAT GTA GAA GAG CAA AAC AAC CAC CGT TCG GTC CTT GTT ATC CCA			3216
Val Asp Val Glu Glu Gln Asn Asn His Arg Ser Val Leu Val Ile Pro			
1060	1065	1070	
GAA TGG GAG GCA GAA GTG TCA CAA GAG GTT CGT GTC TGT CCA GGT CGT			3264
Glu Trp Glu Ala Glu Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg			
1075	1080	1085	
GGC TAT ATC CTT CGT GTC ACA GCA TAT AAA GAG GGA TAT GGA GAG GGC			3312
Gly Tyr Ile Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr Glu Gly			
1090	1095	1100	
TGC GTA ACG ATC CAT GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC			3360
Cys Val Thr Ile His Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe			
1105	1110	1115	1120
AGC AAC TGT GTA GAA GAG GAA GTA TAT CCA AAC AAC ACA GTA ACG TGT			3408
Ser Asn Cys Val Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys			

1125	1130	1135	
AAT AAT TAT ACT GGG ACT CAA GAA GAA TAT GAG GGT ACG TAC ACT TCT Asn Asn Tyr Thr Gly Thr Gln Glu Glu Tyr Glu Gly Thr Tyr Thr Ser			3456
1140	1145	1150	
CGT AAT CAA GGA TAT GAC GAA GCC TAT GGT AAT AAC CCT TCC GTA CCA Arg Asn Gln Gly Tyr Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro			3504
1155	1160	1165	
GCT GAT TAC GCT TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA Ala Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg			3552
1170	1175	1180	
AGA GAG AAT CCT TGT GAA TCT AAC AGA GGC TAT GGG GAT TAC ACA CCA Arg Glu Asn Pro Cys Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro			3600
1185	1190	1195	1200
CTA CCG GCT GGT TAT GTA ACA AAG GAT TTA GAG TAC TTC CCA GAG ACC Leu Pro Ala Gly Tyr Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr			3648
1205	1210	1215	
GAT AAG GTA TGG ATT GAG ATC GGA GAA ACA GAA GGA ACA TTC ATC GTG Asp Lys Val Trp Ile Glu Ile Gly Glu Thr Glu Gly Thr Phe Ile Val			3696
1220	1225	1230	
GAT AGC GTG GAA TTA CTC CTT ATG GAG GAA Asp Ser Val Glu Leu Leu Met Glu Glu			3726
1235	1240		

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1242 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Asn Gln Asn Lys His Gly Ile Ile Gly Ala Ser Asn Cys Gly Cys			
1	5	10	15

Ala Ser Asp Asp Val Ala Lys Tyr Pro Leu Ala Asn Asn Pro Tyr Ser			
20	25	30	

Ser Ala Leu Asn Leu Asn Ser Cys Gln Asn Ser Ser Ile Leu Asn Trp			
35	40	45	

Ile Asn Ile Ile Gly Asp Ala Ala Lys Glu Ala Val Ser Ile Gly Thr			
50	55	60	

Thr Ile Val Ser Leu Ile Thr Ala Pro Ser Leu Thr Gly Leu Ile Ser
 65 70 75 80
 Ile Val Tyr Asp Leu Ile Gly Lys Val Leu Gly Gly Ser Ser Gly Gln
 85 90 95
 Ser Ile Ser Asp Leu Ser Ile Cys Asp Leu Leu Ser Ile Ile Asp Leu
 100 105 110
 Arg Val Ser Gln Ser Val Leu Asn Asp Gly Ile Ala Asp Phe Asn Gly
 115 120 125
 Ser Val Leu Leu Tyr Arg Asn Tyr Leu Glu Ala Leu Asp Ser Trp Asn
 130 135 140 ~
 Lys Asn Pro Asn Ser Ala Ser Ala Glu Glu Leu Arg Thr Arg Phe Arg
 145 150 155 160
 Ile Ala Asp Ser Glu Phe Asp Arg Ile Leu Thr Arg Gly Ser Leu Thr
 165 170 175
 Asn Gly Gly Ser Leu Ala Arg Gln Asn Ala Gln Ile Leu Leu Pro
 180 185 190
 Ser Phe Ala Ser Ala Ala Phe Phe His Leu Leu Leu Leu Arg Asp Ala
 195 200 205
 Thr Arg Tyr Gly Thr Asn Trp Gly Leu Tyr Asn Ala Thr Pro Phe Ile
 210 215 220
 Asn Tyr Gln Ser Lys Leu Val Glu Leu Ile Glu Leu Tyr Thr Asp Tyr
 225 230 235 240
 Cys Val His Trp Tyr Asn Arg Gly Phe Asn Glu Leu Arg Gln Arg Gly
 245 250 255
 Thr Ser Ala Thr Ala Trp Leu Glu Phe His Arg Tyr Arg Arg Glu Met
 260 265 270
 Thr Leu Met Val Leu Asp Ile Val Ala Ser Phe Ser Ser Leu Asp Ile
 275 280 285
 Thr Asn Tyr Pro Ile Glu Thr Asp Phe Gln Leu Ser Arg Val Ile Tyr
 290 295 300
 Thr Asp Pro Ile Gly Phe Val His Arg Ser Ser Leu Arg Gly Glu Ser
 305 310 315 320
 Trp Phe Ser Phe Val Asn Arg Ala Asn Phe Ser Asp Leu Glu Asn Ala
 325 330 335
 Ile Pro Asn Pro Arg Pro Ser Trp Phe Leu Asn Asn Met Ile Ile Ser

340

345

350

Thr Gly Ser Leu Thr Leu Pro Val Ser Pro Ser Thr Asp Arg Ala Arg
 355 360 365

Val Trp Tyr Gly Ser Arg Asp Arg Ile Ser Pro Ala Asn Ser Gln Phe
 370 375 380

Ile Thr Glu Leu Ile Ser Gly Gln His Thr Thr Ala Thr Gln Thr Ile
 385 390 395 400

Leu Gly Arg Asn Ile Phe Arg Val Asp Ser Gln Ala Cys Asn Leu Asn
 405 410 415

Asp Thr Thr Tyr Gly Val Asn Arg Ala Val Phe Tyr His Asp Ala Ser
 420 425 430

Glu Gly Ser Gln Arg Ser Val Tyr Glu Gly Tyr Ile Arg Thr Thr Gly
 435 440 445

Ile Asp Asn Pro Arg Val Gln Asn Ile Asn Thr Tyr Leu Pro Gly Glu
 450 455 460

Asn Ser Asp Ile Pro Thr Pro Glu Asp Tyr Thr His Ile Leu Ser Thr
 465 470 475 480

Thr Ile Asn Leu Thr Gly Leu Arg Gln Val Ala Ser Asn Arg Arg
 485 490 495

Ser Ser Leu Val Met Tyr Gly Trp Thr His Lys Ser Leu Ala Arg Asn
 500 505 510

Asn Thr Ile Asn Pro Asp Arg Ile Thr Gln Ile Pro Leu Val Lys Gly
 515 520 525

Phe Arg Val Trp Gly Gly Thr Ser Val Ile Thr Gly Pro Gly Phe Thr
 530 535 540

Gly Gly Asp Ile Leu Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu
 545 550 555 560

Gln Val Asn Ile Asn Ser Pro Ile Thr Gln Arg Tyr Arg Leu Arg Phe
 565 570 575

Arg Tyr Ala Ser Ser Arg Asp Ala Arg Val Ile Val Leu Thr Gly Ala
 580 585 590

Ala Ser Thr Gly Val Gly Gly Gln Val Ser Val Asn Met Pro Leu Gln
 595 600 605

Lys Thr Met Glu Ile Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr
 610 615 620

Thr Asp Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp Ile Ile
 625 630 635 640

Gly Ile Ser Glu Gln Pro Leu Phe Gly Ala Gly Ser Ile Ser Ser Gly
 645 650 655

Glu Leu Tyr Ile Asp Lys Ile Glu Ile Ile Leu Ala Asp Ala Thr Phe
 660 665 670

Glu Ala Glu Ser Asp Leu Glu Arg Ala Gln Lys Ala Val Asn Ala Leu
 675 680 685

Phe Thr Ser Ser Asn Gln Ile Gly Leu Lys Thr Asp Val Thr Asp Tyr
 690 695 700

His Ile Asp Gln Val Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe
 705 710 715 720

Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys
 725 730 735

Arg Leu Ser Asp Glu Arg Asn Leu Leu Gln Asp Pro Asn Phe Arg Gly
 740 745 750

Ile Asn Arg Gln Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp Ile Thr
 755 760 765

Ile Gln Gly Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro
 770 775 780

Gly Thr Val Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gln Lys Ile Asp
 785 790 795 800

Glu Ser Lys Leu Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr Ile
 805 810 815

Glu Asp Ser Gln Asp Leu Glu Ile Tyr Leu Ile Arg Tyr Asn Ala Lys
 820 825 830

His Glu Ile Val Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser
 835 840 845

Ala Gln Ser Pro Ile Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro
 850 855 860

His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu
 865 870 875 880

Lys Cys Ala His His Ser His His Phe Thr Leu Asp Ile Asp Val Gly
 885 890 895

Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val Ile Phe Lys Ile
 900 905 910

Lys Thr Gln Asp Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu
 915 920 925

Glu Lys Pro Leu Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu
 930 935 940

Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Gln Leu Glu Thr Asn Ile
 945 950 955 960

Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser
 965 970 975

Gln Tyr Asp Arg Leu Gln Val Asp Thr Asn Ile Ala Met Ile His Ala
 980 985 990

Ala Asp Lys Arg Val His Arg Ile Arg Glu Ala Tyr Leu Pro Glu Leu
 995 1000 1005

Ser Val Ile Pro Gly Val Asn Ala Ala Ile Phe Glu Glu Leu Glu Gly
 1010 1015 1020

Arg Ile Phe Thr Ala Tyr Ser Leu Tyr Asp Ala Arg Asn Val Ile Lys
 1025 1030 1035 1040

Asn Gly Asp Phe Asn Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His
 1045 1050 1055

Val Asp Val Glu Glu Gln Asn Asn His Arg Ser Val Leu Val Ile Pro
 1060 1065 1070

Glu Trp Glu Ala Glu Val Ser Gln Glu Val Arg Val Cys Pro Gly Arg
 1075 1080 1085

Gly Tyr Ile Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly
 1090 1095 1100

Cys Val Thr Ile His Glu Ile Glu Asp Asn Thr Asp Glu Leu Lys Phe
 1105 1110 1115 1120

Ser Asn Cys Val Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys
 1125 1130 1135

Asn Asn Tyr Thr Gly Thr Gln Glu Glu Tyr Glu Gly Thr Tyr Thr Ser
 1140 1145 1150

Arg Asn Gln Gly Tyr Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro
 1155 1160 1165

Ala Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg
 1170 * 1175 1180

Arg Glu Asn Pro Cys Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro

1185	1190	1195	1200
Leu Pro Ala Gly Tyr Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr			
1205		1210	1215
Asp Lys Val Trp Ile Glu Ile Gly Glu Thr Glu Gly Thr Phe Ile Val			
1220	1225	1230	
Asp Ser Val Glu Leu Leu Leu Met Glu Glu			
1235	1240		

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "BglII site downstream of translation termination codon of CryIC."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

ATAAGATCTG TT

12

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCTAGCCATG GATCAAAATA AACACGGAAT TATTG

35

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid
(A) DESCRIPTION: /desc = "primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CTGGTCAGAT CTTTGAAGTA GAGCTCC

27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100